

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C12N 15/12, 15/74, 5/10, C07K 14/47, 16/18, A01K 67/027, C12Q 1/68, G01N 33/577, A61K 31/70, 38/17, 39/395, 48/00	A1	(11) International Publication Number: WO 97/27296 (43) International Publication Date: 31 July 1997 (31.07.97)														
(21) International Application Number: PCT/CA97/00051 (22) International Filing Date: 27 January 1997 (27.01.97) (30) Priority Data: <table border="0"> <tr> <td>08/592,541</td> <td>26 January 1996 (26.01.96)</td> <td>US</td> </tr> <tr> <td>60/021,673</td> <td>5 July 1996 (05.07.96)</td> <td>US</td> </tr> <tr> <td>60/021,700</td> <td>12 July 1996 (12.07.96)</td> <td>US</td> </tr> <tr> <td>60/029,895</td> <td>8 November 1996 (08.11.96)</td> <td>US</td> </tr> <tr> <td>60/034,590</td> <td>2 January 1997 (02.01.97)</td> <td>US</td> </tr> </table> (71) Applicants (for all designated States except US): HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP [CA/CA]; Suite 5270, 555 University Avenue, Toronto, Ontario M5G 1X8 (CA). THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO [CA/CA]; 106 Simcoe Hall, 27 King's College Circle, Toronto, Ontario M5S 1A1 (CA). (72) Inventors; and (75) Inventors/Applicants (for US only): ST. GEORGE-HYSLOP, Peter, H. [CA/CA]; 210 Richview Avenue, Toronto, Ontario M5P 3G3 (CA). FRASER, Paul, E. [CA/CA]; 611 Windermere Avenue, Toronto, Ontario M6S 3L9 (CA). ROM-	08/592,541	26 January 1996 (26.01.96)	US	60/021,673	5 July 1996 (05.07.96)	US	60/021,700	12 July 1996 (12.07.96)	US	60/029,895	8 November 1996 (08.11.96)	US	60/034,590	2 January 1997 (02.01.97)	US	MENS, Johanna, M. [CA/CA]; 105 McCaul Street, Toronto, Ontario M5T 2X4 (CA). (74) Agent: RAE, Patricia, A.; Sim & McBurney, 6th floor, 330 University Avenue, Toronto, Ontario M5G 1R7 (CA). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
08/592,541	26 January 1996 (26.01.96)	US														
60/021,673	5 July 1996 (05.07.96)	US														
60/021,700	12 July 1996 (12.07.96)	US														
60/029,895	8 November 1996 (08.11.96)	US														
60/034,590	2 January 1997 (02.01.97)	US														
(54) Title: NUCLEIC ACIDS AND PROTEINS RELATED TO ALZHEIMER'S DISEASE, AND USES THEREFOR (57) Abstract <p>The present invention describes the identification, isolation, sequencing and characterization of several human genes which interact with the presenilins, mutations in which may lead to Familial Alzheimer's Disease. These presenilin-interacting protein genes may be involved in the pathways which, when affected by mutant presenilins, lead to the development of Alzheimer's Disease. In addition, mutations in the presenilin-interacting protein genes, even in the absence of defects in the presenilins, may be causative of Alzheimer's Disease. Nucleic acids and proteins comprising or derived from the presenilin-interacting proteins are useful in screening and diagnosing Alzheimer's Disease, in identifying and developing therapeutics for treatment of Alzheimer's Disease, and in producing cell lines and transgenic animals useful as models of Alzheimer's Disease.</p>																

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

**NUCLEIC ACIDS AND PROTEINS
RELATED TO ALZHEIMER'S DISEASE,
AND USES THEREFOR**

5

Field of the Invention

The present invention relates generally to the field of neurological and physiological dysfunctions associated with Alzheimer's Disease. More particularly, the invention is concerned with the identification, isolation and cloning of genes which are associated with Alzheimer's Disease, as well as their corresponding transcripts and protein products. The present invention also relates to methods for detecting and diagnosing carriers of normal and mutant alleles of these genes, to methods for detecting and diagnosing Alzheimer's Disease, to methods of identifying other genes and proteins related to, or interacting with, the genes and proteins of the invention, to methods of screening for potential therapeutics for Alzheimer's Disease, to methods of treatment for Alzheimer's Disease, and to cell lines and animal models useful in screening for and evaluating potentially useful therapies for Alzheimer's Disease.

20

Background of the Invention

Alzheimer's Disease (AD) is a degenerative disorder of the human central nervous system characterized by progressive memory impairment and cognitive and intellectual decline during mid to late adult life (Katzman, 1986). The disease is accompanied by a constellation of neuro-pathologic features principal amongst which are the presence of extracellular amyloid or senile plaques, and neurofibrillary tangles in neurons. The etiology of this disease is complex, although in some families it appears to be inherited as an autosomal dominant trait. Linkage studies have identified three genes associated with the development of AD: β -amyloid precursor protein (APP) (Chartier-Harlin et al., 1991; Goate et al., 1991; Murrell et al., 1991; Karlinsky et al., 1992; Mullan et al., 1992), presenilin-1 (PS-1) (Sherrington, 1995), and presenilin-2 (PS-2) (Rogaev, 1995, and Levy-Lahad, 1995).

The presenilins are multi-spanning membrane proteins which were described in substantial detail in PCT Publication WO96/34099, the entire disclosure of which is incorporated herein by reference. Although the functions of the presenilins are unknown, a number of autosomal dominant presenilin mutations have been identified

35

-2-

which are strongly associated with the development of early-onset, aggressive, Familial Alzheimer's Disease (FAD).

The present disclosure describes the identification, isolation, sequencing and characterization of several human genes which interact with the presenilins, mutations
5 in which may lead to FAD. These presenilin-interacting protein genes may be involved in the pathways which, when affected by mutant presenilins, lead to the development of Alzheimer's Disease. In addition, mutations in the presenilin-interacting protein genes, even in the absence of defects in the presenilins, may be causative of Alzheimer's Disease.

10 Summary of the Invention

The present invention is based, in part, upon the identification, isolation, sequencing and characterization of several human genes, referred to herein as "presenilin-interacting protein genes" or "PS-interacting protein genes." The products of these genes are believed to interact in vivo with the human presenilin-1 proteins
15 and, therefore, are implicated in the biochemical pathways which are affected in Alzheimer's Disease. Each of these genes, therefore, presents a new therapeutic target for the treatment of Alzheimer's Disease. In addition, PS-interacting protein nucleic acids, PS-interacting proteins and peptides, antibodies to the PS-interacting proteins, cells transformed with PS-interacting protein nucleic acids, and transgenic animals
20 altered with PS-interacting protein nucleic acids, all possess various utilities, as described herein, for the diagnosis, therapy and continued investigation of Alzheimer's Disease and related disorders.

Thus, it is one object of the invention to provide isolated nucleic acids encoding at least a PS-interacting domain of a PS-interacting protein. These PS-
25 interacting proteins include mammalian S5a subunits of the 26S proteasome, the GT24 protein, the p0071 protein, the Rab11 protein, the retinoid X receptor- β , the cytoplasmic chaperonin, and several sequences identified herein as clones Y2H35, Y2H171, and Y2H41. Preferred nucleotide and amino acid sequences are provided herein. It is another object of the invention to provide probes and primers for these

PS-interacting protein genes, and to provide nucleic acids which encode small antigenic determinants of these genes. Therefore, preferred embodiments include sequences of at least 10, 15 or 20 consecutive nucleotides selected from the disclosed sequences.

5 Using the nucleic acid sequences and antibodies disclosed and enabled herein, methods for identifying allelic variants or heterospecific homologues of a human PS-interacting protein and gene are provided. The methods may be practiced using nucleic acid hybridization or amplification techniques, immunochemical techniques, or any other technique known in the art. The allelic variants may include
10 other normal human alleles as well as mutant alleles of the PS-interacting protein genes which may be causative of Alzheimer's Disease. The heterospecific homologues may be from other mammalian species, such as mice, rats, dogs, cats or non-human primates, or may be from invertebrate species, such as Drosophila or C. elegans. Thus, it is another object of the invention to provide nucleic acids which
15 encode allelic or heterospecific variants of the disclosed sequences, as well as the allelic or heterospecific proteins encoded by them.

 The it another object of the invention to provide vectors, and particularly expression vectors, which include any of the above-described nucleic acids. It is a further object of the invention to provide vectors in which PS-interacting protein
20 nucleic acid sequences are operably joined to exogenous regulatory regions to produce altered patterns of expression, or to exogenous coding regions to produce fusion proteins. Conversely, it is another object to provide nucleic acids in which PS-interacting protein regulatory regions are operably joined to exogenous coding regions, including standard marker genes, to produce constructs in which the
25 regulation of PS-interacting protein genes may be studied and used in assays for therapeutics.

 It is another object of the invention to provide host cells and transgenic animals which have been transformed with any of the above-described nucleic acids

-4-

of the invention. The host cells may be prokaryotic or eukaryotic cells and, in particular, may be gametes, zygotes, fetal cells, or stem cells useful in producing transgenic animal models.

In particularly preferred embodiments, the present invention provides a
5 non-human animal model for Alzheimer's Disease, in which the genome of the animal, or an ancestor thereof, has been modified by at least one recombinant construct which has introduced one of the following modifications: (1) insertion of nucleotide sequences encoding at least a functional domain of a heterospecific normal PS-interacting protein, (2) insertion of nucleotide sequences encoding at least a
10 functional domain of a heterospecific mutant PS-interacting protein, (3) insertion of nucleotide sequences encoding at least a functional domain of a conspecific homologue of a heterospecific mutant PS-interacting protein, and (4) inactivation of an endogenous PS-interacting protein gene. Preferred transgenic animal models are rats, mice, hamsters, guinea pigs, rabbits, dogs, cats, goats, sheep, pigs, and non-
15 human primates, but invertebrates are also contemplated for certain utilities.

It is another object of the invention to provide methods for producing at least a functional domain of a PS-interacting protein using the nucleic acids of the invention. In addition, the present invention also provides substantially pure preparations of such proteins, including short peptide sequences for used as
20 immunogens. Thus, the invention provides peptides comprising at least 10 or 15 consecutive amino acid residues from the disclosed and otherwise enabled sequences. The invention further provides substantially pure preparations of peptides which comprise at least a PS-interacting domain of a PS-interacting protein, as well as substantially pure preparations of the entire proteins.

25 Using the substantially pure peptides and proteins enabled herein, the invention also provides methods for producing antibodies which selectively bind to a PS-interacting protein, as well as cell lines which produce these antibodies.

Another object of the present invention is to provide methods of identifying compounds which may have utility in the treatment of Alzheimer's Disease and related disorders. These methods include methods for identifying compounds which can modulate the expression of a PS-interacting protein gene, 5 methods for identifying compounds which can selectively bind to a PS-interacting protein, and methods of identifying compounds which can modulate activity of a PS-interacting protein. These methods may be conducted in vitro or in vivo, and may employ the transformed cell lines and transgenic animal models of the invention. The methods also may be part of a clinical trial in which compounds identified by the 10 methods of the invention are further tested in human subjects.

It is another object of the invention to provide methods of diagnosing or screening for inherited forms of Alzheimer's Disease by determining if a subject bears a mutant PS-interacting protein gene. Mutant PS-interacting genes may be detected by assays including direct nucleotide sequencing, probe specific hybridization, 15 restriction enzyme digest and mapping, PCR mapping, ligase-mediated PCR detection, RNase protection, electrophoretic mobility shift detection, or chemical mismatch cleavage. Alternatively, mutant forms of a PS-interacting protein may be detected by assays including immunoassays, protease assays, or electrophoretic mobility assays.

20 It is also an object of the invention to provide pharmaceutical preparations which may be used in the treatment of Alzheimer's Disease and related disorders which result from aberration in biochemical pathways involving the PS-interacting proteins disclosed and enabled herein. Thus, the present invention also provides pharmaceutical preparations comprising a substantially pure PS-interacting protein, an 25 expression vector operably encoding a PS -interacting protein, an expression vector operably encoding a PS-interacting protein antisense sequence, an antibody which selectively binds to a mutant PS-interacting protein, or an antigenic determinant of a mutant PS-interacting protein. These pharmaceutical preparations may be used to

treat a patient bearing a mutant PS-interacting protein gene which is causative of Alzheimer's Disease or related disorders.

These and other objects of the present invention are described more fully in the following specification and appended claims.

Detailed Description of the Invention

I. Definitions

In order to facilitate review of the various embodiments of the invention, and an understanding of the various elements and constituents used in making and using the invention, the following definitions are provided for particular terms used in the description and appended claims:

Presenilin. As used without further modification herein, the terms “presenilin” or “presenilins” mean the presenilin-1 (PS1) and/or the presenilin-2 (PS2) genes/proteins. In particular, the unmodified terms “presenilin” or “presenilins” refer to the mammalian PS1 and/or PS2 genes/proteins and, preferably, the human PS1 and/or PS2 genes/proteins as described and disclosed in PCT Publication WO96/34099.

Normal. As used herein with respect to genes, the term "normal" refers to a gene which encodes a normal protein. As used herein with respect to proteins, the term "normal" means a protein which performs its usual or normal physiological role and which is not associated with, or causative of, a pathogenic condition or state. Therefore, as used herein, the term "normal" is essentially synonymous with the usual meaning of the phrase "wild type." For any given gene, or corresponding protein, a multiplicity of normal allelic variants may exist, none of which is associated with the development of a pathogenic condition or state. Such normal allelic variants include, but are not limited to, variants in which one or more nucleotide substitutions do not result in a change in the encoded amino acid sequence.

Mutant. As used herein with respect to genes, the term “mutant” refers to a gene which encodes a mutant protein. As used herein with respect to proteins, the term “mutant” means a protein which does not perform its usual or normal

physiological role and which is associated with, or causative of, a pathogenic condition or state. Therefore, as used herein, the term "mutant" is essentially synonymous with the terms "dysfunctional," "pathogenic," "disease-causing," and "deleterious." With respect to the presenilin and presenilin-interacting protein genes and proteins of the present invention, the term "mutant" refers to genes/proteins bearing one or more nucleotide/amino acid substitutions, insertions and/or deletions which typically lead to the development of the symptoms of Alzheimer's Disease and/or other relevant inheritable phenotypes (e.g. cerebral hemorrhage, mental retardation, schizophrenia, psychosis, and depression) when expressed in humans. This definition is understood to include the various mutations that naturally exist, including but not limited to those disclosed herein, as well as synthetic or recombinant mutations produced by human intervention. The term "mutant," as applied to these genes, is not intended to embrace sequence variants which, due to the degeneracy of the genetic code, encode proteins identical to the normal sequences disclosed or otherwise enabled herein; nor is it intended to embrace sequence variants which, although they encode different proteins, encode proteins which are functionally equivalent to normal proteins.

Substantially pure. As used herein with respect to proteins (including antibodies) or other preparations, the term "substantially pure" means that the preparation is essentially free of other substances to an extent practical and appropriate for its intended use. In particular, a protein preparation is substantially pure if it is sufficiently free from other biological constituents so as to be useful in, for example, generating antibodies, sequencing, or producing pharmaceutical preparations. By techniques well known in the art, substantially pure proteins or peptides may be produced in light of the nucleic acid and amino acid sequences disclosed herein. In particular, in light of the nucleic acid and amino acid sequences disclosed herein, one of ordinary skill in the art may, by application or serial application of well-known methods including HPLC or immuno-affinity chromatography or electrophoretic separation, obtain proteins or peptides of any generally feasible purity. Preferably, but not necessarily, "substantially pure"

preparations include at least 60% by weight (dry weight) the compound of interest. More preferably the preparation is at least 75% or 90%, and most preferably at least 99%, by weight the compound of interest. Purity can be measured by any appropriate method, e.g., column chromatography, gel electrophoresis, or HPLC analysis. With
5 respect to proteins, including antibodies, if a preparation includes two or more different compounds of interest (e.g., two or more different antibodies, immunogens, functional domains, or other polypeptides of the invention), a "substantially pure" preparation is preferably one in which the total weight (dry weight) of all the compounds of interest is at least 60% of the total dry weight. Similarly, for such
10 preparations containing two or more compounds of interest, it is preferred that the total weight of the compounds of interest be at least 75%, more preferably at least 90%, and most preferably at least 99%, of the total dry weight of the preparation. Finally, in the event that the protein of interest is mixed with one or more other proteins (e.g., serum albumin) or compounds (e.g., diluents, excipients, salts,
15 polysaccharides, sugars, lipids) for purposes of administration, stability, storage, and the like, such other proteins or compounds may be ignored in calculation of the purity of the preparation.

Isolated nucleic acid. As used herein, an "isolated nucleic acid" is a ribonucleic acid, deoxyribonucleic acid, or nucleic acid analog comprising a
20 polynucleotide sequence that is isolated or separate from sequences that are immediately contiguous (one on the 5' end and one on the 3' end) in the naturally occurring genome of the organism from which it is derived. The term therefore includes, for example, a recombinant nucleic acid which is incorporated into a vector, into an autonomously replicating plasmid or virus, or into the genomic DNA of a
25 prokaryote or eukaryote; or which exists as a separate molecule (e.g., a cDNA or a genomic DNA fragment produced by PCR or restriction endonuclease treatment) independent of other sequences. It also includes a recombinant DNA which is part of a hybrid gene encoding additional polypeptide sequences and/or including exogenous regulatory elements.

Substantially identical sequence. As used herein, a "substantially identical" amino acid sequence is an amino acid sequence which differs only by conservative amino acid substitutions, for example, substitution of one amino acid for another of the same class (e.g., valine for glycine, arginine for lysine, etc.) or by one
5 or more non-conservative substitutions, deletions, or insertions located at positions of the amino acid sequence which do not destroy the function of the protein (assayed, e.g., as described herein). Preferably, such a sequence is at least 85%, more preferably 90%, and most preferably 95% identical at the amino acid level to the sequence of the protein or peptide to which it is being compared. For nucleic acids,
10 the length of comparison sequences will generally be at least 50 nucleotides, preferably at least 60 nucleotides, more preferably at least 75 nucleotides, and most preferably 110 nucleotides. A "substantially identical" nucleic acid sequence codes for a substantially identical amino acid sequence as defined above.

Transformed cell. As used herein, a "transformed cell" is a cell into which
15 (or into an ancestor of which) has been introduced, by means of recombinant DNA techniques, a nucleic acid molecule of interest. The nucleic acid of interest will typically encode a peptide or protein. The transformed cell may express the sequence of interest or may be used only to propagate the sequence. The term "transformed" may be used herein to embrace any method of introducing exogenous nucleic acids
20 including, but not limited to, transformation, transfection, electroporation, microinjection, viral-mediated transfection, and the like.

Operably joined. As used herein, a coding sequence and a regulatory region are said to be "operably joined" when they are covalently linked in such a way as to place the expression or transcription of the coding sequence under the influence or control
25 of the regulatory region. If it is desired that the coding sequences be translated into a functional protein, two DNA sequences are said to be operably joined if induction of promoter function results in the transcription of the coding sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the regulatory region to
30 direct the transcription of the coding sequences, or (3) interfere with the ability of the

corresponding RNA transcript to be translated into a protein. Thus, a regulatory region would be operably joined to a coding sequence if the regulatory region were capable of effecting transcription of that DNA sequence such that the resulting transcript might be translated into the desired protein or polypeptide.

5 Stringent hybridization conditions. Stringent hybridization conditions is a term of art understood by those of ordinary skill in the art. For any given nucleic acid sequence, stringent hybridization conditions are those conditions of temperature, chaotrophic acids, buffer, and ionic strength which will permit hybridization of that nucleic acid sequence to its complementary sequence and not to substantially different
10 sequences. The exact conditions which constitute "stringent" conditions, depend upon the nature of the nucleic acid sequence, the length of the sequence, and the frequency of occurrence of subsets of that sequence within other non-identical sequences. By varying hybridization conditions from a level of stringency at which non-specific hybridization occurs to a level at which only specific hybridization is observed, one of
15 ordinary skill in the art can, without undue experimentation, determine conditions which will allow a given sequence to hybridize only with complementary sequences. Suitable ranges of such stringency conditions are described in Krause and Aaronson (1991). Hybridization conditions, depending upon the length and commonality of a sequence, may include temperatures of 20°C-65°C and ionic strengths from 5x to 0.1x
20 SSC. Highly stringent hybridization conditions may include temperatures as low as 40-42°C (when denaturants such as formamide are included) or up to 60-65°C in ionic strengths as low as 0.1x SSC. These ranges, however, are only illustrative and, depending upon the nature of the target sequence, and possible future technological developments, may be more stringent than necessary. Less than stringent conditions
25 are employed to isolate nucleic acid sequences which are substantially similar, allelic or homologous to any given sequence.

Selectively binds. As used herein with respect to antibodies, an antibody is said to "selectively bind" to a target if the antibody recognizes and binds the target of interest but does not substantially recognize and bind other molecules in a sample,
30 e.g., a biological sample, which includes the target of interest. That is, the antibody

must bind to its target with sufficient specificity so as to distinguish the target from essentially all of molecules which would reasonably be present in a biological sample including the target.

II. The Presenilins and Presenilin-Interacting Proteins

5 The present invention is based, in part, upon the discovery of a family of mammalian genes which, when mutated, are associated with the development of Alzheimer's Disease. The discovery of these genes, designated presenilin-1 (PS1) and presenilin-2 (PS2), as well as the characterization of these genes, their protein products, mutants, invertebrate homologues, and possible functional roles, are
10 described in PCT Publication WO96/34099. The present invention is further based, in part, upon the discovery of a group of proteins which interact with the presenilins under physiological conditions and which, therefore, are believed to be involved in the biochemical pathways which are altered in Alzheimer's Disease. These proteins are referred to herein as presenilin-interacting (PS-interacting) proteins. Because
15 mutations in the presenilins are known to be causative of Alzheimer's Disease, each of the PS-interacting genes and proteins disclosed and described herein presents a novel target for therapeutic intervention in Alzheimer's Disease. That is, modulation of the interactions of these proteins with the presenilins, or modulation of the interactions of at least the PS-interacting domains of these PS-interacting proteins with at least the
20 interacting domains of the presenilins, provides a means of modulating the activity and/or availability of the presenilins, or of modulating the activity and/or availability of the PS-interacting proteins. Furthermore, as aberrations in the interactions of mutant presenilins with one or more of these PS-interacting proteins is causative of Alzheimer's Disease, mutations in one or more of these PS-interacting proteins are
25 also likely to be causative of Alzheimer's Disease. Therefore, each of the PS-interacting genes and proteins disclosed and described herein presents a novel target for diagnosis of forms of familial and/or sporadic Alzheimer's Disease with an etiology independent of mutations in the presenilins. Finally, as described more fully below, the PS-interacting genes and proteins described and disclosed herein provide
30 for new assays for compounds which affect the interactions of the presenilins and PS-

-12-

interacting proteins, assays for other members of the biochemical pathways involved in the etiology of Alzheimer's Disease, and new cell lines and transgenic animal models for use in such assays.

5 1. Presenilin Processing

Employing the antibodies and protein-binding assays described and/or enabled in PCT Publication WO96/34099, the processing and protein-protein interactions of both normal and mutant presenilins were investigated. It was found that mutations in the presenilins appear to lead to changes in both their intracellular
10 processing (e.g., endoproteolytic cleavage, ubiquitination, and clearance) and their intracellular interactions with other proteins expressed in human brain. As described below, knowledge of presenilin processing and interactions, and particularly changes in mutant presenilin processing and interactions, provides for new diagnostic and therapeutic targets for Alzheimer's Disease and related disorders.

15 Western blot analysis suggests that the normal presenilins undergo proteolytic cleavage to yield characteristic N- and C-terminal fragments. As noted above, the normal presenilin proteins have an expected molecular mass of 47-51 kDa depending, in part, upon mRNA splice variations, electrophoretic conditions, etc. Analysis of Western blots suggests, however, that the normal presenilin proteins
20 undergo proteolytic cleavage to yield an approximately 35 kDa N-terminal fragment and an approximately 18 kDa C-terminal fragment. In particular, Western blots bearing lysates from wild-type native human fibroblasts, human neocortical brain tissue from control subjects, and neocortical brain tissue from non-transgenic and PS1 transgenic mice using antibodies ("14.2") recognizing PS1-specific residues 1-25 at
25 the N-terminus reveal the presence of a strong immunoreactive band of approximately 35 kDa and, after longer exposures, a weaker band of approximately 45 kDa which presumably represents the full-length PS1 protein. Antibodies ("520") directed at residues 304-318 at the apex of the TM6→7 loop of PS1, and antibodies ("4627") directed at residues 457-467 in the C-terminus of PS1, both recognize the same strong
30 band of approximately 18 kDa. Antibodies 520 also recognize a weak band of 45 kDa

coincident with the PS1 band detected by 14.2. Sequencing of the major C-terminal fragment from PS1-transfected human embryonic kidney cells (HEK 293) showed that the principal endoproteolytic cleavage occurs near M298 in the proximal portion of the TM6→7 loop, possibly by enzymes other than the proteasome. These
5 observations suggest that an endoproteolytic cleavage event occurs near the junction of exons 9 and 10 of PS1. Full length PS1 in these cells is quickly turned over ($t_{1/2} < 60$ min.) by the proteasome.

To determine whether mutations in the presenilin proteins result in alterations of their proteolytic cleavage, Western blots containing lysates of fibroblast
10 and neocortical brain homogenates from normal subjects and subjects carrying PS1 mutations were investigated with the PS1 specific antibody Ab 14.2. In fibroblasts, there were no obvious differences in the relative intensities of the protein bands when lysates from heterozygous carriers of the PS1 mutations were compared with normal homozygotes. In contrast, there appeared to be a difference between PS1 mutation
15 carriers and normals in homogenates of temporal neocortex from AD affected heterozygous carriers of either the PS1 A246E or C410Y mutations (which are located in TM6 and TM7 respectively). In heterozygotes, a strongly immunoreactive band of approximately 45 kDa was detected which initially appeared to correspond to the full-length PS1 protein. Further analysis, however, revealed that this band represents an
20 alternatively processed presenilin product. A similar band corresponding to this mutant processed PS1 was observed in neocortical homogenates from some sporadic late-onset AD patients. These data suggest that (1) some pathogenic PS1 mutations associated with early-onset AD alter the way in which the presenilins are processed through endoproteolytic and proteasome pathways and (2) the presenilin proteins, and
25 changes in the processing of the presenilins in the brain, are also implicated in late-onset and sporadic AD.

2. Presenilin-Interacting Proteins

In order to identify proteins which may bind to or otherwise interact with
30 the presenilins in vivo, a yeast two-hybrid system was used as described below

-14-

(Example 1). In particular, because mutations in the TM6→7 loop domains are known to be causative of AD, a yeast two-hybrid system was used to identify cellular proteins which may interact with normal and mutant presenilin TM6→7 loop domains. Yeast two-hybrid studies were also done with cDNAs corresponding to the C-terminal 18 kDa endoproteolytic cleavage fragment, and with cDNAs corresponding to the TM1→2 intraluminal loop domain, which is also the site of the FAD associated Y115H missense mutation. In brief, cDNA sequences encoding the TM6→7 loop (i.e., residues 266 to 409 of PS1) were ligated in-frame to the GAL4 DNA-binding domain in the pAS2-1 yeast expression plasmid vector (Clontech). This plasmid was then co-transformed into *S. cerevisiae* strain Y190 together with a library of human brain cDNAs ligated into the pACT2 yeast expression vector bearing the GAL4 activation domain (Clontech). After appropriate selection and re-screening, a number of clones were recovered and sequenced bearing human brain cDNAs encoding peptides which interacted with the normal presenilin TM6→7 domain. To determine whether these presenilin interactions would be modified by AD related mutations within the TM6→7 loop, the yeast two-hybrid system was again used with TM6→7 loop peptides containing the L286V, the L392V, and the exon 10 splicing mutants. When these mutant constructs were used as "bait" to re-screen the brain cDNA:GAL4 activation domain library, some but not all of the brain cDNA sequences which interacted with the normal presenilin were recovered. In addition, several new clones were identified which interacted with the mutant but not the normal presenilins. The clones corresponding to the PS-interacting proteins with the highest presenilin affinity are described in Example 1 and below.

PS-interacting proteins, particularly those which interact selectively with either the normal or mutant presenilins, provide new targets for the identification of useful pharmaceuticals, new targets for diagnostic tools in the identification of individuals at risk, new sequences for the production of transformed cell lines and transgenic animal models, and new bases for therapeutic intervention in Alzheimer's Disease. In particular, the onset of AD may be associated with aberrant interactions between mutant presenilin proteins and normal forms of PS-interacting proteins such

as those identified using the methods described herein. These changes may increase or decrease interactions present with normal PS1 or may cause interaction with a novel mutation-specific PS-interacting protein. In addition, however, aberrant interactions may result from normal presenilins binding to mutant forms of the PS-interacting proteins and, therefore, mutations in the PS-interacting proteins may also be causative of AD.

A. The S5a Subunit of the 26S Proteasome

Two overlapping clones have been identified as representing a portion of the human protein alternatively known as Antisecretory Factor ("ASF") or the Multiubiquitin chain-binding S5a subunit of the 26S proteasome ("S5a"). These clones, which together include residues 70-377 of S5a, were shown to interact with the normal presenilin TM6→7 loop domain but only weakly with two TM6→7 loop domain mutants tested (L286V, L392V). The PS1:S5a interaction was confirmed by co-immunoprecipitation studies, and immunocytochemical studies showed S5a and PS1 are expressed in contiguous intracellular compartments in brain cells typically affected by AD.

The interaction between PS1 and the proteasome could be relevant to the pathogenesis of Alzheimer's Disease (AD) through several possible mechanisms. First, most mammalian cells seem to maintain very low levels of the PS1 holoprotein. A notable exception to this are cells expressing the PS1 Δ 290-319 splicing mutation, which results in a mutant PS1 holoprotein which is not endoproteolytically cleaved and which is, therefore, readily detectable. In the case of the Δ 290-319 splicing mutation at least, the presence of the mutant PS1 holoprotein, or the absence or reduction in the 35 kDa N-terminal and 18 kDa C-terminal fragments, appears sufficient to cause AD. It is possible, therefore, that even very subtle changes in the turnover of the mutant PS1 holoprotein might have significant pathophysiological effects. Thus, mutations in either the presenilins or S5a which perturb the PS1:S5a interaction in the mammalian CNS may cause the presenilin holoprotein to be aberrantly processed and cause AD. Therefore, modulation of presenilin proteolytic pathways might be applied therapeutically to enhance removal of mutant holoprotein.

-16-

To assess a potential in vivo relationship between PS1 and the S5a subunit of the 26S proteasome, the effects of proteasome inhibitors on PS1 metabolism were investigated. Short term organotypic cultures of neonatal rat hippocampus and carcinoma of colon (CaCo2) cells (which express high levels of both PS1 and PS2) were administered either the specific, reversible proteasome inhibitor N-acetyl-leuciny-leuciny-norleuciny-H (LLnL) (Rock et al., 1994), or the specific irreversible proteasome inhibitor lactacystin (Fenteany et al., 1995). Both agents caused an increase in the steady state levels of PS1 holoprotein. Both agents also prolonged the half-life of the PS1 holoprotein in pulse chase experiments in hippocampal slices from ~15 minutes to ~35 minutes. As noted above, the PS1 holoprotein appears to be rapidly turned over in normal cells. However, even after four hours of metabolic labelling, neither of the proteasome inhibitors affected the level of the 35 kDa N-terminal PS1 fragment, or resulted in the appearance of novel species. These studies imply that the majority of the PS1 holoprotein is catabolized directly via a rapid, proteasome dependent pathway in a manner similar to several other integral membrane proteins (e.g. Sec61 and CFTR). On the other hand, because the ~35 kDa and ~18 kDa terminal fragments are still produced in the presence of proteasome inhibitors, this endoproteolytic cleavage of PS1 is probably not mediated by the proteasome pathway. Therefore, it appears that at least two proteolytic pathways act upon the PS1 holoprotein.

An alternate possibility is that mutant PS1:S5a interactions may modify the function or the cellular regulation of S5a. To address this possibility, S5a levels were examined by Western blotting of lysates from postmortem temporal neocortex from non-AD neurologic controls (n = 8), sporadic AD (n = 8) and PS1-linked FAD (n = 4). In the majority of non-AD brains, polyclonal anti-S5a antibodies specifically detected an S5a species with Mr of ~ 50 kDa, which could be abolished by preabsorption of the antibody with recombinant His₆-S5a or with extracts of myc-S5a transfected cells. In a subset of these control cases an additional S5a reactive band was observed at ~34 kDa. In contrast, in tissue from all subjects with sporadic late onset AD, the predominant S5a reactive species was observed at ~ 40 kDa which was

not seen in control tissue. The origin, and the functional significance of this altered electrophoretic mobility is unclear but indicates that S5a processing is altered in AD brains, irrespective of whether the AD is presenilin-linked or sporadic.

Thus, the presenilin-proteasome interaction appears significant in several respects. First, the facts that the normal presenilin TM6→7 loop domain interacts with the S5a protein, that the mutant presenilin TM6→7 loop domains fail to interact (or interact very weakly) with the S5a protein, that presenilins bearing mutations in the TM6→7 loop domain appear to be differently cleaved and multiubiquitinated, that proteasomes are known to be involved in the cleavage and clearance of a variety of proteins (particularly multiubiquitinated proteins), that inhibition of proteasome activity inhibits cleavage of the presenilin holoproteins, and that S5a processing is altered in AD brains, all suggest (1) that the S5a subunit and the 26S proteasome are involved in the normal processing of the presenilins and that mutations which disrupt this normal interaction may be responsible for the abnormal processing observed in TM6→7 loop domain mutants; or (2) that the presenilin-proteasome interaction may modulate the activity of PS1, S5a, or both, with or without involving proteasome-mediated presenilin processing; or (3) that modulation of the normal quality control function of proteasome-mediated degradation of misfolded or mutant membrane proteins trafficking through the ER and Golgi (such as APP, Notch, or Prion proteins), and of misfolded, mutant, or ubiquitinated cytoplasmic proteins (including structural proteins such as tau, and short lived, proteasome processed signaling molecules such as NFkB). Thus, defective proteasome function might selectively cause these proteins (especially βAPP, tau, Prion) to be aberrantly metabolized. The latter would lead to the accumulation of neurotoxic, amyloidogenic protease-resistant derivatives such as Aβ and PrPsc, the accumulation of neurofibrillary tangles, and defective intracellular signaling functions. In support of these hypotheses, it should be noted that failure to clear hyperubiquitinated phosphorylated tau and other microtubule associated proteins is a prominent feature of Alzheimer's Disease (Kosik and Greenberg, 1994), suggesting a possible link between TM6→7 loop domain mutants, presenilin-proteasome interactions, tau-proteasome interactions, and the neurofibrillary tangles

-18-

of tau protein in AD brains. Finally, proteasomes are known to be capable of degrading APP and of binding the A β peptides which are associated with Alzheimer's Disease, suggesting a possible link between TM6 \rightarrow 7 loop domain mutants, presenilin-proteasome interactions, APP-proteasome interactions, and the amyloid
5 plaques characteristic of AD brains. Furthermore, administration of proteasome inhibitors such as LLnL and Lactacystin cause severe disturbances in β APP metabolism with increases in intracellular immature N-glycosylated β APP, and the secretion of much larger amounts of A β_{12} isoforms into the media (Klafki, et al., 1996).

10 Therefore, presenilin processing and the presenilin-proteasome interaction are clear targets for the diagnosis as well as therapeutic intervention in AD. Thus, as described below, assays may now be provided for drugs which affect the proteasome-mediated cleavage of the presenilins, which affect the alternative endoproteolytic cleavage and ubiquitination of the mutant presenilins, or which otherwise affect the
15 processing and trafficking of the presenilins or the S5a subunit of the proteasome. In addition, as mutations in the 26S proteasome which disrupt the normal processing of the presenilins are likely to be causative of Alzheimer's Disease, additional diagnostic assays are provided for detecting mutations in the S5a or other subunits of the proteasome. Finally, additional transformed cell lines and transgenic models may
20 now be provided which have been altered by the introduction of a normal or mutant sequence encoding at least a functional domain of the proteasome. The appearance of abnormal electrophoretic forms of S5a (and/or other proteasome subunits) in biologic tissues and fluids can be used as a clinical test for diagnosis and monitoring of disease activity in subjects with sporadic forms of AD.

25 B. GT24: A Protein with "Armadillo" Repeats

Another PS-interacting protein, designated GT24, was identified from several over-lapping clones obtained using a PS1₂₆₆₋₄₀₉ domain as bait in the yeast two-hybrid system and a human adult brain cDNA library. Six longer GT24 clones of
~3.8 kb in size were subsequently obtained by screening of conventional cDNA
30 libraries. The open reading frame within the longest GT24 clone obtained to date

(Accession number U81004) suggests that GT24 is a protein of at least 1040 amino acids with a unique N-terminus, and considerable homology to several armadillo (arm) repeat proteins at its C-terminus. Thus, for example, residues 440-862 of GT24 (numbering from Accession number U81004) have 32-56% identity ($p=1.2e^{-133}$) to residues 440-854 of murine p120 protein (Accession number Z17804), and residues 367-815 of GT24 have 26-42% identity ($p=0.0017$) to residues 245-465 of the D. melanogaster armadillo segment polarity protein (Accession number P18824). The GT24 gene maps to chromosome 5p15 near the anonymous microsatellite marker D5S748 and the Cri-du-Chat syndrome locus.

Hybridization of unique 5' sequences of GT24 to Northern blots reveals that the GT24 gene is expressed as a range of transcripts varying in size between ~3.9 and 5.0 kb in several regions of human brain, and in several non-neurologic tissues such as heart. In addition, in situ hybridization studies using a 289 bp single copy fragment from the 5' end of GT24 in four month old murine brain reveal GT24 transcription closely parallels that of PS1, with robust expression in dentate and hippocampal neurons, in scattered neocortical neurons, and in cerebellar Purkinje cells. In day E13 murine embryos, GT24 is widely expressed at low levels, but is expressed at somewhat higher levels in somites and in the neural tube. A physiological in vivo interaction between GT24 and PS1 is supported by co-immunoprecipitation studies in HEK293 cells transiently transfected with a wild type human PS1 cDNA, a c-myc-tagged cDNA encoding residues 484-1040 of GT24 (including the C-terminal arm repeats), or both cDNAs. Cell lysates were immunoprecipitated with anti-PS1 antibodies and then investigated for the presence of the myc-GT24 protein by immuno-blotting. In PS1/myc-GT24 double transfected cells, the immunoprecipitates contained a robust anti-myc reactive band of Mr ~60 kDa, which co-migrated with a myc-GT24 control. In cells transfected with myc-GT24 only, a very weak band was detected after long exposures, presumably reflecting interaction of the myc-GT24 with low levels of endogenous PS1. No myc-reactive bands were detected in cells transfected with PS1 alone, or in any of the transfected cells immunoprecipitated with pre-immune serum. Taken together, these

observations strongly suggest that the observed PS1:GT24 interaction is physiologically relevant.

To explore whether mutations in the TM6-TM7 loop of PS1 might influence the PS1:GT24 interaction, we employed quantitative liquid β -galactosidase assays to directly compare the yeast-two-hybrid interaction of the C-terminal residues 499-1040 of GT24 with wildtype and mutant PS1₂₆₆₋₄₀₉. These studies revealed that the interaction of GT24₄₉₉₋₁₀₄₀ with a L286V mutant PS1 domain was not significantly different from the interaction with the corresponding wild type PS1 domain. In contrast, there was a significant reduction in the GT24₄₉₉₋₁₀₄₀ interaction with the L392V mutant PS1 construct. The absence of an effect of the L286V mutation, and the presence of an effect with the L392V mutation, may suggest that some mutations may effect PS1:GT24 binding, while others may modulate the PS1 response to GT24 binding.

The PS1:GT24 interaction could support several functions. The arm repeat motif of GT24 has been detected in several proteins with diverse functions including β -catenin and its invertebrate homologue armadillo, plakoglobin, p120, the adenomatous polyposis coli (APC) gene, suppressor of RNA polymerase 1 in yeast (SRP1), and smGDS. For example, β -catenin, p120 and plakoglobin play an essential role in intercellular adhesion. β -catenin/armadillo is involved in transduction of wingless/Wnt signals during cell fate specification, and β -catenin and p120 may play a role in other receptor mediated signal transduction events including responses to trophic factors such as PDGF, EGF, CSF-1 and NGF.

If the PS1:GT24 interaction is part of intercellular signaling pathways for trophic factors, or is involved in cell-cell adherence, disruption of the interaction may be involved in the neurodegenerative processes in PS-linked FAD brains, and in the increased sensitivity of PS1 or PS2 transfected cells to apoptosis (Wolozin et al., 1996). It is of note that at least one arm protein, smGDS, stimulates GDP/GTP exchange on intracellular G-proteins (Kikuchi et al. 1992; Borguski et al., 1993), and that mutant forms of both β APP and PS2 are thought to activate programmed cell

death pathways through mechanisms involving heterotrimeric GTP/GDP proteins (Wolozin et al, 1996; Okamoto, et al., 1995; Yamatsuji, et al, 1996).

The interaction between PS1 and GT24 may also be involved in some of the developmental phenotypes associated with homozygous PS1 knockouts in mice
5 such as failed somitogenesis of the caudal embryo, short tail, and fatal cerebral hemorrhage at around day E13.5 (Wong et al., 1996). The resemblance of these skeletal phenotypes to those associated with null mutations in PAX1 and Notch, and the apparent suppressor effect of mutations in sel12 on Notch/lin12 mediated signaling in C. elegans suggest that the PS proteins function in the Notch signaling
10 pathway. In addition, mice homozygous for a knockout of the Wnt-3a gene (Takada et al., 1994), and murine homozygotes for a spontaneous mutation, "vestigial tail" or vt, in the Wnt-3a gene (Greco et al., 1996), have skeletal phenotypes of defective caudal somite and tail bud formation. The Wnt-3a knockouts are embryonic lethal by day 12.5. These phenotypes are similar to those of homozygous knockouts of the
15 murine PS1 gene (Wong et al., 1996). The observation that GT24 binds to PS1, is expressed in embryonic somites, and contains the armadillo repeat motif of other proteins used in the downstream signaling in the Wingless/Wnt pathway suggests that PS1 is a downstream element in the GT24-Wingless/Wnt pathway. This can be exploited to create a bioassay for drugs affecting the GT24-PS1 interaction directly, or
20 affecting upstream or downstream components of that interaction pathway, and can therefore be used to monitor the effects of presenilin mutations. For example, cells transfected with normal or mutant presenilins may be exposed to soluble Wnt-3a protein (or other Wnt proteins such as Wnt-1) and assayed for changes which are specific to the Wingless/Wnt signaling pathway, or for any of the other changes
25 described herein for cell assays (e.g., intracellular ion levels, A β processing, apoptosis, etc.).

Thus, the GT24 protein also presents new targets for diagnosis as well as therapeutic intervention in AD. For example, as mutations in the GT24 protein may also be causative of Alzheimer's Disease, additional diagnostic assays are provided for
30 detecting mutations in these sequences. Similarly, additional transformed cell lines

-22-

and transgenic models may now be provided which have been altered by introduction of a normal or mutant nucleic acid encoding at least a functional domain of the GT24 protein, and particularly the functional domains (e.g., residues 70-377) which interact with the presenilins. Such transformed cells and transgenics will have utility in assays for compounds which modulate the presenilin-GT24 interactions.

C. p0071: A Protein with "Armadillo" Repeats

Another independent clone isolated in the initial screening with the wild type PS1₂₆₆₋₄₀₉ "bait" also encodes a peptide with C-terminal arm repeats (clone Y2H25, Accession number U81005). A longer cDNA sequence corresponding to the Y2H25 clone has been deposited with GenBank as human protein p0071 (Accession number X81889) and is reproduced herein as SEQ ID NO: 5. Clone Y2H25 corresponds essentially to nucleotide positions 1682-1994 of SEQ ID NO: 5. Comparison of the predicted sequence of the Y2H25/p0071 ORF with that of GT24 confirms that they are related proteins with 47% overall amino acid sequence identity, and with 70% identity between residues 346-862 of GT24 and residues 509-1022 of p0071. This suggests that PS1 interacts with a novel class of arm repeat containing proteins. The broad ~4.5 kb hybridization signal obtained on Northern blots with the unique 5' end of GT24 could reflect either alternative splicing/polyadenylation of GT24 or, less likely, the existence of additional members of this family with higher degrees of N-terminal homology to GT24 than p0071. Cells transformed with these sequences, or transgenic animals including these sequences, will have additional utility as animal models of AD and for use in screening for compounds which modulate the action of normal and mutant presenilins.

D. Rab 11

One clone (Y2H9), disclosed herein as SEQ ID NO: 5, was identified as interacting with the normal PS1 TM6→7 loop domain and appears to correspond to a known gene, Rab11, available through Accession numbers X56740 and X53143. Rab11 is believed to be involved in protein/vesicle trafficking in the ER/Golgi. Note the possible relationship to processing of membrane proteins such as β APP and Notch

-23-

with resultant overproduction of toxic A β peptides (especially neurotoxic A $\beta_{1-42(43)}$ isoforms) (Scheuner, et al, 1995).

E. Retinoid X Receptor- β

One clone (Y2H23b), disclosed herein as SEQ ID NO: 6, was identified as
5 interacting with the normal PS1 TM6 \rightarrow 7 loop domain and appears to correspond to a
known gene, known variously as the retinoid X receptor- β , nuclear receptor co-
regulator, or MHC Class I regulatory element, and is available through Accession
numbers M84820, X63522 and M81766. This gene is believed to be involved in
intercellular signaling, suggesting a possible relationship to the intercellular signaling
10 function mediated by C. elegans sell2 and Notch/lin-12 (transcription activator).

F. Cytoplasmic Chaperonin

One clone (Y2H27), disclosed herein as SEQ ID NO: 8, was identified as
interacting with the normal PS1 TM6 \rightarrow 7 loop domain and appears to correspond to a
known gene, a cytoplasmic chaperonin containing TCP-1, available through
15 Accession numbers U17104 and X74801.

G. Clone Y2H35

One clone (Y2H35), disclosed herein as SEQ ID NO: 7, was identified as
interacting with the normal PS1 TM6 \rightarrow 7 loop domain and appears to correspond to a
sequence that codes for a protein of unknown function, available through Accession
20 number R12984, but which displays evolutionary conservation in yeast sequences.

H. Clone Y2H171

One clone (Y2H171), disclosed herein as SEQ ID NO: 9, was identified as
interacting with the normal PS1 TM6 \rightarrow 7 loop domain and appears to correspond to a
known expressed repeat sequence available through Accession number D55326.

25 I. Clone Y2H41

One clone (Y2H41) was identified which reacts strongly with the TM6 \rightarrow 7
loop domains of both PS1 and PS2 as well as the mutant loop domains of PS1. The
sequence, disclosed as SEQ ID NO: 10, shows strong homology to an EST of
unknown function (Accession number T64843).

III. Preferred Embodiments

Based, in part, upon the discoveries disclosed and described herein, the following preferred embodiments of the present invention are provided.

5

1. Isolated Nucleic Acids

In one series of embodiments, the present invention provides isolated nucleic acids corresponding to, or relating to, the nucleic acid sequences disclosed herein, which encode at least the PS-interacting domain of a PS-interacting protein.

10 As described more fully below, the disclosed and enabled sequences include normal sequences from humans and other mammalian species, mutant sequences from humans and other mammalian species, homologous sequences from non-mammalian species such as Drosophila and C. elegans, subsets of these sequences useful as probes and PCR primers, subsets of these sequences encoding fragments of the PS-interacting
15 proteins or corresponding to particular structural domains or polymorphic regions, complementary or antisense sequences corresponding to fragments of the PS-interacting protein genes, sequences in which the PS-interacting protein coding regions have been operably joined to exogenous regulatory regions, and sequences encoding fusion proteins in which portions of the PS-interacting proteins are fused to
20 other proteins useful as markers of expression, as "tags" for purification, or in screens and assays for other proteins which interact with the PS-interacting proteins.

Thus, in a first series of embodiments, isolated nucleic acid sequences are provided which encode at least a PS-interacting domain of a normal or mutant version of a PS-interacting protein. Examples of such nucleic acid sequences are disclosed
25 herein as SEQ ID NOs: 1, 3, and 5-10. In addition, given the sequences of the PS-interacting domains of the PS-interacting proteins disclosed herein, one of ordinary skill in the art is clearly enabled to obtain the entire genomic or cDNA sequence encoding the entire PS-interacting proteins. Thus, for example, based upon the initial clone of the GT24 protein obtained using the yeast two-hybrid system (Example 1),
30 the larger GT24 clone disclosed as SEQ ID NO: 3 was obtained by standard methods

known in the art. Complete cDNA or genomic clones of each of the genes encoding the disclosed sequences may be similarly obtained by one of ordinary skill in the art. Therefore, the present invention provides complete genomic sequences as well as cDNA sequences corresponding to the PS-interacting protein genes of the invention.

5 Alternatively, the nucleic acids of the invention may comprise recombinant genes or "minigenes" in which all or some introns of the PS-interacting protein genes have been removed, or in which various combinations of introns and exons and local cis-acting regulatory elements have been engineered in propagation or expression constructs or vectors. For purposes of reducing the size of a recombinant PS-
10 interacting protein gene, a cDNA gene may be employed, or various combinations of introns and untranslated exons may be removed from a DNA construct. These and many variations on these embodiments are now enabled by the identification and description of the PS-interacting proteins provided herein.

In addition to the disclosed PS-interacting protein and gene sequences, one
15 of ordinary skill in the art is now enabled to identify and isolate nucleic acids representing PS-interacting genes or cDNAs which are allelic to the disclosed sequences or which are heterospecific homologues. Thus, the present invention provides isolated nucleic acids corresponding to these alleles and homologues, as well as the various above-described recombinant constructs derived from these sequences,
20 by means which are well known in the art. Briefly, one of ordinary skill in the art may now screen preparations of genomic or cDNA, including samples prepared from individual organisms (e.g., human AD patients or their family members) as well as bacterial, viral, yeast or other libraries of genomic or cDNA, using probes or PCR primers to identify allelic or homologous sequences. Because it is desirable to
25 identify mutations in the PS-interacting proteins which may contribute to the development of AD or other disorders, because it is desirable to identify polymorphisms in the PS-interacting proteins which are not pathogenic, and because it is also desirable to create a variety of animal models which may be used to study AD and screen for potential therapeutics, it is particularly contemplated that additional
30 PS-interacting protein sequences will be isolated from other preparations or libraries

-26-

of human nucleic acids and from preparations or libraries from animals including rats, mice, hamsters, guinea pigs, rabbits, dogs, cats, goats, sheep, pigs, and non-human primates. Furthermore, PS-interacting protein homologues from yeast or invertebrate species, including C. elegans and other nematodes, as well as Drosophila and other insects, may have particular utility for drug screening.

Standard hybridization screening or PCR techniques may be employed (as used, for example, in the identification of the mPS1 gene disclosed in PCT Publication WO96/34099) to identify and/or isolate such allelic and homologous sequences using relatively short PS-interacting protein gene sequences. The sequences may include 8 or fewer nucleotides depending upon the nature of the target sequences, the method employed, and the specificity required. Future technological developments may allow the advantageous use of even shorter sequences. With current technology, sequences of 9-50 nucleotides, and preferably about 18-24 are preferred. These sequences may be chosen from those disclosed herein, or may be derived from other allelic or heterospecific homologues enabled herein. When probing mRNA or screening cDNA libraries, probes and primers from coding sequences (rather than introns) are preferably employed, and sequences which are omitted in alternative splice variants typically are avoided unless it is specifically desired to identify those variants. Allelic variants of the PS-interacting protein genes may be expected to hybridize to the disclosed sequences under stringent hybridization conditions, as defined herein, whereas lower stringency may be employed to identify heterospecific homologues.

In another series of embodiments, the present invention provides for isolated nucleic acids which include subsets of the PS-interacting protein sequences or their complements. As noted above, such sequences will have utility as probes and PCR primers in the identification and isolation of allelic and homologous variants of the PS-interacting protein genes. Subsequences corresponding to polymorphic regions of the PS-interacting proteins, will also have particular utility in screening and/or genotyping individuals for diagnostic purposes, as described below. In addition, and also as described below, such subsets will have utility for encoding (1)

fragments of the PS-interacting proteins for inclusion in fusion proteins, (2) fragments which comprise functional domains of the PS-interacting proteins for use in binding studies, (3) fragments of the PS-interacting proteins which may be used as immunogens to raise antibodies against the PS-interacting proteins, and (4) fragments of the PS-interacting proteins which may act as competitive inhibitors or as mimetics of the PS-interacting proteins to inhibit or mimic their physiological functions. Finally, such subsets may encode or represent complementary or antisense sequences which can hybridize to the PS-interacting protein genes or PS-interacting protein mRNA transcripts under physiological conditions to inhibit the transcription or translation of those sequences. Therefore, depending upon the intended use, the present invention provides nucleic acid subsequences of the PS-interacting protein genes which may have lengths varying from 8-10 nucleotides (e.g., for use as PCR primers) to nearly the full size of the PS-interacting protein genomic or cDNAs. Thus, the present invention provides isolated nucleic acids comprising sequences corresponding to at least 8-10, preferably 15, and more preferably at least 20 consecutive nucleotides of the PS-interacting protein genes, as disclosed or otherwise enabled herein, or to their complements. As noted above, however, shorter sequences may be useful with different technologies.

In another series of embodiments, the present invention provides nucleic acids in which the coding sequences for the PS-interacting proteins, with or without introns or recombinantly engineered as described above, are operably joined to endogenous or exogenous 5' and/or 3' regulatory regions. Using the present disclosure and standard genetic techniques (e.g., PCR extensions, targeting gene walking), one of ordinary skill in the art is now enabled to clone the 5' and/or 3' endogenous regulatory regions of any of the disclosed PS-interacting protein genes. Similarly, allelic variants of these endogenous regulatory regions, as well as endogenous regulatory regions from other mammalian homologues, are similarly enabled without undue experimentation. Alternatively, exogenous regulatory regions (i.e., regulatory regions from a different conspecific gene or a heterospecific regulatory region) may be operably joined to the PS-interacting protein coding sequences in order to drive

-28-

expression. Appropriate 5' regulatory regions will include promoter elements and may also include additional elements such as operator or enhancer sequences, ribosome binding sequences, RNA capping sequences, and the like. The regulatory region may be selected from sequences that control the expression of genes of

5 prokaryotic or eukaryotic cells, their viruses, and combinations thereof. Such regulatory regions include, but are not limited to, the lac system, the trp system, the tac system, and the trc system; major operator and promoter regions of phage λ ; the control region of the fd coat protein; early and late promoters of SV40; promoters derived from polyoma, adenovirus, retrovirus, baculovirus, and simian virus; 3-

10 phosphoglycerate kinase promoter; yeast acid phosphatase promoters; yeast alpha-mating factors; promoter elements of other eukaryotic genes expressed in neurons or other cell types; and combinations thereof. In particular, regulatory elements may be chosen which are inducible or repressible (e.g., the β -galactosidase promoter) to allow for controlled and/or manipulable expression of the PS-interacting protein genes in

15 cells transformed with these nucleic acids. Alternatively, the PS-interacting protein coding regions may be operably joined with regulatory elements which provide for tissue specific expression in multicellular organisms. Such constructs are particularly useful for the production of transgenic organisms to cause expression of the PS-interacting protein genes only in appropriate tissues. The choice of appropriate

20 regulatory regions is within the ability and discretion of one of ordinary skill in the art and the recombinant use of many such regulatory regions is now established in the art.

In another series of embodiments, the present invention provides for isolated nucleic acids encoding all or a portion of the PS-interacting proteins in the form of a fusion protein. In these embodiments, a nucleic acid regulatory region

25 (endogenous or exogenous) is operably joined to a first coding region which is covalently joined in-frame to a second coding region. The second coding region optionally may be covalently joined to one or more additional coding regions and the last coding region is joined to a termination codon and, optionally, appropriate 3' regulatory regions (e.g., polyadenylation signals). The PS-interacting protein

30 sequences of the fusion protein may represent the first, second, or any additional

coding regions. The PS-interacting protein sequences may be conserved or non-conserved domains and can be placed in any coding region of the fusion. The non-PS-interacting protein sequences of the fusion may be chosen according to the needs and discretion of the practitioner and are not limited by the present invention. Useful
5 non-PS-interacting protein sequences include, for example, short sequence "tags" such as antigenic determinants or poly-His tags which may be used to aid in the identification or purification of the resultant fusion protein. Alternatively, the non-PS-interacting protein coding region may encode a large protein or protein fragment, such as an enzyme or binding protein which also may assist in the identification and
10 purification of the protein, or which may be useful in an assay such as those described below. Particularly contemplated fusion proteins include poly-His and GST (glutathione S-transferase) fusions which are useful in isolating and purifying the presenilins-interacting proteins, and the yeast two hybrid fusions, described below, which are useful in assays to identify other proteins which bind to or interact with the
15 PS-interacting proteins.

In another series of embodiments, the present invention provides isolated nucleic acids in the form of recombinant DNA constructs in which a marker or reporter gene (e.g., β -galactosidase, luciferase) is operably joined to the 5' regulatory region of a PS-interacting protein gene such that expression of the marker gene is
20 under the control of those regulatory sequences. Using the PS-interacting protein regulatory regions enabled herein, including regulatory regions from human and other mammalian species, one of ordinary skill in the art is now enabled to produce such constructs. As discussed more fully below, such isolated nucleic acids may be used to produce cells, cell lines or transgenic animals which are useful in the identification of
25 compounds which can, directly or indirectly, differentially affect the expression of the PS-interacting proteins.

Finally, the isolated nucleic acids of the present invention include any of the above described sequences when included in vectors. Appropriate vectors include cloning vectors and expression vectors of all types, including plasmids, phagemids,
30 cosmids, episomes, and the like, as well as integration vectors. The vectors may also

-30-

include various marker genes (e.g., antibiotic resistance or susceptibility genes) which are useful in identifying cells successfully transformed therewith. In addition, the vectors may include regulatory sequences to which the nucleic acids of the invention are operably joined, and/or may also include coding regions such that the nucleic acids of the invention, when appropriately ligated into the vector, are expressed as fusion proteins. Such vectors may also include vectors for use in yeast "two hybrid," baculovirus, and phage-display systems. The vectors may be chosen to be useful for prokaryotic, eukaryotic or viral expression, as needed or desired for the particular application. For example, vaccinia virus vectors or simian virus vectors with the SV40 promoter (e.g., pSV2), or Herpes simplex virus or adeno-associated virus may be useful for transfection of mammalian cells including neurons in culture or *in vivo*, and the baculovirus vectors may be used in transfecting insect cells (e.g., butterfly cells). A great variety of different vectors are now commercially available and otherwise known in the art, and the choice of an appropriate vector is within the ability and discretion of one of ordinary skill in the art.

2. Substantially Pure Proteins

The present invention provides for substantially pure preparations of the PS-interacting proteins, fragments of the PS-interacting proteins, and fusion proteins including the PS-interacting proteins or fragments thereof. The proteins, fragments and fusions have utility, as described herein, in the generation of antibodies to normal and mutant PS-interacting proteins, in the identification of proteins (aside from the presenilins) which bind to the PS-interacting proteins, and in diagnostic and therapeutic methods. Therefore, depending upon the intended use, the present invention provides substantially pure proteins or peptides comprising amino acid sequences which are subsequences of the complete PS-interacting proteins and which may have lengths varying from 4-10 amino acids (e.g., for use as immunogens), or 10-100 amino acids (e.g., for use in binding assays), to the complete PS-interacting proteins. Thus, the present invention provides substantially pure proteins or peptides comprising sequences corresponding to at least 4-5, preferably 6-10, and more

preferably at least 50 or 100 consecutive amino acids of the PS-interacting proteins, as disclosed or otherwise enabled herein.

The proteins or peptides of the invention may be isolated and purified by any of a variety of methods selected on the basis of the properties revealed by their protein sequences. For example, the PS-interacting proteins may be isolated from
5 cells in which the PS-interacting protein is normally highly expressed. Alternatively the PS-interacting protein, fusion protein, or fragment thereof, may be purified from cells transformed or transfected with expression vectors (e.g., baculovirus systems such as the pPbac and pMbac vectors (Stratagene, La Jolla, CA); yeast expression
10 systems such as the pYESHIS Xpress vectors (Invitrogen, San Diego, CA); eukaryotic expression systems such as pcDNA3 (Invitrogen, San Diego, CA) which has constant constitutive expression, or LacSwitch (Stratagene, La Jolla, CA) which is inducible; or prokaryotic expression vectors such as pKK233-3 (Clontech, Palo Alto, CA). In the event that the protein or fragment integrates into the endoplasmic reticulum or
15 plasma membrane of the recombinant cells (e.g., eukaryotic cells), the protein may be purified from the membrane fraction. Alternatively, if the protein aggregates in inclusion bodies within the recombinant cells (e.g., prokaryotic cells), the protein may be purified from whole lysed cells or from solubilized inclusion bodies.

Purification can be achieved using standard protein purification procedures
20 including, but not limited to, gel-filtration chromatography, ion-exchange chromatography, high-performance liquid chromatography (RP-HPLC, ion-exchange HPLC, size-exclusion HPLC, high-performance chromatofocusing chromatography, hydrophobic interaction chromatography, immunoprecipitation, or immunoaffinity purification. Gel electrophoresis (e.g., PAGE, SDS-PAGE) can also be used to isolate
25 a protein or peptide based on its molecular weight, charge properties and hydrophobicity.

A PS-interacting protein, or a fragment thereof, may also be conveniently purified by creating a fusion protein including the desired PS-interacting protein sequence fused to another peptide such as an antigenic determinant or poly-His tag
30 (e.g., QIAexpress vectors, QIAGEN Corp., Chatsworth, CA), or a larger protein (e.g.,

-32-

GST using the pGEX-27 vector (Amrad, USA) or green fluorescent protein using the Green Lantern vector (GIBCO/BRL, Gaithersburg, MD). The fusion protein may be expressed and recovered from prokaryotic or eukaryotic cells and purified by any standard method based upon the fusion vector sequence. For example, the fusion
5 protein may be purified by immunoaffinity or immunoprecipitation with an antibody to the non-PS-interacting protein portion of the fusion or, in the case of a poly-His tag, by affinity binding to a nickel column. The desired PS-interacting protein or fragment may then be further purified from the fusion protein by enzymatic cleavage of the fusion protein. Methods for preparing and using such fusion constructs for the
10 purification of proteins are well known in the art and several kits are commercially available for this purpose. In light of the present disclosure, one is now enabled to employ such fusion constructs with the PS-interacting proteins.

3. Antibodies to the PS-interacting Proteins

15 The present invention also provides antibodies, and methods of making antibodies, which selectively bind to the PS-interacting proteins or fragments thereof. Of particular importance, by identifying the PS-interacting domains of the PS-interacting proteins, and methods of identifying mutant forms of the PS-interacting proteins associated with Alzheimer's Disease, the present invention provides
20 antibodies, and methods of making antibodies, which will selectively bind to and, thereby, identify and/or distinguish normal and mutant (i.e., pathogenic) forms of the PS-interacting proteins. The antibodies of the invention have utility as laboratory reagents for, inter alia, immunoaffinity purification of the PS-interacting proteins, Western blotting to identify cells or tissues expressing the PS-interacting proteins, and
25 immunocytochemistry or immunofluorescence techniques to establish the subcellular location of the proteins. In addition, as described below, the antibodies of the invention may be used as diagnostics tools to identify carriers of AD-related PS-interacting protein alleles, or as therapeutic tools to selectively bind and inhibit pathogenic forms of the PS-interacting proteins in vivo.

The antibodies of the invention may be generated using the entire PS-interacting proteins of the invention, or using any PS-interacting protein epitope which is characteristic of that protein and which substantially distinguishes it from other host proteins. Any method of choosing antigenic determinants known in the art may, of course, be employed. Such epitopes may be identified by comparing
5 sequences of, for example, 4-10 amino acid residues from a PS-interacting protein sequence to computer databases of protein sequences from the relevant host. In addition, larger fragments (e.g., 8-20 or, preferably, 9-15 residues) including one or more potential epitopes may also be employed. Antibodies to the PS-interacting
10 domains (identified by the yeast two-hybrid assays described below) are expected to have the greatest utility both diagnostically and therapeutically. On the other hand, antibodies against highly conserved domains are expected to have the greatest utility for purification or identification of PS-interacting proteins.

PS-interacting protein immunogen preparations may be produced from
15 crude extracts (e.g., lysates or membrane fractions of cells highly expressing the proteins), from proteins or peptides substantially purified from cells which naturally or recombinantly express them or, for short immunogens, by chemical peptide synthesis. The immunogens may also be in the form of a fusion protein in which the non-PS-interacting protein region is chosen for its adjuvant properties. As used
20 herein, a PS-interacting protein immunogen shall be defined as a preparation including a peptide comprising at least 4-8, and preferably at least 9-15 consecutive amino acid residues of a PS-interacting proteins, as disclosed or otherwise enabled herein. Sequences of fewer residues may, of course, also have utility depending upon the intended use and future technological developments. Therefore, any PS-
25 interacting protein derived sequences which are employed to generate antibodies to the PS-interacting proteins should be regarded as PS-interacting protein immunogens.

The antibodies of the invention may be polyclonal or monoclonal, or may be antibody fragments, including Fab fragments, $F(ab')_2$, and single chain antibody fragments. In addition, after identifying useful antibodies by the method of the
30 invention, recombinant antibodies may be generated, including any of the antibody

-34-

fragments listed above, as well as humanized antibodies based upon non-human antibodies to the PS-interacting proteins. In light of the present disclosure, as well as the characterization of other PS-interacting proteins enabled herein, one of ordinary skill in the art may produce the above-described antibodies by any of a variety of standard means well known in the art. For an overview of antibody techniques, see 5 Antibody Engineering: A Practical Guide, Borrebaek, ed., W.H. Freeman & Company, NY (1992), or Antibody Engineering, 2nd Ed., Borrebaek, ed., Oxford University Press, Oxford (1995).

As a general matter, polyclonal antibodies may be generated by first immunizing a mouse, rabbit, goat or other suitable animal with the PS-interacting protein immunogen in a suitable carrier. To increase the immunogenicity of the preparation, the immunogen may be coupled to a carrier protein or mixed with an adjuvant (e.g., Freund's adjuvant). Booster injections, although not necessary are recommended. After an appropriate period to allow for the development of a humoral response, preferably several weeks, the animals may be bled and the sera may be 15 purified to isolate the immunoglobulin component.

Similarly, as a general matter, monoclonal anti-PS-interacting protein antibodies may be produced by first injecting a mouse, rabbit, goat or other suitable animal with a PS-interacting protein immunogen in a suitable carrier. As above, 20 carrier proteins or adjuvants may be utilized and booster injections (e.g., bi- or tri-weekly over 8-10 weeks) are recommended. After allowing for development of a humoral response, the animals are sacrificed and their spleens are removed and resuspended in, for example, phosphate buffered saline (PBS). The spleen cells serve as a source of lymphocytes, some of which are producing antibody of the appropriate specificity. These cells are then fused with an immortalized cell line (e.g., myeloma), 25 and the products of the fusion are plated into a number of tissue culture wells in the presence of a selective agent such as HAT. The wells are serially screened and replated, each time selecting cells making useful antibody. Typically, several screening and replating procedures are carried out until over 90% of the wells contain 30 single clones which are positive for antibody production. Monoclonal antibodies

-35-

produced by such clones may be purified by standard methods such as affinity chromatography using Protein A Sepharose, by ion-exchange chromatography, or by variations and combinations of these techniques.

5 The antibodies of the invention may be labelled or conjugated with other compounds or materials for diagnostic and/or therapeutic uses. For example, they may be coupled to radionuclides, fluorescent compounds, or enzymes for imaging or therapy, or to liposomes for the targeting of compounds contained in the liposomes to a specific tissue location.

10 4. Transformed Cell Lines

The present invention also provides for cells or cell lines, both prokaryotic and eukaryotic, which have been transformed or transfected with the nucleic acids of the present invention so as to cause clonal propagation of those nucleic acids and/or expression of the proteins or peptides encoded thereby. Such cells or cell lines will
15 have utility both in the propagation and production of the nucleic acids and proteins of the present invention but also, as further described herein, as model systems for diagnostic and therapeutic assays. In particular, it is expected that cells co-transformed with PS-interacting protein sequences as well as presenilin sequences will have improved utility as models of the biochemical pathways which may be affected
20 in AD. For example, cells co-transformed with the interacting domains of PS-interacting sequences and presenilins in yeast two-hybrid fusion constructs, will have utility in screening for compounds which either enhance or inhibit interactions between these domains. Similarly, for cells transformed with a heterospecific presenilin, co-transformation with a similarly heterospecific PS-interacting protein, or
25 co-transformation and homologous recombination to introduce a similarly heterospecific PS-interacting domain of a PS-interacting protein (e.g., "humanizing" a non-human endogenous PS-interacting protein), will result in a better model system for studying the interactions of the presenilins and the PS-interacting proteins. Cells transformed with only PS-interacting sequences will, of course, have utility of their

own for studying the role of these proteins in the etiology of AD, and also as precursors for presenilin co-transformed cells.

As used herein, the term "transformed cell" is intended to embrace any cell, or the descendant of any cell, into which has been introduced any of the nucleic acids of the invention, whether by transformation, transfection, infection, or other means. Methods of producing appropriate vectors, transforming cells with those vectors, and identifying transformants are well known in the art and are only briefly reviewed here (see, for example, Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York).

Prokaryotic cells useful for producing the transformed cells of the invention include members of the bacterial genera Escherichia (e.g., E. coli), Pseudomonas (e.g., P. aeruginosa), and Bacillus (e.g., B. subtilis, B. stearothermophilus), as well as many others well known and frequently used in the art. Prokaryotic cells are particularly useful for the production of large quantities of the proteins or peptides of the invention (e.g., normal or mutant PS-interacting proteins, fragments of the PS-interacting proteins, fusion proteins of the PS-interacting proteins). Bacterial cells (e.g., E. coli) may be used with a variety of expression vector systems including, for example, plasmids with the T7 RNA polymerase/promoter system, bacteriophage λ regulatory sequences, or M13 Phage mGPI-2. Bacterial hosts may also be transformed with fusion protein vectors which create, for example, lacZ, trpE, maltose-binding protein, poly-His tags, or glutathione-S-transferase fusion proteins. All of these, as well as many other prokaryotic expression systems, are well known in the art and widely available commercially (e.g., pGEX-27 (Amrad, USA) for GST fusions).

Eukaryotic cells and cell lines useful for producing the transformed cells of the invention include mammalian cells and cell lines (e.g., PC12, COS, CHO, fibroblasts, myelomas, neuroblastomas, hybridomas, human embryonic kidney 293, oocytes, embryonic stem cells), insect cells lines (e.g., using baculovirus vectors such as pPbac or pMbac (Stratagene, La Jolla, CA)), yeast (e.g., using yeast expression

vectors such as pYESHIS (Invitrogen, CA)), and fungi. Eukaryotic cells are particularly useful for embodiments in which it is necessary that the PS-interacting proteins, or functional fragments thereof, perform the functions and/or undergo the intracellular interactions associated with either the normal or mutant proteins. Thus, for example, transformed eukaryotic cells are preferred for use as models of PS-interacting protein function or interaction, and assays for screening candidate therapeutics preferably employ transformed eukaryotic cells.

To accomplish expression in eukaryotic cells, a wide variety of vectors have been developed and are commercially available which allow inducible (e.g., LacSwitch expression vectors, Stratagene, La Jolla, CA) or cognate (e.g., pcDNA3 vectors, Invitrogen, Chatsworth, CA) expression of PS-interacting protein nucleotide sequences under the regulation of an artificial promoter element. Such promoter elements are often derived from CMV or SV40 viral genes, although other strong promoter elements which are active in eukaryotic cells can also be employed to induce transcription of PS-interacting protein nucleotide sequences. Typically, these vectors also contain an artificial polyadenylation sequence and 3' UTR which can also be derived from exogenous viral gene sequences or from other eukaryotic genes. Furthermore, in some constructs, artificial, non-coding, spliceable introns and exons are included in the vector to enhance expression of the nucleotide sequence of interest. These expression systems are commonly available from commercial sources and are typified by vectors such as pcDNA3 and pZeoSV (Invitrogen, San Diego, CA). Innumerable commercially-available as well as custom-designed expression vectors are available from commercial sources to allow expression of any desired PS-interacting protein transcript in more or less any desired cell type, either constitutively or after exposure to a certain exogenous stimulus (e.g., withdrawal of tetracycline or exposure to IPTG).

Vectors may be introduced into the recipient or "host" cells by various methods well known in the art including, but not limited to, calcium phosphate transfection, strontium phosphate transfection, DEAE dextran transfection, electroporation, lipofection (e.g., Dosper Liposomal transfection reagent, Boehringer

Mannheim, Germany), microinjection, ballistic insertion on micro-beads, protoplast fusion or, for viral or phage vectors, by infection with the recombinant virus or phage.

5. Transgenic Animal Models

5 The present invention also provides for the production of transgenic non-human animal models in which mutant or wild type PS-interacting protein sequences are expressed, or in which the PS-interacting protein genes have been inactivated (e.g., "knock-out" deletions), for the study of Alzheimer's Disease, for the screening of candidate pharmaceutical compounds, for the creation of explanted mammalian CNS
10 cell cultures (e.g., neuronal, glial, organotypic or mixed cell cultures), and for the evaluation of potential therapeutic interventions. Prior to the present invention, a partial animal model for Alzheimer's Disease existed via the insertion and over-expression of a mutant form of the human amyloid precursor protein gene as a minigene under the regulation of the platelet-derived growth factor β receptor
15 promoter element (Games et al., 1995). This mutant (β APP₇₁₇ Val \rightarrow Ile) causes the appearance of synaptic pathology and amyloid β peptide deposition in the brain of transgenic animals bearing this transgene in high copy number. These changes in the brain of the transgenic animal are very similar to that seen in human AD (Games et al., 1995). It is, however, as yet unclear whether these animals become demented, but
20 there is general consensus that it is now possible to recreate at least some aspects of AD in mice. In addition, transgenic animal models in which the presenilin genes are genetically engineered are disclosed in PCT Publication WO96/34099. These transgenic animal models have been shown to have altered A β production and altered hippocampus-dependent memory function.

25 Animal species suitable for use in the animal models of the present invention include, but are not limited to, rats, mice, hamsters, guinea pigs, rabbits, dogs, cats, goats, sheep, pigs, and non-human primates (e.g., Rhesus monkeys, chimpanzees). For initial studies, transgenic rodents (e.g., mice) may be preferred due to their relative ease of maintenance and shorter life spans. However, transgenic yeast
30 or invertebrates (e.g., nematodes, insects) may be preferred for some studies because

they will allow for even more rapid and inexpensive screening. For example, invertebrates bearing mutant PS-interacting protein homologues (or mammalian PS-interacting protein transgenes) which cause a rapidly occurring and easily scored phenotype (e.g., abnormal vulva or eye development after several days) can be used as
5 screens for drugs which block the effect of the mutant gene. Such invertebrates may prove far more rapid and efficient for mass screenings than larger vertebrate animals. Once lead compounds are found through such screens, they may be tested in higher animals such as rodents. Ultimately, transgenic non-human primates may be preferred for longer term studies due to their greater similarity to humans and their higher
10 cognitive abilities.

Using the nucleic acids disclosed and otherwise enabled herein, there are now several available approaches for the creation of a transgenic animal model for Alzheimer's Disease. Thus, the enabled animal models include: (1) Animals in which sequences encoding at least a functional domain of a normal human PS-interacting
15 protein gene have been recombinantly introduced into the genome of the animal as an additional gene, under the regulation of either an exogenous or an endogenous promoter element, and as either a minigene or a large genomic fragment; in which sequences encoding at least a functional domain of a normal human PS-interacting protein gene have been recombinantly substituted for one or both copies of the
20 animal's homologous PS-interacting protein gene by homologous recombination or gene targeting; and/or in which one or both copies of one of the animal's homologous PS-interacting protein genes have been recombinantly "humanized" by the partial substitution of sequences encoding the human homologue by homologous recombination or gene targeting. These animals are useful for evaluating the effects
25 of the transgenic procedures, and the effects of the introduction or substitution of a human or humanized PS-interacting protein gene. (2) Animals in which sequences encoding at least a functional domain of a mutant (i.e., pathogenic) human PS-interacting protein gene have been recombinantly introduced into the genome of the animal as an additional gene, under the regulation of either an exogenous or an
30 endogenous promoter element, and as either a minigene or a large genomic fragment;

-40-

in which sequences encoding at least a functional domain of a mutant human PS-interacting protein gene have been recombinantly substituted for one or both copies of the animal's homologous PS-interacting protein gene by homologous recombination or gene targeting; and/or in which one or both copies of one of the animal's

5 homologous PS-interacting protein genes have been recombinantly "humanized" by the partial substitution of sequences encoding a mutant human homologue by homologous recombination or gene targeting. These animals are useful as models which will display some or all of the characteristics, whether at the biochemical, physiological and/or behavioral level, of humans carrying one or more alleles which

10 are pathogenic of Alzheimer's Disease or other diseases associated with mutations in the PS-interacting protein genes. (3) Animals in which sequences encoding at least a functional domain of a mutant version of one of that animal's PS-interacting protein genes (bearing, for example, a specific mutation corresponding to, or similar to, one of the pathogenic mutations of the human PS-interacting proteins) have been

15 recombinantly introduced into the genome of the animal as an additional gene, under the regulation of either an exogenous or an endogenous promoter element, and as either a minigene or a large genomic fragment; and/or in which sequences encoding at least a functional domain of a mutant version of one of that animal's PS-interacting protein genes (bearing, for example, a specific mutation corresponding to, or similar

20 to, one of the pathogenic mutations of the human PS-interacting proteins) have been recombinantly substituted for one or both copies of the animal's homologous PS-interacting protein gene by homologous recombination or gene targeting. These animals are also useful as models which will display some or all of the characteristics, whether at the biochemical, physiological and/or behavioral level, of humans carrying

25 one or more alleles which are pathogenic of Alzheimer's Disease. (4) "Knock-out" animals in which one or both copies of one of the animal's PS-interacting protein genes have been partially or completely deleted by homologous recombination or gene targeting, or have been inactivated by the insertion or substitution by homologous recombination or gene targeting of exogenous sequences (e.g., stop

30 codons, lox p sites). Such animals are useful models to study the effects which loss of

PS-interacting protein gene expression may have, to evaluate whether loss of function is preferable to continued expression of mutant forms, and to examine whether other genes can be recruited to replace a mutant PS-interacting protein or to intervene with the effects of other genes (e.g., PS1, PS2, APP or ApoE) causing AD as a treatment
5 for AD or other disorders. For example, a normal PS-interacting protein gene may be necessary for the action of mutant presenilin or APP genes to actually be expressed as AD and, therefore, transgenic PS-interacting protein animal models may be of use in elucidating such multigenic interactions.

In addition to transgenic animal models in which the expression of one or
10 more of the PS-interacting proteins is altered, the present invention also provides for the production of transgenic animal models in which the expression of one or more of the presenilins, APP, or ApoE is altered. The nucleic acids encoding the presenilins, APP, and ApoE are known in the art, a methods for producing transgenic animals with these sequences are also known (see, e.g., PCT Publication WO96/34099; Games et
15 al., 1995). Indeed, because non-human animals may differ from humans not only in their PS-interacting protein sequences, but also in the sequences of their presenilin, APP and/or ApoE homologues, it is particularly contemplated that transgenics may be produced which bear recombinant normal or mutant human sequences for at least one presenilin, APP and/or ApoE gene in addition to recombinant sequences for one or
20 more PS-interacting proteins. Such co-transformed animal models would possess more elements of the human molecular biology and, therefore, are expected to be better models of human disorders. Thus, in accordance with the present invention, transgenic animal models may be produced bearing normal or mutant sequences for one or more PS-interacting proteins, or interacting domains of these proteins. These
25 animals will have utility in that they can be crossed with animals bearing a variety of normal or mutant presenilin, APP or ApoE sequences to produce co-transformed animal models. Furthermore, as detailed below, it is expected that mutations in the PS-interacting genes, like mutations in the presenilins themselves, may be causative of Alzheimer's Disease and/or other disorders as well (e.g., other cognitive,
30 intellectual, neurological or psychological disorders such as cerebral hemorrhage,

schizophrenia, depression, mental retardation and epilepsy). Therefore, transgenic animal models bearing normal or mutant sequences corresponding to the PS-interacting proteins, absent transformation with any presenilin, APP or ApoE sequences, will have utility of their own in the study of such disorders.

5 As detailed below, preferred choices for transgenic animal models transformed with PS-interacting proteins, or domains of PS-interacting proteins, include those transformed with normal or mutant sequences corresponding to the clones identified and described in Example 1 and disclosed in SEQ ID NOs: 1-12. These clones, which interact with normal or mutant PS1 TM6→7 loop domains, were
10 identified according to the methods described in Example 1, below, and PCT Publication WO96/34099. These clones, longer nucleic acid sequences comprising these clones, and other clones identified according to this and other methods of the invention (e.g., allelic and splice variants or heterospecific homologues of these clones) may all be employed in accordance with the present invention to produce
15 animal models which, with or without co-transformation with presenilin, APP and/or ApoE sequences, will have utility in the study of Alzheimer's Disease and/or other cognitive, intellectual, neurological or psychological disorders.

Thus, using the nucleic acids disclosed and otherwise enabled herein, one of ordinary skill in the art may now produce any of the following types of transgenic
20 animal models with altered PS-interacting protein expression: (1) Animals in which sequences encoding at least a functional domain of a normal human PS-interacting protein gene have been recombinantly introduced into the genome of the animal as an additional gene, under the regulation of either an exogenous or an endogenous promoter element, and as either a minigene or a large genomic fragment; in which
25 sequences encoding at least a functional domain of a normal human PS-interacting protein gene have been recombinantly substituted for one or both copies of the animal's homologous PS-interacting protein gene by homologous recombination or gene targeting; and/or in which one or both copies of one of the animal's homologous PS-interacting protein genes have been recombinantly "humanized" by the partial
30 substitution of sequences encoding the human homologue by homologous

-43-

recombination or gene targeting. These animals are particularly useful for providing transgenic models which express human PS-interacting proteins as well as human presenilin proteins. They are also useful in evaluating the effects of the transgenic procedures, and the effects of the introduction or substitution of a human or

5 humanized PS-interacting protein gene. (2) Animals in which sequences encoding at least a functional domain of a mutant (i.e., pathogenic) human PS-interacting protein gene have been recombinantly introduced into the genome of the animal as an additional gene, under the regulation of either an exogenous or an endogenous promoter element, and as either a minigene or a large genomic fragment; in which

10 sequences encoding at least a functional domain of a mutant human PS-interacting protein gene have been recombinantly substituted for one or both copies of the animal's homologous PS-interacting protein gene by homologous recombination or gene targeting; and/or in which one or both copies of one of the animal's homologous PS-interacting protein genes have been recombinantly "humanized" by the partial

15 substitution of sequences encoding a mutant human homologue by homologous recombination or gene targeting. These animals are useful as models which will display some or all of the characteristics, whether at the biochemical, physiological and/or behavioral level, of humans carrying one or more alleles which are pathogenic of Alzheimer's Disease or other diseases associated with mutations in these PS-

20 interacting genes. (3) Animals in which sequences encoding at least a functional domain of a mutant version of one of that animal's PS-interacting protein genes (bearing, for example, a specific mutation corresponding to, or similar to, one of the pathogenic mutations of the human PS-interacting proteins) have been recombinantly introduced into the genome of the animal as an additional gene, under the regulation

25 of either an exogenous or an endogenous promoter element, and as either a minigene or a large genomic fragment; and/or in which sequences encoding at least a functional domain of a mutant version of one of that animal's PS-interacting protein genes (bearing, for example, a specific mutation corresponding to, or similar to, one of the pathogenic mutations of the humans PS-interacting proteins) have been recombinantly

30 substituted for one or both copies of the animal's homologous PS-interacting protein

-44-

gene by homologous recombination or gene targeting. These animals are also useful as models which will display some or all of the characteristics, whether at the biochemical, physiological and/or behavioral level, of humans carrying one or more alleles which are pathogenic of Alzheimer's Disease. (4) "Knock-out" animals in which one or both copies of one of the animal's PS-interacting protein genes have been partially or completely deleted by homologous recombination or gene targeting, or have been inactivated by the insertion or substitution by homologous recombination or gene targeting of exogenous sequences (e.g., stop codons, lox p sites). Such animals are useful models to study the effects which loss of PS-interacting protein gene expression may have, to evaluate whether loss of function is preferable to continued expression, and to examine whether other genes can be recruited to replace a mutant PS-interacting protein or to intervene with the effects of other genes (e.g., APP or ApoE) causing AD as a treatment for AD or other disorders. For example, a normal PS-interacting protein may be necessary for the action of mutant PS1, PS2 or APP genes to actually be expressed as AD and, therefore, transgenic PS-interacting protein animal models may be of use in elucidating such multigenic interactions.

In some preferred embodiments, transgenic animal models are produced in which just the PS-interacting domains of the PS-interacting proteins are introduced into the genome of the animal by homologous recombination. Thus, for example, preferred embodiments include transgenic animals in which the PS-interacting domains of PS-interacting proteins are "humanized" by homologous recombination with sequences from human PS-interacting proteins. These animals may then be bred with transgenics in which normal or mutant presenilin sequences have been introduced. The progeny of these animals, having both human presenilin and human PS-interacting protein sequences, will provide improved animal models for Alzheimer's Disease.

To create an animal model (e.g., a transgenic mouse), a normal or mutant PS-interacting gene (e.g., normal or mutant S5a, GT24, p0071, Rab11, etc.), or a normal or mutant version of a recombinant nucleic acid encoding at least a functional

domain of a PS-interacting gene (e.g., the PS-interacting domains obtained in the yeast two-hybrid system), can be inserted into a germ line or stem cell using standard techniques of oocyte microinjection, or transfection or microinjection into embryonic stem cells. Animals produced by these or similar processes are referred to as
5 transgenic. Similarly, if it is desired to inactivate or replace an endogenous presenilin or PS-interacting protein gene, homologous recombination using embryonic stem cells may be employed. Animals produced by these or similar processes are referred to as "knock-out" (inactivation) or "knock-in" (replacement) models.

For oocyte injection, one or more copies of the recombinant DNA
10 constructs of the present invention may be inserted into the pronucleus of a just-fertilized oocyte. This oocyte is then reimplanted into a pseudo-pregnant foster mother. The liveborn animals are screened for integrants using analysis of DNA (e.g., from the tail veins of offspring mice) for the presence of the inserted recombinant transgene sequences. The transgene may be either a complete genomic sequence
15 injected as a YAC, BAC, PAC or other chromosome DNA fragment, a cDNA with either the natural promoter or a heterologous promoter, or a minigene containing all of the coding region and other elements found to be necessary for optimum expression.

Retroviral infection of early embryos can also be done to insert the recombinant DNA constructs of the invention. In this method, the transgene (e.g., a
20 normal or mutant S5a, GT24, p0071, Rab 11, etc., sequence) is inserted into a retroviral vector which is used to infect embryos (e.g., mouse or non-human primate embryos) directly during the early stages of development to generate chimeras, some of which will lead to germline transmission.

Homologous recombination using stem cells allows for the screening of
25 gene transfer cells to identify the rare homologous recombination events. Once identified, these can be used to generate chimeras by injection of blastocysts, and a proportion of the resulting animals will show germline transmission from the recombinant line. This methodology is especially useful if inactivation of a gene is desired. For example, inactivation of the S5a gene in mice may be accomplished by
30 designing a DNA fragment which contains sequences from an S5a coding region

flanking a selectable marker. Homologous recombination leads to the insertion of the marker sequences in the middle of the coding region, causing inactivation of the S5a gene and/or deletion of internal sequences. DNA analysis of individual clones can then be used to recognize the homologous recombination events.

5 The techniques of generating transgenic animals, as well as the techniques for homologous recombination or gene targeting, are now widely accepted and practiced. A laboratory manual on the manipulation of the mouse embryo, for example, is available detailing standard laboratory techniques for the production of transgenic mice (Hogan et al., 1986). To create a transgene, the target sequence of
10 interest (e.g., normal or mutant presenilin sequences, normal or mutant PS-interacting protein sequences) are typically ligated into a cloning site located downstream of some promoter element which will regulate the expression of RNA from the sequence. Downstream of the coding sequence, there is typically an artificial polyadenylation sequence. In the transgenic models that have been used to
15 successfully create animals which mimic aspects of inherited human neurodegenerative diseases, the most successful promoter elements have been the platelet-derived growth factor receptor β gene subunit promoter and the hamster prion protein gene promoter, although other promoter elements which direct expression in central nervous system cells would also be useful. An alternate approach to creating a
20 transgene is to use an endogenous presenilin or PS-interacting protein gene promoter and regulatory sequences to drive expression of the transgene. Finally, it is possible to create transgenes using large genomic DNA fragments such as YACs which contain the entire desired gene as well as its appropriate regulatory sequences. Such constructs have been successfully used to drive human APP expression in transgenic
25 mice (Lamb et al., 1993).

Animal models can also be created by targeting the endogenous presenilin or PS-interacting protein gene in order to alter the endogenous sequence by homologous recombination. These targeting events can have the effect of removing endogenous sequence (knock-out) or altering the endogenous sequence to create an
30 amino acid change associated with human disease or an otherwise abnormal sequence

-47-

(e.g., a sequence which is more like the human sequence than the original animal sequence) (knock-in animal models). A large number of vectors are available to accomplish this and appropriate sources of genomic DNA for mouse and other animal genomes to be targeted are commercially available from companies such as

5 GenomeSystems Inc. (St. Louis, Missouri, USA). The typical feature of these targeting vector constructs is that 2 to 4 kb of genomic DNA is ligated 5' to a selectable marker (e.g., a bacterial neomycin resistance gene under its own promoter element termed a "neomycin cassette"). A second DNA fragment from the gene of

10 interest is then ligated downstream of the neomycin cassette but upstream of a second selectable marker (e.g., thymidine kinase). The DNA fragments are chosen such that mutant sequences can be introduced into the germ line of the targeted animal by homologous replacement of the endogenous sequences by either one of the sequences included in the vector. Alternatively, the sequences can be chosen to cause deletion of

15 sequences that would normally reside between the left and right arms of the vector surrounding the neomycin cassette. The former is known as a knock-in, the latter is known as a knock-out. Again, innumerable model systems have been created, particularly for targeted knock-outs of genes including those relevant to neurodegenerative diseases (e.g., targeted deletions of the murine APP gene by Zheng et al., 1995; targeted deletion of the murine prion gene associated with adult onset

20 human CNS degeneration by Bueler et al., 1996).

Finally, equivalents of transgenic animals, including animals with mutated or inactivated presenilin genes, or mutated or inactivated PS-interacting protein genes, may be produced using chemical or X-ray mutagenesis of gametes, followed by fertilization. Using the isolated nucleic acids disclosed or otherwise enabled herein,

25 one of ordinary skill may more rapidly screen the resulting offspring by, for example, direct sequencing RFLP, PCR, or hybridization analysis to detect mutants, or Southern blotting to demonstrate loss of one allele by dosage.

6. Assays for Drugs Which Affect PS-Interacting Protein Expression

In another series of embodiments, the present invention provides assays for identifying small molecules or other compounds which are capable of inducing or inhibiting the expression of the PS-interacting genes and proteins (e.g., S5a or GT24). The assays may be performed in vitro using non-transformed cells, immortalized cell lines, or recombinant cell lines, or in vivo using the transgenic animal models enabled herein.

In particular, the assays may detect the presence of increased or decreased expression of S5a, GT24, p0071, Rab 11, or other PS-interacting genes or proteins on the basis of increased or decreased mRNA expression (using, e.g., the nucleic acid probes disclosed and enabled herein), increased or decreased levels of PS-interacting proteins (using, e.g., the anti-PS-interacting protein antibodies disclosed and enabled herein), or increased or decreased levels of expression of a marker gene (e.g., β -galactosidase or luciferase) operably joined to a PS-interacting protein 5' regulatory region in a recombinant construct.

Thus, for example, one may culture cells known to express a particular PS-interacting protein and add to the culture medium one or more test compounds. After allowing a sufficient period of time (e.g., 0-72 hours) for the compound to induce or inhibit the expression of the PS-interacting protein, any change in levels of expression from an established baseline may be detected using any of the techniques described above and well known in the art. In particularly preferred embodiments, the cells are from an immortalized cell line such as a human neuroblastoma, glioblastoma or a hybridoma cell line. Using the nucleic acid probes and /or antibodies disclosed and enabled herein, detection of changes in the expression of a PS-interacting protein, and thus identification of the compound as an inducer or repressor of PS-interacting protein expression, requires only routine experimentation.

In particularly preferred embodiments, a recombinant assay is employed in which a reporter gene such as a β -galactosidase, green fluorescent protein, alkaline phosphatase, or luciferase is operably joined to the 5' regulatory regions of a PS-interacting protein gene. Preferred vectors include the Green Lantern 1 vector (GIBCO/BRL, Gaithersburg, MD) and the Great EScAPe pSEAP vector (Clontech,

Palo Alto). The PS-interacting protein regulatory regions may be easily isolated and cloned by one of ordinary skill in the art in light of the present disclosure of coding regions from these genes. The reporter gene and regulatory regions are joined in-frame (or in each of the three possible reading frames) so that transcription and translation of the reporter gene may proceed under the control of the PS-interacting protein regulatory elements. The recombinant construct may then be introduced into any appropriate cell type, although mammalian cells are preferred, and human cells are most preferred. The transformed cells may be grown in culture and, after establishing the baseline level of expression of the reporter gene, test compounds may be added to the medium. The ease of detection of the expression of the reporter gene provides for a rapid, high through-put assay for the identification of inducers and repressors of the PS-interacting protein gene.

Compounds identified by this method will have potential utility in modifying the expression of the PS-interacting protein genes in vivo. These compounds may be further tested in the animal models disclosed and enabled herein to identify those compounds having the most potent in vivo effects. In addition, as described herein with respect to small molecules having binding activity for PS-interacting proteins, these molecules may serve as "lead compounds" for the further development of pharmaceuticals by, for example, subjecting the compounds to sequential modifications, molecular modeling, and other routine procedures employed in rational drug design.

7. Identification of Compounds with PS-Interacting Protein Binding Capacity

In light of the present disclosure, one of ordinary skill in the art is enabled to practice new screening methodologies which will be useful in the identification of proteins and other compounds which bind to, or otherwise directly interact with, the PS-interacting proteins. The proteins and compounds will include endogenous cellular components, aside from the presenilins, which interact with the PS-interacting proteins in vivo and which, therefore, provide new targets for pharmaceutical and therapeutic interventions, as well as recombinant, synthetic and otherwise exogenous

compounds which may have PS-interacting protein binding capacity and, therefore, may be candidates for pharmaceutical agents. Thus, in one series of embodiments, cell lysates or tissue homogenates (e.g., human brain homogenates, lymphocyte lysates) may be screened for proteins or other compounds which bind to one of the
5 normal or mutant PS-interacting proteins. Alternatively, any of a variety of exogenous compounds, both naturally occurring and/or synthetic (e.g., libraries of small molecules or peptides), may be screened for PS-interacting protein binding capacity. Small molecules are particular preferred in this context because they are more readily absorbed after oral administration, have fewer potential antigenic
10 determinants, and/or are more likely to cross the blood brain barrier than larger molecules such as nucleic acids or proteins. The methods of the present invention are particularly useful in that they may be used to identify molecules which selectively or preferentially bind to a mutant form of a PS-interacting protein (rather than a normal form) and, therefore, may have particular utility in treating cases of AD which arise
15 from mutations in the PS-interacting proteins.

Once identified by the methods described above, the candidate compounds may then be produced in quantities sufficient for pharmaceutical administration or testing (e.g., μg or mg or greater quantities), and formulated in a pharmaceutically acceptable carrier (see, e.g., Remington's Pharmaceutical Sciences, Gennaro, A., ed.,
20 Mack Pub., 1990). These candidate compounds may then be administered to the transformed cells of the invention, to the transgenic animal models of the invention, to cell lines derived from the animal models or from human patients, or to Alzheimer's patients. The animal models described and enabled herein are of particular utility in further testing candidate compounds which bind to normal or mutant PS-interacting
25 proteins for their therapeutic efficacy.

In addition, once identified by the methods described above, the candidate compounds may also serve as "lead compounds" in the design and development of new pharmaceuticals. For example, as is well known in the art, sequential modification of small molecules (e.g., amino acid residue replacement with peptides;
30 functional group replacement with peptide or non-peptide compounds) is a standard

approach in the pharmaceutical industry for the development of new pharmaceuticals. Such development generally proceeds from a "lead compound" which is shown to have at least some of the activity (e.g., PS-interacting protein binding or blocking ability) of the desired pharmaceutical. In particular, when one or more compounds
5 having at least some activity of interest (e.g., modulation of PS-interacting protein activity) are identified, structural comparison of the molecules can greatly inform the skilled practitioner by suggesting portions of the lead compounds which should be conserved and portions which may be varied in the design of new candidate compounds. Thus, the present invention also provides a means of identifying lead
10 compounds which may be sequentially modified to produce new candidate compounds for use in the treatment of Alzheimer's Disease. These new compounds then may be tested both for binding to PS-interacting proteins and/or blocking PS-interacting protein activity, and for therapeutic efficacy (e.g., in the animal models described herein). This procedure may be iterated until compounds having the desired
15 therapeutic activity and/or efficacy are identified.

In each of the present series of embodiments, an assay is conducted to detect binding between a "PS-interacting protein component" and some other moiety. Of particular utility will be sequential assays in which compounds are tested for the ability to bind to only normal or only mutant forms of the PS-interacting domains of
20 PS-interacting proteins in the binding assays. Such compounds are expected to have the greatest therapeutic utilities, as described more fully below. The "PS-interacting protein component" in these assays may be a complete normal or mutant form of a PS-interacting protein (e.g., S5a, GT24, p0071, Rab 11, etc.) but need not be. Rather, particular functional domains of the PS-interacting proteins, particularly the PS-
25 interacting domains as described above, may be employed either as separate molecules or as part of a fusion protein. For example, to isolate proteins or compounds that interact with these functional domains, screening may be carried out using fusion constructs and/or synthetic peptides corresponding to these regions. Thus, for S5a, GST-fusion peptides may be made including sequences corresponding
30 approximately to amino acids 70-377 of SEQ ID NO: 2 (included in clones Y2H29

and Y2H31, see Example 1), approximately to amino acids 206-377 of SEQ ID NO: 2 (which includes protein-protein interaction motifs, see Ferrell et al., 1996), or to any other S5a domain of interest. Similarly, for GT24, GST- or other fusion peptides may be produced including sequences corresponding approximately to amino acids 440-
5 815 of SEQ ID NO: 4 (including part of the armadillo repeat segment). Obviously, various combinations of fusion proteins and PS-interacting protein functional domains are possible and these are merely examples. In addition, the functional domains may be altered so as to aid in the assay by, for example, introducing into the functional domain a reactive group or amino acid residue (e.g., cysteine) which will facilitate
10 immobilization of the domain on a substrate (e.g., using sulfhydryl reactions). Thus, for example, the PS-interacting domain of S5a may be synthesized containing an additional C-terminal cysteine residue to facilitate immobilization of the domain. Such peptides may be used to create an affinity substrate for affinity chromatography (Sulfo-link; Pierce) to isolate binding proteins for microsequencing. Similarly, other
15 functional domain or antigenic fragments may be created with modified residues (see, e.g., Example 4).

The proteins or other compounds identified by these methods may be purified and characterized by any of the standard methods known in the art. Proteins may, for example, be purified and separated using electrophoretic (e.g., SDS-PAGE,
20 2D PAGE) or chromatographic (e.g., HPLC) techniques and may then be microsequenced. For proteins with a blocked N-terminus, cleavage (e.g., by CNBr and/or trypsin) of the particular binding protein is used to release peptide fragments. Further purification/characterization by HPLC and microsequencing and/or mass spectrometry by conventional methods provides internal sequence data on such
25 blocked proteins. For non-protein compounds, standard organic chemical analysis techniques (e.g., IR, NMR and mass spectrometry; functional group analysis; X-ray crystallography) may be employed to determine their structure and identity.

Methods for screening cellular lysates, tissue homogenates, or small molecule libraries for candidate PS-interaction protein-binding molecules are well
30 known in the art and, in light of the present disclosure, may now be employed to

-53-

identify compounds which bind to normal or mutant PS-interacting protein components or which modulate PS-interacting protein activity as defined by non-specific measures (e.g., changes in intracellular Ca^{2+} , GTP/GDP ratio) or by specific measures (e.g., changes in A β peptide production or changes in the expression of other downstream genes which can be monitored by differential display, 2D gel electrophoresis, differential hybridization, or SAGE methods). The preferred methods involve variations on the following techniques: (1) direct extraction by affinity chromatography; (2) co-isolation of PS-interacting protein components and bound proteins or other compounds by immunoprecipitation; (3) the Biomolecular Interaction Assay (BIAcore); and (4) the yeast two-hybrid systems. These and others are discussed separately below.

A. Affinity Chromatography

In light of the present disclosure, a variety of affinity binding techniques well known in the art may be employed to isolate proteins or other compounds which bind to the PS-interacting protein disclosed or otherwise enabled herein. In general, a PS-interacting protein component may be immobilized on a substrate (e.g., a column or filter) and a solution including the test compound(s) is contacted with the PS-interacting protein, fusion or fragment under conditions which are permissive for binding. The substrate is then washed with a solution to remove unbound or weakly bound molecules. A second wash may then elute those compounds which strongly bound to the immobilized normal or mutant PS-interacting protein component. Alternatively, the test compounds may be immobilized and a solution containing one or more PS-interacting protein components may be contacted with the column, filter or other substrate. The ability of the PS-interacting protein component to bind to the test compounds may be determined as above or a labeled form of the PS-interacting protein component (e.g., a radio-labeled or chemiluminescent functional domain) may be used to more rapidly assess binding to the substrate-immobilized compound(s).

B. Co-Immunoprecipitation

Another well characterized technique for the isolation of PS-interacting protein components and their associated proteins or other compounds is direct

immunoprecipitation with antibodies. This procedure has been successfully used, for example, to isolate many of the synaptic vesicle associated proteins (Phizicky and Fields, 1994). Thus, either normal or mutant, free or membrane-bound PS-interacting protein components may be mixed in a solution with the candidate compound(s)
5 under conditions which are permissive for binding, and the PS-interacting protein component may be immunoprecipitated. Proteins or other compounds which co-immunoprecipitate with the PS-interacting protein component may then be identified by standard techniques as described above. General techniques for immunoprecipitation may be found in, for example, Harlow and Lane, (1988)
10 Antibodies: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, NY.

The antibodies employed in this assay, as described and enabled herein, may be polyclonal or monoclonal, and include the various antibody fragments (e.g., Fab, F(ab')₂,) as well as single chain antibodies, and the like.

15 C. The Biomolecular Interaction Assay

Another useful method for the detection and isolation of binding proteins is the Biomolecular Interaction Assay or "BIAcore" system developed by Pharmacia Biosensor and described in the manufacturer's protocol (LKB Pharmacia, Sweden). In light of the present disclosure, one of ordinary skill in the art is now enabled to
20 employ this system, or a substantial equivalent, to identify proteins or other compounds having PS-interacting protein binding capacity. The BIAcore system uses an affinity purified anti-GST antibody to immobilize GST-fusion proteins onto a sensor chip. Obviously, other fusion proteins and corresponding antibodies may be substituted. The sensor utilizes surface plasmon resonance which is an optical
25 phenomenon that detects changes in refractive indices. A homogenate of a tissue of interest is passed over the immobilized fusion protein and protein-protein interactions are registered as changes in the refractive index. This system can be used to determine the kinetics of binding and to assess whether any observed binding is of physiological relevance.

D. The Yeast Two-Hybrid System

The yeast "two-hybrid" system takes advantage of transcriptional factors that are composed of two physically separable, functional domains (Phizicky and Fields, 1994). The most commonly used is the yeast GAL4 transcriptional activator consisting of a DNA binding domain and a transcriptional activation domain. Two different cloning vectors are used to generate separate fusions of the GAL4 domains to genes encoding potential binding proteins. The fusion proteins are co-expressed, targeted to the nucleus and, if interactions occur, activation of a reporter gene (e.g., lacZ) produces a detectable phenotype. For example, the Clontech Matchmaker System-2 may be used with the Clontech brain cDNA GAL4 activation domain fusion library with PS-interacting protein-GAL4 binding domain fusion clones (Clontech, Palo Alto, CA). In light of the disclosures herein, one of ordinary skill in the art is now enabled to produce a variety of PS-interacting protein fusions, including fusions including either normal or mutant functional domains of the PS-interacting proteins, and to screen such fusion libraries in order to identify PS-interacting protein binding proteins.

E. Other Methods

The nucleotide sequences and protein products, including both mutant and normal forms of these nucleic acids and their corresponding proteins, can be used with the above techniques to isolate other interacting proteins, and to identify other genes whose expression is altered by the over-expression of normal PS-interacting protein sequences, by the under-expression of normal PS-interacting protein sequences, or by the expression of mutant PS-interacting protein sequences. Identification of these other interacting proteins, as well as the identification of other genes whose expression levels are altered in AD will identify other gene targets which have direct relevance to the pathogenesis of this disease in its clinical or pathological forms. Specifically, other genes will be identified which may themselves be the site of other mutations causing Alzheimer's Disease, or which can themselves be targeted therapeutically (e.g., to reduce their expression levels to normal, or to pharmacologically block the effects of their over-expression) as a potential treatment

for this disease. Specifically, these techniques rely on PCR-based and/or hybridization-based methods to identify genes which are differentially expressed between two conditions (a cell line expressing normal PS-interacting proteins compared to the same cell type expressing a mutant PS-interacting protein). These techniques include differential display, serial analysis of gene expression (SAGE), and mass-spectrometry of protein 2D-gels and subtractive hybridization (reviewed in Nowak, 1995 and Kahn, 1995).

As will be obvious to one of ordinary skill in the art, there are numerous other methods of screening individual proteins or other compounds, as well as large libraries of proteins or other compounds (e.g., phage display libraries and cloning systems from Stratagene, La Jolla, CA) to identify molecules which bind to normal or mutant PS-interacting protein components. All of these methods comprise the step of mixing a normal or mutant PS-interacting protein, fusion, or fragment with test compounds, allowing for binding (if any), and assaying for bound complexes. All such methods are now enabled by the present disclosure of substantially pure PS-interacting proteins, substantially pure PS-interacting functional domain fragments, PS-interacting protein fusion proteins, PS-interacting protein antibodies, and methods of making and using the same.

8. Disrupting PS-Interacting Protein Interactions

The ability to disrupt specific interactions of the PS-interacting proteins with the presenilins, or with other proteins, is potentially of great therapeutic value, and will be important in understanding the etiology of AD and in identifying additional targets for therapy. The methods used to identify compounds which disrupt PS-interacting protein interactions may be applied equally well to interactions involving either normal or mutant PS-interacting proteins.

Assays for compounds which can disrupt PS-interacting protein interactions may be performed by any of a variety of methods well known in the art. In essence, such assays will parallel those assays for identifying proteins and compounds with binding activity toward the PS-interacting proteins. Thus, once a

compound with binding activity for a PS-interacting protein is identified by any method, that method or an equivalent method may be performed in the presence of candidate compounds to identify compounds which disrupt the interaction. Thus, for example, the assay may employ methods including (1) affinity chromatography; (2) immunoprecipitation; (3) the Biomolecular Interaction Assay (BIAcore); or (4) the yeast two-hybrid systems. Such assays can be developed using either normal or mutant purified PS-interacting proteins, and/or either normal or mutant purified binding proteins (e.g., normal or mutant presenilins).

For affinity methods, either the PS-interacting protein or its binding partner may be affixed to a matrix, for example in a column, and the counterpart protein (e.g., the PS-interacting protein if presenilin or another binding partner is affixed to the matrix; or a presenilin or other binding partner if the PS-interacting protein is affixed to the matrix) is then exposed to the affixed protein/compound either before or after adding the candidate compound(s). In the absence of a disruptive effect by the candidate compound(s), the interaction between the PS-interacting protein and its binding partner will cause the counterpart protein to bind to the affixed protein. Any compound which disrupts the interaction will cause release of the counterpart protein from the matrix. Release of the counterpart protein from the matrix can be measured using methods known in the art.

For PS-interacting protein interactions which are detectable by yeast two-hybrid systems, these assays may also be employed to identify compounds which disrupt the interaction. Briefly, a PS-interacting protein and its binding partner (or appropriate structural domains of each) are employed in the fusion proteins of the system, and the cells are exposed to candidate compounds to determine their effect upon the expression of the reporter gene. By appropriate choice of a reporter gene, such a system can be readily adapted for high through-put screening of large libraries of compounds by, for example, using a reporter gene which confers resistance to an antibiotic which is present in the medium, or which rescues an auxotrophic strain grown in minimal medium.

These assays may be used to screen many different types of compounds for their disruptive effect on the interactions of the PS-interacting proteins. For example, the compounds may belong to a library of synthetic molecules, or be specifically designed to disrupt the interaction. The compounds may also be peptides

5 corresponding to the interacting domain of either protein. This type of assay can be used to identify compounds that disrupt a specific interaction between a given PS-interacting protein variant and a given binding partner. In addition, compounds that disrupt all interactions with PS-interacting proteins may be identified. For example, a compound that specifically disrupts the folding of PS-interacting proteins would be

10 expected to disrupt all interactions between PS-interacting proteins and other proteins. Alternatively, this type of disruption assay can be used to identify compounds which disrupt only a range of different PS-interacting protein interactions, or only a single PS-interacting protein interaction.

15 9. Methods of Identifying Compounds Modulating PS-Interacting Protein Activity

In another series of embodiments, the present invention provides for methods of identifying compounds with the ability to modulate the activity of normal and mutant PS-interacting proteins. As used with respect to this series of

embodiments, the term "activity" broadly includes gene and protein expression, PS-

20 interacting protein post-translation processing, trafficking and localization, and any functional activity (e.g., enzymatic, receptor-effector, binding, channel), as well as downstream affects of any of these. It is known that Alzheimer's Disease is associated with increased production of the long form of A β peptides, the appearance of amyloid plaques and neurofibrillary tangles, decreases in cognitive function, and apoptotic cell

25 death. Therefore, using the transformed cells and transgenic animal models of the present invention, cells obtained from subjects bearing normal or mutant PS-interacting protein genes, or animals or human subjects bearing naturally occurring normal or mutant PS-interacting proteins, it is now possible to screen candidate pharmaceuticals and treatments for their therapeutic effects by detecting changes in

one or more of these functional characteristics or phenotypic manifestations of normal or mutant PS-interacting protein expression.

Thus, the present invention provides methods for screening or assaying for proteins, small molecules or other compounds which modulate PS-interacting protein activity by contacting a cell in vivo or in vitro with a candidate compound and assaying for a change in a marker associated with normal or mutant PS-interacting protein activity. The marker associated with PS-interacting protein activity may be any measurable biochemical, physiological, histological and/or behavioral characteristic associated with PS-interacting protein expression. In particular, useful markers will include any measurable biochemical, physiological, histological and/or behavioral characteristic which distinguishes cells, tissues, animals or individuals bearing at least one mutant presenilin or PS-interacting protein gene from their normal counterparts. In addition, the marker may be any specific or non-specific measure of presenilin or PS-interacting protein activity. PS-interacting protein specific measures include measures of PS-interacting protein expression (e.g., PS-interacting protein mRNA or protein levels) which may employ the nucleic acid probes or antibodies of the present invention. Non-specific measures include changes in cell physiology such as pH, intracellular calcium, cyclic AMP levels, GTP/GDP ratios, phosphatidylinositol activity, protein phosphorylation, etc., which can be monitored on devices such as the cytosensor microphysiometer (Molecular Devices Inc., United States). The activation or inhibition of PS-interacting protein activity in its mutant or normal form can also be monitored by examining changes in the expression of other genes (e.g., the presenilins) which are specific to the PS-interacting protein pathway leading to Alzheimer's Disease. These can be assayed by such techniques as differential display, differential hybridization, and SAGE (sequential analysis of gene expression), as well as by two dimensional gel electrophoresis of cellular lysates. In each case, the differentially-expressed genes can be ascertained by inspection of identical studies before and after application of the candidate compound. Furthermore, as noted elsewhere, the particular genes whose expression is modulated by the administration of the candidate compound can be ascertained by cloning,

-60-

nucleotide sequencing, amino acid sequencing, or mass spectrometry (reviewed in Nowak, 1995).

In general, a cell may be contacted with a candidate compound and, after an appropriate period (e.g., 0-72 hours for most biochemical measures of cultured cells), the marker of presenilin or PS-interacting protein activity may be assayed and compared to a baseline measurement. The baseline measurement may be made prior to contacting the cell with the candidate compound or may be an external baseline established by other experiments or known in the art. The cell may be a transformed cell of the present invention or an explant from an animal or individual. In particular, the cell may be an explant from a carrier of a presenilin or PS-interacting protein mutation (e.g., a human subject with Alzheimer's Disease) or an animal model of the invention (e.g., a transgenic nematode or mouse bearing a mutant presenilin or PS-interacting protein gene). To augment the effect of presenilin or PS-interacting protein mutations on the A β pathway, transgenic cells or animals may be employed which have increased A β production. Preferred cells include those from neurological tissues such as neuronal, glial or mixed cell cultures; and cultured fibroblasts, liver, kidney, spleen, or bone marrow. The cells may be contacted with the candidate compounds in a culture in vitro or may be administered in vivo to a live animal or human subject. For live animals or human subjects, the test compound may be administered orally or by any parenteral route suitable to the compound. For clinical trials of human subjects, measurements may be conducted periodically (e.g., daily, weekly or monthly) for several months or years.

Because most individuals bearing a mutation in a particular gene are heterozygous at that locus (i.e., bearing one normal and one mutant allele), compounds may be tested for their ability to modulate normal as well as mutant presenilin or PS-interacting protein activity. Thus, for example, compounds which enhance the function of normal presenilins or PS-interacting proteins may have utility in treating Alzheimer's Disease or related disorders. Alternatively, because suppression of the activity of both normal and mutant copies of a gene in a heterozygous individual may have less severe clinical consequences than progression

of the associated disease, it may be desired to identify compound which inactivate or suppress all forms of the presenilins, the PS-interacting proteins, or their interactions. Preferably, however, compounds are identified which selectively or specifically inactivate or suppress the activity of mutant presenilin or PS-interacting proteins
5 without disrupting the function of their normal counterparts.

In light of the identification, characterization, and disclosure herein of a novel group of PS-interacting genes and proteins, the PS-interacting protein nucleic acid probes and antibodies, and the PS-interacting protein transformed cells and transgenic animals of the invention, one of ordinary skill in the art is now enabled by
10 perform a great variety of assays which will detect the modulation of presenilin and/or PS-interacting protein activity by candidate compounds. Particularly preferred and contemplated embodiments are discussed in some detail below.

A. PS-Interacting Protein Expression

In one series of embodiments, specific measures of PS-interacting protein
15 expression are employed to screen candidate compounds for their ability to affect presenilin activity. Thus, using the PS-interacting protein nucleic acids and antibodies disclosed and otherwise enabled herein, one may use mRNA levels or protein levels as a marker for the ability of a candidate compound to modulate PS-interacting protein activity. The use of such probes and antibodies to measure gene and protein
20 expression is well known in the art and discussed elsewhere herein. Of particular interest may be the identification of compounds which can alter the relative levels of different variants (e.g., mutant and normal) of the PS-interacting proteins.

B. Intracellular Localization

In another series of embodiments, compounds may be screened for their
25 ability to modulate the activity of the PS-interacting proteins based upon their effects on the trafficking and intracellular localization of the PS-interacting proteins. The presenilins and some of the PS-interacting proteins (e.g., S5a) have been seen immunocytochemically to be localized in membrane structures associated with the endoplasmic reticulum and Golgi apparatus. Differences in localization of mutant and
30 normal presenilins or PS-interacting proteins may, therefore, contribute to the etiology

of Alzheimer's Disease and related disorders. Compounds which can affect the localization of these proteins may, therefore, be identified as potential therapeutics. Standard techniques known in the art may be employed to detect the localization of the presenilins and PS-interacting proteins. Generally, these techniques will employ the antibodies of the present invention, and in particular antibodies which selectively bind to one or more mutant PS-interacting proteins but not to normal proteins. As is well known in the art, such antibodies may be labeled by any of a variety of techniques (e.g., fluorescent or radioactive tags, labeled secondary antibodies, avidin-biotin, etc.) to aid in visualizing the intracellular location of these proteins. The PS-interacting proteins may be co-localized to particular structures, as is known in the art, using antibodies to markers of those structures (e.g., TGN38 for the Golgi, transferrin receptor for post-Golgi transport vesicles, LAMP2 for lysosomes). Western blots of purified fractions from cell lysates enriched for different intracellular membrane bound organelles (e.g., lysosomes, synaptosomes, Golgi) may also be employed.

B. Ion Regulation/Metabolism

In another series of embodiments, compounds may be screened for their ability to modulate the activity of the presenilins or PS-interacting proteins based upon measures in intracellular Ca^{2+} , Na^{+} or K^{+} levels or metabolism. As noted above, the presenilins are membrane associated proteins which may serve as, or interact with, ion receptors or ion channels. Thus, compounds may be screened for their ability to modulate presenilin and PS-interacting protein-related metabolism of calcium or other ions either in vivo or in vitro by, for example, measurements of ion channel fluxes and/or transmembrane voltage and/or current fluxes, using patch clamps, voltage clamps or fluorescent dyes sensitive to intracellular ion levels or transmembrane voltage. Ion channel or receptor function can also be assayed by measurements of activation of second messengers such as cyclic AMP, cGMP tyrosine kinases, phosphates, increases in intracellular Ca^{2+} levels, etc. Recombinantly made proteins may also be reconstructed in artificial membrane systems to study ion channel conductance and, therefore, the "cell" employed in such assays may comprise an

artificial membrane or cell. Assays for changes in ion regulation or metabolism can be performed on cultured cells expressing endogenous normal or mutant presenilins and PS-interacting proteins. Such studies also can be performed on cells transfected with vectors capable of expressing one of the presenilins or PS-interacting proteins, or
5 functional domains of one of the presenilins or PS-interacting proteins, in normal or mutant form. In addition, to enhance the signal measured in such assays, cells may be co-transfected with genes encoding ion channel proteins. For example, Xenopus oocytes or rat kidney (HEK293) cells may be co-transfected with sequences encoding rat brain Na⁺ β 1 subunits, rabbit skeletal muscle Ca²⁺ β 1 subunits, or rat heart K⁺ β 1
10 subunits. Changes in presenilin or PS-interacting protein-mediated ion channel activity can be measured by, for example, two-microelectrode voltage-clamp recordings in oocytes, by whole-cell patch-clamp recordings in HEK293 cells. or by equivalent means.

C. Apoptosis or Cell Death

15 In another series of embodiments, compounds may be screened for their ability to modulate the activity of the presenilins or PS-interacting proteins based upon their effects on presenilin or PS-interacting protein-related apoptosis or cell death. Thus, for example, baseline rates of apoptosis or cell death may be established for cells in culture, or the baseline degree of neuronal loss at a particular age may be
20 established post-mortem for animal models or human subjects, and the ability of a candidate compound to suppress or inhibit apoptosis or cell death may be measured. Cell death may be measured by standard microscopic techniques (e.g., light microscopy) or apoptosis may be measured more specifically by characteristic nuclear morphologies or DNA fragmentation patterns which create nucleosomal ladders (see,
25 e.g., Gavrieli et al., 1992; Jacobson et al., 1993; Vito et al., 1996). TUNEL may also be employed to evaluate cell death in brain (see, e.g., Lassmann et al., 1995). In preferred embodiments, compounds are screened for their ability to suppress or inhibit neuronal loss in the transgenic animal models of the invention. Transgenic mice bearing, for example, a mutant human, mutant mouse, or humanized mutant presenilin
30 or PS-interacting protein gene may be employed to identify or evaluate compounds

which may delay or arrest the neurodegeneration associated with Alzheimer's Disease. A similar transgenic mouse model, bearing a mutant APP gene, has recently been reported by Games et al. (1995).

D. A β Peptide Production

5 In another series of embodiments, compounds may be screened for their ability to modulate presenilin or PS-interacting protein-related changes in APP processing. The A β peptide is produced in several isoforms resulting from differences in APP processing. The A β peptide is a 39 to 43 amino acid derivative of β APP which is progressively deposited in diffuse and senile plaques and in blood vessels of
10 subjects with AD. In human brain, A β peptides are heterogeneous at both the N- and C-termini. Several observations, however, suggest that both the full length and N-terminal truncated forms of the long-tailed A β peptides ending at residue 42 or 43 (i.e., A β 1-42/43 and A β x-42/43) have a more important role in AD than do peptides ending at residue 40. Thus, A β 1-42/43 and A β x-42/43 are an early and prominent
15 feature of both senile plaques and diffuse plaques, while peptides ending at residue 40 (i.e., A β 1-40 and A β x-40) are predominantly associated with a subset of mature plaques and with amyloidotic blood vessels (see, e.g., Iwatsubo et al., 1995; Gravina et al., 1995; Tamaoka et al., 1995; Podlisny et al. 1995). Furthermore, the long-tailed isoforms have a greater propensity to fibril formation, and are thought to be more
20 neurotoxic than A β 1-40 peptides (Pike et al., 1993; Hilbich et al., 1991). Finally, missense mutations at codon 717 of the β APP gene are associated with early onset FAD, and result in overproduction of long-tailed A β in the brain of affected mutation carriers, in peripheral cells and plasma of both affected and presymptomatic carriers, and in cell lines transfected with β APP₇₁₇ mutant cDNAs (Tamaoka et al., 1994;
25 Suzuki et al., 1994).

Thus, in one series of embodiments, the present invention provides methods for screening candidate compounds for their ability to block or inhibit the increased production of long isoforms of the A β peptides in cells or transgenic animals expressing a normal or mutant presenilin gene and/or a normal or mutant PS-
30 interacting protein gene. In particular, the present invention provides such methods in

which cultured mammalian cells, such as brain cells or fibroblasts, have been transformed according to the methods disclosed herein, or in which transgenic animals, such as rodents or non-human primates, have been produced by the methods disclosed herein, to express relatively high levels of a normal or mutant presenilin or PS-interacting protein. Optionally, such cells or transgenic animals may also be transformed so as to express a normal or mutant form of the β APP protein at relatively high levels.

In this series of embodiments, the candidate compound is administered to the cell line or transgenic animals (e.g., by addition to the media of cells in culture; or by oral or parenteral administration to an animal) and, after an appropriate period (e.g., 0-72 hours for cells in culture, days or months for animal models), a biological sample is collected (e.g., cell culture supernatant or cell lysate from cells in culture; tissue homogenate or plasma from an animal) and tested for the level of the long isoforms of the $A\beta$ peptides. The levels of the peptides may be determined in an absolute sense (e.g., nMol/ml) or in a relative sense (e.g., ratio of long to short $A\beta$ isoforms). The $A\beta$ isoforms may be detected by any means known in the art (e.g., electrophoretic separation and sequencing) but, preferably, antibodies which are specific to the long isoform are employed to determine the absolute or relative levels of the $A\beta_{1-42/43}$ or $A\beta_{x-42/43}$ peptides. Candidate pharmaceuticals or therapies which reduce the absolute or relative levels of these long $A\beta$ isoforms, particularly in the transgenic animal models of the invention, are likely to have therapeutic utility in the treatment of Alzheimer's Disease, or other disorders caused by mutations in the presenilins or PS-interacting proteins, or by other aberrations in APP metabolism.

E. Phosphorylation of Microtubule Associated Proteins

In another series of embodiments, candidate compounds may be screened for their ability to modulate presenilin or PS-interacting protein activity by assessing the effect of the compound on levels of phosphorylation of microtubule associated proteins (MAPs) such as tau. The abnormal phosphorylation of tau and other MAPs in the brains of victims of Alzheimer's Disease is well known in the art. Thus, compounds which prevent or inhibit the abnormal phosphorylation of MAPs may

-66-

have utility in treating presenilin or PS-interacting protein-associated diseases such as AD. As above, cells from normal or mutant animals or subjects, or the transformed cell lines and animal models of the invention may be employed. Preferred assays will employ cell lines or animal models transformed with a mutant human or humanized mutant presenilin or PS-interacting protein gene. The baseline phosphorylation state of MAPs in these cells may be established and then candidate compounds may be tested for their ability to prevent, inhibit or counteract the hyperphosphorylation associated with mutants. The phosphorylation state of the MAPs may be determined by any standard method known in the art but, preferably, antibodies which bind selectively to phosphorylated or unphosphorylated epitopes are employed. Such antibodies to phosphorylation epitopes of the tau protein are known in the art (e.g., ALZ50).

10. Screening and Diagnostics for Alzheimer's Disease

15 A. General Diagnostic Methods

The PS-interacting genes and gene products, as well as the PS-interacting protein derived probes, primers and antibodies, disclosed or otherwise enabled herein, are useful in the screening for carriers of alleles associated with Alzheimer's Disease, for diagnosis of victims of Alzheimer's Disease, and for the screening and diagnosis of related presenile and senile dementias, psychiatric diseases such as schizophrenia and depression, and neurologic diseases such as stroke and cerebral hemorrhage, all of which are seen to a greater or lesser extent in symptomatic human subjects bearing mutations in the PS1 or PS2 genes or in the APP gene. Individuals at risk for Alzheimer's Disease, such as those with AD present in the family pedigree, or individuals not previously known to be at risk, may be routinely screened using probes to detect the presence of a mutant PS-interacting protein gene or protein by a variety of techniques. Diagnosis of inherited cases of these diseases can be accomplished by methods based upon the nucleic acids (including genomic and mRNA/cDNA sequences), proteins, and/or antibodies disclosed and enabled herein, including functional assays designed to detect failure or augmentation of the normal

-67-

presenilin or PS-interacting protein activity and/or the presence of specific new activities conferred by mutant PS-interacting proteins. Preferably, the methods and products are based upon the human nucleic acids, proteins or antibodies, as disclosed or otherwise enabled herein. As will be obvious to one of ordinary skill in the art, however, the significant evolutionary conservation of large portions of nucleotide and amino acid sequences, even in species as diverse as humans, mice, C. elegans, and Drosophila, allow the skilled artisan to make use of non-human homologues of the PS-interacting proteins to produce useful nucleic acids, proteins and antibodies, even for applications directed toward human or other animal subjects. Thus, for brevity of exposition, but without limiting the scope of the invention, the following description will focus upon uses of the human homologues of PS-interacting proteins and genes. It will be understood, however, that homologous sequences from other species will be equivalent for many purposes.

As will be appreciated by one of ordinary skill in the art, the choice of diagnostic methods of the present invention will be influenced by the nature of the available biological samples to be tested and the nature of the information required. Alzheimer's Disease is, of course, primarily a disease of the brain, but brain biopsies are invasive and expensive procedures, particularly for routine screening. Other tissues which express the presenilins or PS-interacting proteins at significant levels may, therefore, be preferred as sources for samples.

B. Protein Based Screens and Diagnostics

When a diagnostic assay is to be based upon PS-interacting proteins, a variety of approaches are possible. For example, diagnosis can be achieved by monitoring differences in the electrophoretic mobility of normal and mutant proteins. Such an approach will be particularly useful in identifying mutants in which charge substitutions are present, or in which insertions, deletions or substitutions have resulted in a significant change in the electrophoretic migration of the resultant protein. Alternatively, diagnosis may be based upon differences in the proteolytic cleavage patterns of normal and mutant proteins, differences in molar ratios of the

-68-

various amino acid residues, or by functional assays demonstrating altered function of the gene products.

In preferred embodiments, protein-based diagnostics will employ differences in the ability of antibodies to bind to normal and mutant PS-interacting proteins. Such diagnostic tests may employ antibodies which bind to the normal proteins but not to mutant proteins, or vice versa. In particular, an assay in which a plurality of monoclonal antibodies, each capable of binding to a mutant epitope, may be employed. The levels of anti-mutant antibody binding in a sample obtained from a test subject (visualized by, for example, radiolabelling, ELISA or chemiluminescence) may be compared to the levels of binding to a control sample. Alternatively, antibodies which bind to normal but not mutant proteins may be employed, and decreases in the level of antibody binding may be used to distinguish homozygous normal individuals from mutant heterozygotes or homozygotes. Such antibody diagnostics may be used for in situ immunohistochemistry using biopsy samples of CNS tissues obtained antemortem or postmortem, including neuropathological structures associated with these diseases such as neurofibrillary tangles and amyloid plaques, or may be used with fluid samples such as cerebrospinal fluid or with peripheral tissues such as white blood cells.

C. Nucleic Acid Based Screens and Diagnostics

When the diagnostic assay is to be based upon nucleic acids from a sample, the assay may be based upon mRNA, cDNA or genomic DNA. When mRNA is used from a sample, there are considerations with respect to source tissues and the possibility of alternative splicing. That is, there may be little or no expression of transcripts unless appropriate tissue sources are chosen or available, and alternative splicing may result in the loss of some information or difficulty in interpretation. Whether mRNA, cDNA or genomic DNA is assayed, standard methods well known in the art may be used to detect the presence of a particular sequence either in situ or in vitro (see, e.g., Sambrook et al., (1989) Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Press, Cold Spring Harbor, NY). As a general matter, however, any tissue with nucleated cells may be examined.

Genomic DNA used for the diagnosis may be obtained from body cells, such as those present in the blood, tissue biopsy, surgical specimen, or autopsy material. The DNA may be isolated and used directly for detection of a specific sequence or may be amplified by the polymerase chain reaction (PCR) prior to analysis.

- 5 Similarly, RNA or cDNA may also be used, with or without PCR amplification. To detect a specific nucleic acid sequence, direct nucleotide sequencing, hybridization using specific oligonucleotides, restriction enzyme digest and mapping, PCR mapping, RNase protection, chemical mismatch cleavage, ligase-mediated detection, and various other methods may be employed. Oligonucleotides specific to particular
- 10 sequences can be chemically synthesized and labeled radioactively or non-radioactively (e.g., biotin tags, ethidium bromide), and hybridized to individual samples immobilized on membranes or other solid-supports (e.g., by dot-blot or transfer from gels after electrophoresis), or in solution. The presence or absence of the target sequences may then be visualized using methods such as autoradiography,
- 15 fluorometry, or colorimetry. These procedures can be automated using redundant, short oligonucleotides of known sequence fixed in high density to silicon chips.

(1) Appropriate Probes and Primers

- Whether for hybridization, RNase protection, ligase-mediated detection, PCR amplification or any other standards methods described herein and well known in the
- 20 art, a variety of subsequences of the PS-interacting protein sequences disclosed or otherwise enabled herein will be useful as probes and/or primers. These sequences or subsequences will include both normal sequences and deleterious mutant sequences. In general, useful sequences will include at least 8-9, more preferably 10-50, and most preferably 18-24 consecutive nucleotides from introns, exons or intron/exon
- 25 boundaries. Depending upon the target sequence, the specificity required, and future technological developments, shorter sequences may also have utility. Therefore, any PS-interacting protein derived sequence which is employed to isolate, clone, amplify, identify or otherwise manipulate a PS-interacting protein sequence may be regarded as an appropriate probe or primer. Particularly contemplated as useful will be sequences

including nucleotide positions from the PS-interacting protein genes in which disease-causing mutations are known to be present, or sequences which flank these positions.

(2) Hybridization Screening

For in situ detection of a normal or mutant PS-interacting protein-related
5 nucleic acid sequence, a sample of tissue may be prepared by standard techniques and then contacted with one or more of the above-described probes, preferably one which is labeled to facilitate detection, and an assay for nucleic acid hybridization is conducted under stringent conditions which permit hybridization only between the probe and highly or perfectly complementary sequences. Because many mutations
10 consist of a single nucleotide substitution, high stringency hybridization conditions may be required to distinguish normal sequences from most mutant sequences. When the PS-interacting protein genotypes of the subject's parents are known, probes may be chosen accordingly. Alternatively, probes to a variety of mutants may be employed sequentially or in combination. Because most individuals carrying
15 mutations in the PS-interacting proteins will be heterozygous, probes to normal sequences also may be employed and homozygous normal individuals may be distinguished from mutant heterozygotes by the amount of binding (e.g., by intensity of radioactive signal). In another variation, competitive binding assays may be employed in which both normal and mutant probes are used but only one is labeled.

20 (3) Restriction Mapping

Sequence alterations may also create or destroy fortuitous restriction enzyme recognition sites which are revealed by the use of appropriate enzyme digestion followed by gel-blot hybridization. DNA fragments carrying the site (normal or mutant) are detected by their increase or reduction in size, or by the increase or
25 decrease of corresponding restriction fragment numbers. Such restriction fragment length polymorphism analysis (RFLP), or restriction mapping, may be employed with genomic DNA, mRNA or cDNA. The PS-interacting protein sequences may be amplified by PCR using the above-described primers prior to restriction, in which case the lengths of the PCR products may indicate the presence or absence of
30 particular restriction sites, and/or may be subjected to restriction after amplification.

-71-

The restriction fragments may be visualized by any convenient means (e.g., under UV light in the presence of ethidium bromide).

(4) PCR Mapping

In another series of embodiments, a single base substitution mutation may be detected based on differential PCR product length or production in PCR. Thus, primers which span mutant sites or which, preferably, have 3' termini at mutation sites, may be employed to amplify a sample of genomic DNA, mRNA or cDNA from a subject. A mismatch at a mutational site may be expected to alter the ability of the normal or mutant primers to promote the polymerase reaction and, thereby, result in product profiles which differ between normal subjects and heterozygous and/or homozygous mutants. The PCR products of the normal and mutant gene may be differentially separated and detected by standard techniques, such as polyacrylamide or agarose gel electrophoresis and visualization with labeled probes, ethidium bromide or the like. Because of possible non-specific priming or readthrough of mutation sites, as well as the fact that most carriers of mutant alleles will be heterozygous, the power of this technique may be low.

(5) Electrophoretic Mobility

Genetic testing based on DNA sequence differences also may be achieved by detection of alterations in electrophoretic mobility of DNA, mRNA or cDNA fragments in gels. Small sequence deletions and insertions, for example, can be visualized by high resolution gel electrophoresis of single or double stranded DNA, or as changes in the migration pattern of DNA heteroduplexes in non-denaturing gel electrophoresis. Mutations or polymorphisms in the PS-interacting protein genes may also be detected by methods which exploit mobility shifts due to single-stranded conformational polymorphisms (SSCP) associated with mRNA or single-stranded DNA secondary structures.

(6) Chemical Cleavage of Mismatches

Mutations in the PS-interacting protein genes may also be detected by employing the chemical cleavage of mismatch (CCM) method (see, e.g., Saleeba and Cotton, 1993, and references therein). In this technique, probes (up to ~ 1 kb) may be

-72-

mixed with a sample of genomic DNA, cDNA or mRNA obtained from a subject. The sample and probes are mixed and subjected to conditions which allow for heteroduplex formation (if any). Preferably, both the probe and sample nucleic acids are double-stranded, or the probe and sample may be PCR amplified together, to

5 ensure creation of all possible mismatch heteroduplexes. Mismatched T residues are reactive to osmium tetroxide and mismatched C residues are reactive to hydroxylamine. Because each mismatched A will be accompanied by a mismatched T, and each mismatched G will be accompanied by a mismatched C, any nucleotide differences between the probe and sample (including small insertions or deletions)

10 will lead to the formation of at least one reactive heteroduplex. After treatment with osmium tetroxide and/or hydroxylamine to modify any mismatch sites, the mixture is subjected to chemical cleavage at any modified mismatch sites by, for example, reaction with piperidine. The mixture may then be analyzed by standard techniques such as gel electrophoresis to detect cleavage products which would indicate

15 mismatches between the probe and sample.

(7) Other Methods

Various other methods of detecting PS-interacting protein mutations, based upon the sequences disclosed and otherwise enabled herein, will be apparent to those of ordinary skill in the art. Any of these may be employed in accordance with the

20 present invention. These include, but are not limited to, nuclease protection assays (S1 or ligase-mediated), ligated PCR, denaturing gradient gel electrophoresis (DGGE; see, e.g., Fischer and Lerman, 1983), restriction endonuclease fingerprinting combined with SSCP (REF-SSCP; see, e.g., Liu and Sommer, 1995), and the like.

D. Other Screens and Diagnostics

25 In inherited cases, as the primary event, and in non-inherited cases as a secondary event due to the disease state, abnormal processing of the presenilins, PS-interacting proteins, APP, or proteins reacting with the presenilins, PS-interacting proteins, or APP may occur. This can be detected as abnormal phosphorylation, glycosylation, glycation amidation or proteolytic cleavage products in body tissues or

30 fluids (e.g., CSF or blood).

Diagnosis also can be made by observation of alterations in transcription, translation, and post-translational modification and processing, as well as alterations in the intracellular and extracellular trafficking of gene products in the brain and peripheral cells. Such changes will include alterations in the amount of messenger RNA and/or protein, alteration in phosphorylation state, abnormal intracellular location/distribution, abnormal extracellular distribution, etc. Such assays will include: Northern Blots (e.g., with PS-interacting protein-specific and non-specific nucleotide probes), Western blots and enzyme-linked immunosorbent assays (ELISA) (e.g., with antibodies raised specifically to a PS-interacting protein or PS-interacting functional domain, including various post-translational modification states including glycosylated and phosphorylated isoforms). These assays can be performed on peripheral tissues (e.g., blood cells, plasma, cultured or other fibroblast tissues, etc.) as well as on biopsies of CNS tissues obtained antemortem or postmortem, and upon cerebrospinal fluid. Such assays might also include in situ hybridization and immunohistochemistry (to localize messenger RNA and protein to specific subcellular compartments and/or within neuropathological structures associated with these diseases such as neurofibrillary tangles and amyloid plaques).

E. Screening and Diagnostic Kits

In accordance with the present invention, diagnostic kits are also provided which will include the reagents necessary for the above-described diagnostic screens. For example, kits may be provided which include antibodies or sets of antibodies which are specific to one or more mutant epitopes. These antibodies may, in particular, be labeled by any of the standard means which facilitate visualization of binding. Alternatively, kits may be provided in which oligonucleotide probes or PCR primers, as described above, are present for the detection and/or amplification of normal or mutant presenilin and/or PS-interacting protein nucleotide sequences. Again, such probes may be labeled for easier detection of specific hybridization. As appropriate to the various diagnostic embodiments described above, the oligonucleotide probes or antibodies in such kits may be immobilized to substrates and appropriate controls may be provided.

11. Methods of Treatment

The present invention now provides a basis for therapeutic intervention in diseases which are caused, or which may be caused, by mutations in the PS-

5 interacting proteins. As noted above, mutations in the hPS1 and hPS2 genes have been associated with the development of early onset forms of Alzheimer's Disease and, therefore, the present invention is particularly directed to the treatment of subjects diagnosed with, or at risk of developing, Alzheimer's Disease.

Without being bound to any particular theory of the invention, the effect of
10 the Alzheimer's Disease related mutations in the presenilins appears to be a gain of a novel function, or an acceleration of a normal function, which directly or indirectly causes aberrant processing of the Amyloid Precursor Protein (APP) into A β peptide, abnormal phosphorylation homeostasis, and/or abnormal apoptosis in the brain. Such a gain of function or acceleration of function model would be consistent with the adult
15 onset of the symptoms and the dominant inheritance of Alzheimer's Disease. Nonetheless, the mechanism by which mutations in the presenilins may cause these effects remains unknown.

The present invention, by identifying a set of PS-interacting proteins, provides new therapeutic targets for intervening in the etiology of presenilin-related
20 AD. In addition, as mutations in the presenilins may cause AD, it is likely that mutations in the PS-interacting proteins may also cause AD. The fact that the PS-interacting protein S5a is alternately processed in the brains of victims of sporadic AD, as well as in the brains of victims of presenilin-linked AD, suggests that, at the very least, this PS-interacting protein is involved in the etiology of AD independent of
25 mutations in the presenilins. It is likely that the other PS-interacting proteins also may be involved in non-presenilin-linked AD.

Therapies to treat PS-interacting protein-associated diseases such as AD may be based upon (1) administration of normal PS-interacting proteins, (2) gene therapy with normal PS-interacting protein genes to compensate for or replace the
30 mutant genes, (3) gene therapy based upon antisense sequences to mutant PS-

-75-

interacting protein genes or which "knock-out" the mutant genes, (4) gene therapy based upon sequences which encode a protein which blocks or corrects the deleterious effects of PS-interacting protein mutants, (5) immunotherapy based upon antibodies to normal and/or mutant PS-interacting proteins, or (6) small molecules (drugs) which
5 alter PS-interacting protein expression, alter interactions between PS-interacting proteins and other proteins or ligands, or which otherwise block the aberrant function of mutant presenilin or PS-interacting proteins by altering the structure of the mutant proteins, by enhancing their metabolic clearance, or by inhibiting their function.

A. Protein Therapy

10 Treatment of Alzheimer's Disease, or other disorders resulting from PS-interacting protein mutations, may be performed by replacing the mutant protein with normal protein, by modulating the function of the mutant protein, or by providing an excess of normal protein to reduce the effect of any aberrant function of the mutant proteins.

15 To accomplish this, it is necessary to obtain, as described and enabled herein, large amounts of substantially pure PS-interacting protein from cultured cell systems which can express the protein. Delivery of the protein to the affected brain areas or other tissues can then be accomplished using appropriate packaging or administration systems including, for example, liposome mediated protein delivery to
20 the target cells.

B. Gene Therapy

In one series of embodiments, gene therapy may be employed in which normal copies of a PS-interacting protein gene are introduced into patients to code successfully for normal protein in one or more different affected cell types. The gene
25 must be delivered to those cells in a form in which it can be taken up and code for sufficient protein to provide effective function. Thus, it is preferred that the recombinant gene be operably joined to a strong promoter so as to provide a high level of expression which will compensate for, or out-compete, the mutant proteins. As noted above, the recombinant construct may contain endogenous or exogenous

regulatory elements, inducible or repressible regulatory elements, or tissue-specific regulatory elements.

In another series of embodiments, gene therapy may be employed to replace the mutant gene by homologous recombination with a recombinant construct.

- 5 The recombinant construct may contain a normal copy of the targeted PS-interacting protein gene, in which case the defect is corrected in situ, or may contain a "knock-out" construct which introduces a stop codon, missense mutation, or deletion which abolished function of the mutant gene. It should be noted in this respect that such a construct may knock-out both the normal and mutant copies of the targeted gene in a heterozygous individual, but the total loss of gene function may be less deleterious to the individual than continued progression of the disease state.

- In another series of embodiments, antisense gene therapy may be employed. The antisense therapy is based on the fact that sequence-specific suppression of gene expression can be achieved by intracellular hybridization between mRNA or DNA and a complementary antisense species. The formation of a hybrid duplex may then interfere with the transcription of the gene and/or the processing, transport, translation and/or stability of the target mRNA. Antisense strategies may use a variety of approaches including the administration of antisense oligonucleotides or antisense oligonucleotide analogs (e.g., analogs with phosphorothioate backbones) or transfection with antisense RNA expression vectors. Again, such vectors may include exogenous or endogenous regulatory regions, inducible or repressible regulatory elements, or tissue-specific regulatory elements.

- In another series of embodiments, gene therapy may be used to introduce a recombinant construct encoding a protein or peptide which blocks or otherwise corrects the aberrant function caused by a mutant presenilin or PS-interacting protein gene. In one embodiment, the recombinant gene may encode a peptide which corresponds to a domain of a PS-interacting which has been found to abnormally interact with another cell protein or other cell ligand (e.g., a mutant presenilin). Thus, for example, if a mutant PS1 TM6→7 domain is found to interact with a PS-interacting protein but the corresponding normal TM6→7 domain does not undergo

-77-

this interaction, gene therapy may be employed to provide an excess of the mutant TM6→7 domain which may compete with the mutant presenilin protein and inhibit or block the aberrant interaction. Alternatively, the PS-interacting domain of a PS-interacting protein which interacts with a mutant, but not a normal, presenilin may be encoded and expressed by a recombinant construct in order to compete with, and thereby inhibit or block, the aberrant interaction.

Retroviral vectors can be used for somatic cell gene therapy especially because of their high efficiency of infection and stable integration and expression. A full length PS-interacting protein gene, subsequences encoding functional domains of these proteins, or any of the other therapeutic peptides described above, can be cloned into a retroviral vector and expression may be driven from its endogenous promoter, from the retroviral long terminal repeat, or from a promoter specific for the target cell type of interest (e.g., neurons). Other viral vectors which can be used include adeno-associated virus, vaccinia virus, bovine papilloma virus, or a herpes virus such as Epstein-Barr virus.

C. Immunotherapy

Immunotherapy is also possible for Alzheimer's Disease. Antibodies may be raised to a normal or mutant PS-interacting protein (or a portion thereof) and are administered to the patient to bind or block an aberrant interaction (e.g., with a mutant presenilin) and prevent its deleterious effects. Simultaneously, expression of the normal protein product could be encouraged. Alternatively, antibodies may be raised to specific complexes between mutant or wild-type PS-interacting proteins and their interaction partners.

A further approach is to stimulate endogenous antibody production to the desired antigen. Administration could be in the form of a one time immunogenic preparation or vaccine immunization. The PS-interacting protein or other antigen may be mixed with pharmaceutically acceptable carriers or excipients compatible with the protein. The immunogenic composition and vaccine may further contain auxiliary substances such as emulsifying agents or adjuvants to enhance effectiveness.

-78-

Immunogenic compositions and vaccines may be administered parenterally by injection subcutaneously or intramuscularly.

D. Small Molecule Therapeutics

As described and enabled herein, the present invention provides for a number of methods of identifying small molecules or other compounds which may be useful in the treatment of Alzheimer's Disease or other disorders caused by mutations in the presenilins or PS-interacting proteins. Thus, for example, the present invention provides for methods of identifying proteins which bind to normal or mutant PS-interacting proteins (aside from the presenilins). The invention also provides for methods of identifying small molecules which can be used to disrupt aberrant interactions between mutant presenilins and/or PS-interacting proteins and such other binding proteins or other cell components.

Examples

15 Example 1. Isolation of PS-interacting proteins by two-hybrid yeast system.

To identify proteins interacting with the presenilin proteins, a commercially available yeast two-hybrid kit ("Matchmaker System 2" from Clontech, Palo Alto, CA) was employed to screen a brain cDNA library for clones which interact with functional domains of the presenilins. In view of the likelihood that the TM6→7 loop domains of the presenilins are important functional domains, partial cDNA sequences encoding either residues 266-409 of the normal PS1 protein or residues 272-390 of the normal PS2 protein were ligated in-frame into the EcoRI and BamHI sites of the pAS2-1 fusion-protein expression vector (Clontech). The resultant fusion proteins contain the GAL4 DNA binding domain coupled in-frame either to the TM6→7 loop of the PS1 protein or to the TM6→7 loop of the PS2 protein. These expression plasmids were co-transformed into S. cerevisiae strain Y190 together with a library of human brain cDNAs ligated into the pACT2 yeast fusion-protein expression vector (Clontech) bearing the GAL4 activation domain using modified lithium acetate protocols of the "Matchmaker System 2" yeast two-hybrid kit (Clontech, Palo Alto, CA). Yeast clones bearing human brain cDNAs which interact

-79-

with the TM6→7 loop domain were selected for His⁻ resistance by plating on SD minimal medium lacking histidine and for βgal⁺ activation by color selection. The His⁺ βgal⁺ clones were then purged of the pAS2-1 "bait" construct by culture in 10μg/ml cyclohexamide and the unknown "trapped" inserts of the human brain

5 cDNAs encoding PS-interacting proteins were isolated by PCR and sequenced. Of 6 million initial transformants, 200 positive clones were obtained after His⁻ selection, and 42 after βgal⁺ color selection, carried out in accordance with the manufacturer's protocol for selection of positive colonies. Of these 42 clones there were several independent clones representing the same genes.

10 To address the likelihood that mutations in the presenilins cause AD through the acquisition of a novel but toxic function (i.e., dominant gain of function mutation) which is mediated by a novel interaction between the mutant proteins and one or more other cellular proteins, the human brain cDNA library cloned into the pACT2 expression vector (Clontech) was re-screened using mutant TM6→7 loop

15 domain sequences as described above and according to manufacturer's protocols. In particular, mutant presenilin sequences corresponding to residues 260-409 of PS1 TM6→7 loop domains bearing mutations L286V, L392V and Δ290-319 were ligated in-frame into the GAL4 DNA-binding domain of the pAS2-1 vector (Clontech) and used to screen the human brain cDNA:GAL4 activation domain library of pACT

20 vectors (Clontech). Yeast were co-transformed, positive colonies were selected, and "trapped" sequences were recovered and sequenced as described above. In addition to some of the same sequences recovered with the normal TM6→7 loop domains, several new sequences were obtained which reflect aberrant interactions of the mutant presenilins with normal cellular proteins.

25 The recovered and sequenced clones corresponding to these PS-interacting proteins were compared to the public sequence databases using the BL:ASTN algorithm via the NCBI e-mail server. Descriptions of several of these clones follow:

Antisecretory Factor/ Proteasome S5a Subunit. Two overlapping clones (Y2H29 and Y2H31) were identified which correspond to a C-terminal fragment of a

30 protein alternatively identified as Antisecretory Factor ("ASF") or the Multiubiquitin

-80-

chain binding S5a subunit of the 26S proteasome ("S5a") (Johansson et al. 1995; Ferrell et al., 1996). The complete nucleotide and amino acid sequences of the S5a subunit are available through the public databases under Accession number U51007 and are reproduced here as SEQ ID NO: 1 and SEQ ID NO: 2. The nucleotide
5 sequences of the Y2H29 and Y2H31 clones include nucleotides 351-1330 of SEQ ID NO: 1 and amino acid residues 70-377 of SEQ ID NO: 2. Thus, residues 70-377 of the full S5a subunit include the PS-interacting domain of this protein. Residues 206-377 of S5a contain certain motifs that are important for protein-protein interactions (Ferrell et al., 1996).

10 The PS1-S5a subunit interaction was directly re-tested for both wild type and mutant PS1 TM6→7 loop (residues 260-409) by transforming Y187 yeast cells with the appropriate wild type or mutant (L286V, L392V or Δ290-319) cDNA ligated in-frame to the GAL4-DNA binding domain of pACT2. The Δ290-319 mutant fusion construct displayed autonomous βgal activation in the absence of any S5a "target
15 sequence" and, therefore, could not be further analyzed. In contrast, both the L286V and L392V mutant constructs interacted specifically with the S5a construct. Quantitative assays, however, showed that these interactions were weaker than those involving the wild type PS1₂₆₀₋₄₀₉ sequence and that the degree of interaction was crudely correlated with the age of onset of FAD. The difference in βgal activation
20 was not attributable to instability of the mutant PS1₂₆₀₋₄₀₉ construct mRNAs or fusion proteins because Western blots of lysates of transformed yeast showed equivalent quantities of mutant or wild-type fusion proteins.

Because one of the putative functions of S5a is to bind multi-ubiquitinated proteins, the PS1:S5a interaction observed in S. cerevisiae could arise either through
25 yeast-dependent ubiquitination of the PS1₂₆₀₋₄₀₉ construct, or by direct interaction. The former would reflect a degradative pathway, a functional and perhaps reciprocal interaction between PS1 and S5a, or both. A direct interaction is favored by the fact that the PS1:S5a interaction is decreased rather than increased by the presence of the L286V and L392V mutations, and by the fact that neither of these mutations affect
30 ubiquitin conjugation sites in the PS1₂₆₀₋₄₀₉ loop (i.e., K265, K311, K314 or K395).

-81-

To further examine this possibility, we investigated the direct interaction of recombinant His-tagged fusion proteins corresponding to full length S5a and the PS1₂₆₀₋₄₀₉ loop. Partially purified recombinant His-tagged PS1₂₆₀₋₄₀₉ loop and His-tagged S5a proteins and appropriate controls were mixed in phosphate buffered saline.

5 The mixture was then subjected to size exclusion chromatography, and eluates were examined by SDS-PAGE and Western blotting using anti-His-tag monoclonal antibodies (Quiagen). In the crude PS1₂₆₀₋₄₀₉ loop preparation alone, the PS1₂₆₀₋₄₀₉ loop eluted from the size exclusion column as a broad peak at 35 minutes. In the crude S5a preparation alone, S5a eluted at 25 minutes. However, when the crude PS1₂₆₀₋₄₀₉ loop and S5a preparations were mixed, there was a significant shift in the elution of PS1₂₆₀₋₄₀₉ toward a higher molecular weight complex. Co-elution of S5a and PS1₂₆₀₋₄₀₉ in the same fraction was confirmed by SDS-PAGE and Western blotting of fractions using the anti-His-tag antibody. These results are consistent with a ubiquitin-independent and, therefore, possibly functional interaction.

15 GT24 and related genes with homology to p120/plakoglobin family. Five over-lapping clones (Y2H6, Y2H10b, Y2H17h2, Y2H24, and Y2H25) were obtained which interact with the normal PS1 TM6→7 loop domain and which appear to represent at least one novel gene. The Y2H24 clone was also found to interact with the mutant PS1 TM6→7 loop domains. Note that it appears that more than one member of the gene family was isolated, suggesting a family of genes interacting differentially with different presenilins. The most complete available cDNA corresponding to these clones was designated GT24 and is disclosed herein as SEQ ID NO: 3 and has been deposited with GenBank as Accession number U81004. The open reading frame suggests that GT24 is a protein of at least 1040 amino acids with a unique N-terminus, and considerable homology to several armadillo (arm) repeat proteins at its C-terminus. The predicted amino acid sequence of GT24 is disclosed herein as SEQ ID NO: 4. Thus, for example, residues 440-862 of GT24 have 32-56% identity ($p=1.2e^{-133}$) to residues 440-854 of murine p120 protein (Accession number Z17804), and residues 367-815 of GT24 have 26-42% identity ($p=0.0017$) to residues 245-465 of the D. melanogaster armadillo segment polarity protein (Accession

20

25

30

-82-

number P18824). The GT24 gene maps to chromosome 5p15 near the anonymous microsatellite marker D5S748 and the Cri-du-Chat syndrome locus. This sequence is also nearly identical to portions of two human ESTs of unknown function (i.e., nucleotides 2701-3018 of Accession number F08730 and nucleotides 2974-3348 of
5 Accession number T18858). These clones also show lower degrees of homology with other partial cDNA and gDNA sequences (e.g., H17245, T06654, T77214, H24294, M62015, T87427 and G04019).

p0071 gene. An additional His⁻, βgal⁺ clone isolated in the initial screening with wild type PS1₂₆₆₋₄₀₉ "bait" had a similar nucleotide sequence to GT24 (target
10 clone Y2H25; Accession number U81005), and would also be predicted to encode a peptide with C-terminal arm repeats. A longer cDNA sequence closely corresponding to the Y2H25 clone has been deposited in GenBank as human protein p0071 (Accession number X81889). The nucleotide and corresponding amino acid sequences of p0071 are reproduced herein as SEQ ID NOs: 5 and 6. Comparison of
15 the predicted sequence of the p0071 ORF with that of GT24 confirms that they are related proteins with 47% overall amino acid sequence identity, and with 70% identity between residues 346-862 of GT24, and residues 509-1022 of p0071 (which includes residues encoded by the Y2H25 cDNA). The latter result strongly suggests that PS1 interacts with a novel class of arm repeat containing proteins. The broad ~ 4 kb
20 hybridization signal obtained on Northern blots with the unique 5' end of GT24 could reflect either alternate splicing/polyadenylation of GT24, or the existence of additional members of this family with higher degrees of N-terminal homology to GT24 than p0071.

Rab11 gene. This clone (Y2H9), disclosed herein as SEQ ID NO: 7, was
25 identified as interacting with the normal PS1 TM6→7 loop domain and appears to correspond to a known gene, Rab11, available through Accession numbers X56740 and X53143. Rab11 is believed to be involved in protein/vesicle trafficking in the ER/Golgi. Note the possible relationship to processing of membrane proteins such as βAPP and Notch with resultant overproduction of toxic Aβ peptides (especially
30 neurotoxic Aβ₁₋₄₂₍₄₃₎ isoforms) (Scheuner, et al, 1995).

Retinoid X receptor- β gene. This clone (Y2H23b), disclosed herein as SEQ ID NO: 8, was identified as interacting with the normal PS1 TM6 \rightarrow 7 loop domain and appears to correspond to a known gene, known variously as the retinoid X receptor- β , nuclear receptor co-regulator or MHC Class I regulatory element, and
5 available through Accession numbers M84820, X63522 and M81766. This gene is believed to be involved in intercellular signaling, suggesting a possible relationship to the intercellular signaling function mediated by C. elegans sel12 and Notch/lin-12 (transcription activator).

Cytoplasmic chaperonin gene. This clone (Y2H27), disclosed herein as
10 SEQ ID NO: 9, was identified as interacting with the normal PS1 TM6 \rightarrow 7 loop domain and appears to correspond to a known gene, a cytoplasmic chaperonin containing TCP-1, available through Accession numbers U17104 and X74801.

Unknown gene (Y2H35). This clone (Y2H35), disclosed herein as SEQ ID NO: 10, was identified as interacting with the normal PS1 TM6 \rightarrow 7 loop domain
15 and appears to correspond to a known gene of unknown function, available through Accession number R12984, which shows conservation down through yeast.

Unknown gene (Y2H171). This clone (Y2H171), disclosed herein as SEQ ID NO: 11, was identified as interacting with the normal PS1 TM6 \rightarrow 7 loop domain and appears to correspond to a known expressed repeat sequence available through
20 Accession number D55326.

Unknown gene (Y2H41). This clone (Y2H41) was identified which reacts strongly with the TM6 \rightarrow 7 loop domains of both PS1 and PS2 as well as the mutant loop domains of PS1. The sequence, disclosed as SEQ ID NO: 12, shows strong homology to an EST of unknown function (Accession number T64843).

25 Example 2. Isolation of presenilin binding proteins by affinity chromatography.

To identify the proteins which may be involved in the biochemical function of the presenilins, PS-interacting proteins were isolated using affinity chromatography. A GST-fusion protein containing the PS1 TM6 \rightarrow 7 loop, prepared as described in Example 3, was used to probe human brain extracts, prepared by
30 homogenizing brain tissue by Polytron in physiological salt solution. Non-specific

binding was eliminated by pre-clearing the brain homogenates of endogenous GST-binding components by incubation with glutathione-Sepharose beads. These GST-free homogenates were then incubated with the GST-PS fusion proteins to produce the desired complexes with functional binding proteins. These complexes were then
5 recovered using the affinity glutathione-Sepharose beads. After extensive washing with phosphate buffered saline, the isolated collection of proteins was separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE; Tris-tricine gradient gel 4-20%). Two major bands were observed at ~14 and 20 kD in addition to several weaker bands ranging from 50 to 60 kD.

10 The same approach may now be used to identify proteins which have binding activity for the PS-interacting proteins and, thereby, to further elucidate the etiology of AD and to identify additional therapeutics targets for intervention in AD and related disorders.

Example 3. Eukaryotic and prokaryotic expression vector systems.

15 Constructs suitable for use in eukaryotic and prokaryotic expression systems have been generated using different classes of PS1 nucleotide cDNA sequence inserts. In the first class, termed full-length constructs, the entire PS1 cDNA sequence is inserted into the expression plasmid in the correct orientation, and includes both the natural 5' UTR and 3' UTR sequences as well as the entire open
20 reading frame. The open reading frames bear a nucleotide sequence cassette which allows either the wild type open reading frame to be included in the expression system or alternatively, single or a combination of double mutations can be inserted into the open reading frame. This was accomplished by removing a restriction fragment from the wild type open reading frame using the enzymes NarI and PflmI and replacing it
25 with a similar fragment generated by reverse transcriptase PCR and bearing the nucleotide sequence encoding either the M146L mutation or the H163R mutation. A second restriction fragment was removed from the wild type normal nucleotide sequence for the open reading frame by cleavage with the enzymes PflmI and NcoI and replaced with a restriction fragment bearing the nucleotide sequence encoding the
30 A246E mutation, the A260V mutation, the A285V mutation, the L286V mutation, the

L392V mutation or the C410Y mutation. A third variant, bearing a combination of either the M146L or H163R mutation in tandem with one of the remaining mutations, was made by linking a NarI-PflmI fragment bearing one of the former mutations and a PflmI-NcoI fragment bearing one of the latter mutations.

5 The second class of cDNA inserts, termed truncated constructs, was constructed by removing the 5' UTR and part of the 3' UTR sequences from full length wild type or mutant cDNA sequences. The 5' UTR sequence was replaced with a synthetic oligonucleotide containing a KpnI restriction site (GGTAC/C) and a small sequence (GCCACC) to create a Kozak initiation site around the ATG at the
10 beginning of the PS1 ORF. The 3' UTR was replaced with an oligonucleotide with an artificial EcoRI site at the 5' end. Mutant variants of this construct were then made by inserting the mutant sequences described above at the NarI-PflmI and PflmI-NcoI sites as described above.

 For eukaryotic expression, these various cDNA constructs bearing wild
15 type and mutant sequences, as described above, were cloned into the expression vector pZeoSV in which the SV60 promoter cassette had been removed by restriction digestion and replaced with the CMV promoter element of pcDNA3 (Invitrogen). For prokaryotic expression, constructs have been made using the glutathione S-transferase (GST) fusion vector pGEX-kg. The inserts which have been attached to the GST
20 fusion nucleotide sequence are the same nucleotide sequences described above bearing either the normal open reading frame nucleotide sequence, or bearing a combination of single and double mutations as described above. These GST fusion constructs allow expression of the partial or full-length protein in prokaryotic cell systems as mutant or wild type GST fusion proteins, thus allowing purification of the
25 full-length protein followed by removal of the GST fusion product by thrombin digestion. A further cDNA construct was made with the GST fusion vector, to allow the production of the amino acid sequence corresponding to the hydrophilic acidic loop domain between TM6 and TM7 of the full-length protein, either as a wild type nucleotide sequence or as a mutant sequence bearing either the A285V mutation, the
30 L286V mutation or the L392V mutation. This was accomplished by recovering wild

type or mutant sequence from appropriate sources of RNA using a 5' oligonucleotide primer with a 5' BamHI restriction site (G/GATCC), and a 3' primer with a 5' EcoRI restriction site (G/AATTC). This allowed cloning of the appropriate mutant or wild type nucleotide sequence corresponding to the hydrophilic acidic loop domain at the BamHI and the EcoRI sites within the pGEX-KG vector.

The PS-interacting protein genes may be similarly manipulated by recombinant means for expression in prokaryotic or eukaryotic hosts. In particular, GST or other fusion proteins may be produced which will be useful in assays (e.g., yeast two-hybrid studies) for therapeutics.

10 Example 4. Antibody production.

Peptide antigens corresponding to portions of the PS1 protein were synthesized by solid-phase techniques and purified by reverse phase high pressure liquid chromatography. Peptides were covalently linked to keyhole limpet hemocyanin (KLH) via disulfide linkages that were made possible by the addition of a cysteine residue at the peptide C-terminus of the presenilin fragment. This additional residue does not appear normally in the protein sequence and was included only to facilitate linkage to the KLH molecule.

A total of three New Zealand white rabbits were immunized with peptide-KLH complexes for each peptide antigen in combination with Freund's adjuvant and were subsequently given booster injections at seven day intervals. Antisera were collected for each peptide and pooled and IgG precipitated with ammonium sulfate. Antibodies were then affinity purified with Sulfo-link agarose (Pierce) coupled with the appropriate peptide. This final purification is required to remove non-specific interactions of other antibodies present in either the pre- or post-immune serum.

25 The specificity of each antibody was confirmed by three tests. First, each detected single predominant bands of the approximate size predicted for presenilin-1 on Western blots of brain homogenate. Second, each cross-reacted with recombinant fusion proteins bearing the appropriate sequence. Third each could be specifically blocked by pre-absorption with recombinant PS1 or the immunizing peptide.

Antibodies to peptides derived from the PS-interacting proteins may be produced by similar means.

Example 5. Transgenic mice.

5 A series of wild type and mutant PS1 and PS2 genes were constructed for use in the preparation of transgenic mice. Mutant versions of PS1 and PS2 were generated by site-directed mutagenesis of the cloned cDNAs using standard techniques.

10 The cDNAs and their mutant versions were used to prepare two classes of mutant and wild type PS1 and PS2 cDNAs, as described in Example 3. The first class, referred to as "full-length" cDNAs, were prepared by removing approximately 200 bp of the 3' untranslated region immediately before the polyA site by digestion with EcoRI (PS1) or PvuII (PS2). The second class, referred to as "truncated" cDNAs, were prepared by replacing the 5' untranslated region with a ribosome binding site (Kozak consensus sequence) placed immediately 5' of the ATG start
15 codon.

Various full length and truncated wild type and mutant PS1 and PS2 cDNAs, prepared as described above, were introduced into one or more of the following vectors and the resulting constructs were used as a source of gene for the production of transgenic mice.

20 The cos.TET expression vector: This vector was derived from a cosmid clone containing the Syrian hamster PrP gene. It has been described in detail by Scott et al. (1992) and Hsiao et al. (1995). PS1 and PS2 cDNAs (full length or truncated) were inserted into this vector at its SalI site. The final constructs contain 20 kb of 5' sequence flanking the inserted cDNA. This 5' flanking sequence includes the PrP
25 gene promoter, 50 bp of a PrP gene 5' untranslated region exon, a splice donor site, a 1 kb intron, and a splice acceptor site located immediately adjacent to the SalI site into which the PS1 or PS2 cDNA was inserted. The 3' sequence flanking the inserted cDNA includes an approximately 8 kb segment of PrP 3' untranslated region including a polyadenylation signal. Digestion of this construct with NotI (PS1) or
30 FseI (PS2) released a fragment containing a mutant or wild type PS gene under the

-88-

control of the PrP promoter. The released fragment was gel purified and injected into the pronuclei of fertilized mouse eggs using the method of Hsiao et al. (1995).

Platelet-derived growth factor receptor β -subunit constructs: PS cDNAs were also introduced between the Sall (full length PS1 cDNAs) or HindIII (truncated PS1 cDNAs, full length PS2 cDNAs, and truncated PS2 cDNAs) at the 3' end of the human platelet derived growth factor receptor β -subunit promoter and the EcoRI site at the 5' end of the SV40 polyA sequence and the entire cassette was cloned into the pZeoSV vector (Invitrogen, San Diego, CA.). Fragments released by ScaI/BamHI digestion were gel purified and injected into the pronuclei of fertilized mouse eggs using the method of Hsiao et al. (1995).

Human β -actin constructs: PS1 and PS2 cDNAs were inserted into the Sall site of pBACGH. The construct produced by this insertion includes 3.4 kb of the human β actin 5' flanking sequence (the human β actin promoter, a spliced 78 bp human β actin 5' untranslated exon and intron) and the PS1 or PS2 insert followed by 2.2 kb of human growth hormone genomic sequence containing several introns and exons as well as a polyadenylation signal. SfiI was used to release a PS-containing fragment which was gel purified and injected into the pronuclei of fertilized mouse eggs using the method of Hsiao et al. (1995).

Phosphoglycerate kinase constructs: PS1 and PS2 cDNAs were introduced into the pkJ90 vector. The cDNAs were inserted between the KpnI site downstream of the human phosphoglycerate kinase promoter and the XbaI site upstream of the 3' untranslated region of the human phosphoglycerate kinase gene. PvuII/HindIII (PS1 cDNAs) or PvuII (PS2 cDNAs) digestion was used to release a PS-containing fragment which was then gel purified and injected into the pronuclei of fertilized mouse eggs as described above.

Analysis of A β in transgenic murine hippocampus: To analyze the effect of a mutant human PS1 transgene in mice, a PS1 mutation observed in conjunction with a particularly severe form of early-onset PS1-linked Alzheimer's disease was used, namely the M146L missense mutation (Sherrington et al., 1995). The animals, which were heterozygous for the PS1 mutant transgene on a mixed FVB-C57BL/6

-89-

strain background, were cross-bred with similar mice bearing the human wild-type β APP₆₉₅ cDNA under the same Syrian hamster PrP promoter similar to those animals recently described by Hsiao et al., 1995. These cross breedings were done because it is thought that human A β is more susceptible to the formation of aggregates than are murine A β peptides.

The progeny of these PS1_{M146L} x β APP_{WT} cross-breedings were then genotyped to identify animals that contained both the human wild-type β APP₆₉₅ transgene and also the mutant human PS1_{M146L} transgene. These mice were aged until two to three months of age and then sacrificed, with the hippocampus and neocortex being dissected rapidly from the brain and frozen. Litter mates of these mice, which contained only the wild-type human β APP₆₉₅ transgene were also sacrificed, and their hippocampi and neocortices were dissected and rapidly frozen as well.

The concentration of both total A β peptides (A β _{X-40} and A β _{X-42 (43)}) as well as the subset of A β peptides ending on residues 42 or 43 (long-tailed A β ₄₂ peptides) were then measured using a two-sandwich ELISA as described previously (Tamaoka et al., 1994; Suzuki et al., 1994). These results convincingly showed a small increase in total A β peptides in the double transgenic animals bearing wild-type human β APP₆₉₅ and mutant human PS1_{M146L} transgenes compared to the wild-type human β APP₆₉₅ controls. More impressively, these measurements also showed that there was an increase in the amount of long-tailed A β peptides ending on residues 42 or 43 (A β ₄₂). In contrast, litter mates bearing only the wild-type human β APP₆₉₅ transgene had A β ₄₂ long-tailed peptide values which were below the limit of quantitation ("BLQ").

These observations therefore confirm that the construction of transgenic animals can recapitulate some of the biochemical features of human Alzheimer's disease (namely the overproduction of A β peptide and, in particular, overproduction of long-tailed isoforms of A β peptide). These observations thus prove that the transgenic models are in fact useful in exploring therapeutic targets relevant to the treatment and prevention of Alzheimer's disease.

-90-

Analysis of hippocampus dependent memory functions in PS1 transgenic mice: Fourteen transgenic C57BL/6 x FVB mice bearing the human PS1_{M146V} mutant transgene under the PrP promoter (as described) above and 12 wild type litter mates aged 2.5-3 months of age (both groups were balanced for age, weight, and sex) were investigated for behavioral differences attributable to the mutant transgene. Also the qualitative observation of murine behavior in their home cages did not indicate bimodal distribution of behaviors in the sample of animals.

Experiment 1. To test for subtle differences in exploratory behavior (e.g. locomotion, scanning of the environment through rearing, and patterns of investigation of unfamiliar environment), both PS1_{M146V} and wild type litter mates were tested in the open-field (Janus, et al. 1995). The results of the test revealed no significant differences between transgenics and controls in exploration of a new environment measured by mice locomotor behaviors (walking, pausing, wall leaning, rearing, grooming), ($F(1,24) = .98$, NS). Thus, differences any in behavior on the Morris water maze test (see below) cannot be attributed to differences in locomotor abilities, etc.

Experiment 2. One week after the open-field test, the PS1_{M146V} mutant transgenic mice and their litter mates were trained in the Morris water maze. In this test, a mouse has to swim in a pool in order to find a submerged escape platform. The animal solves that test through learning the location of the platform using the available extra-maze spatial cues (Morris, 1990). This test was chosen because there is strong evidence that the hippocampal formation is involved in this form of learning. The hippocampus is also a major site of AD neuropathology in humans and defects in spatial learning (geographic disorientation, losing objects, wandering, etc.) are prominent early features of human AD. As a result the test is likely to detect early changes equivalent to those seen in human AD. The Morris test is conducted in three phases. In the first phase (the learning acquisition phase), the mouse has to learn the spatial position of the platform. In the second phase (the probe trial), the platform is removed from the pool and the mouse's search for the platform is recorded. In the final phase (the learning transfer phase), the platform is replaced in

-91-

a new position in the pool, and the mouse has to learn that new spatial position of the platform.

Transgenic and wild type mice did not differ in their latencies to find the platform during learning acquisition ($F(1,24) = 0.81$, NS), and both groups showed rapid learning across trials ($F(10,15) = 11.57$, $p < 0.001$). During the probe trial phase, mice from both groups searched the quadrant of the pool which originally contained the platform significantly longer than other areas of the pool which had not contained the platform ($F(3,22) = 28.9$, $p < 0.001$). However, the wild type controls showed a trend which was not quite statistically significant ($t(24) = 1.21$, $p = 0.24$) for an increased number of crossings of the exact previous position of the platform. In the learning transfer test, both groups showed the same latency of finding the new position of the platform in the initial block of trials ($t(24) = 1.11$, NS). Such long latency to find the new spatial position is expected because the mice spent most of their time searching for the platform in the old spatial position. However, in later trials in the learning transfer phase, the wild type mice showed shorter swim latencies to the new position of the platform compared to the $PS1_{M146V}$ mutant transgenics ($F(1,24) = 2.36$, $p = 0.14$). The results indicate that $PS1_{M146V}$ mutant transgenic mice were less flexible in transferring learned information to a new situation and tended to persevere in their search for the platform in the old location.

Thus, although no differences were found in the spontaneous exploration of a new environment and in the acquisition of new spatial information between the wild type and the $PS1_{M146V}$ mutant transgenic mice, the $PS1_{M146V}$ mutant transgenic mice were impaired in switching and/or adapting this knowledge in later situations.

Electrophysiological Recordings in the hippocampus of mutant transgenic mice: Five to six months old litter mate control and human $PS1_{M146V}$ mutant transgenic mice on the same C57BL/6 x FVB strain backgrounds as above were used to study long term potentiation (LTP) as an electrophysiologic correlate of learning and memory in the hippocampus. Recordings were carried out on 400 μ m thick hippocampal slices according to conventional techniques. Briefly, brains were removed and transverse sections containing hippocampi were obtained within 1 min.

-92-

after mice were decapitated under halothane anesthesia. Slices were kept at room temperature in oxygenated artificial cerebrospinal fluid for one hour prior to recording. One slice at a time was transferred to the recording chamber, where they were maintained at 32 °C in an interface between oxygenated artificial cerebrospinal fluid and humidified air. Slices were then allowed to equilibrate in the recording chamber for another hour.

Extracellular field recordings were carried out in the CA1 subfield of the hippocampus at the Schaeffer collateral-pyramidal cell synapse. Synaptic responses were induced by the stimulation of Schaeffer collaterals at a frequency of 0.03 Hz and an intensity of 30-50 % of maximal response. Tetani to evoke long-term potentiation consisted of 5 trains of 100 Hz stimulation lasting for 200 ms at an intertrain interval of 10 seconds. Field potentials were recorded using an Axopatch 200B amplifier (Axon Instrument). Glass pipettes were fabricated from borosilicate glass with an outer diameter of 1.5 mm, and pulled with a two step Narishige puller. Data were acquired on a 486-IBM compatible computer using PCLAMP6 software (Axon Instrument).

To test for any abnormality in presynaptic function, we investigated the differences in paired-pulse facilitation, which is an example of use-dependent increase in synaptic efficacy and is considered to be presynaptic in origin. In hippocampus, when two stimuli are delivered to the Schaeffer collaterals in rapid succession, paired-pulse facilitation manifests itself as an enhanced dendritic response to the second stimulus as the interstimulus interval gets shorter. In three pairs of wild-type/transgenic mice, we did not observe any difference in the paired-pulse facilitation over an interstimulus interval range of 20 ms to 1 sec. These data suggest that in PS1_{M146V} mutant transgenic mice, the excitability of Schaeffer collateral fibers and neurotransmitter release are likely to be normal.

Tetanic stimulation induced a long-lasting increase in the synaptic strength in both control (n = 3) and PS1_{M146V} mutant transgenic mice (n = 2). In slices obtained from the PS1_{M146V} mutant transgenic mice, long-lasting increase in the synaptic strength was 30.% more than that obtained from control mice.

-93-

Although preferred embodiments of the invention have been described herein in detail, it will be understood by those skilled in the art that variations may be made thereto without departing from the spirit of the invention or the scope of the
5 appended claims.

-94-

References

- Borguski et al. (1993) Nature 366:643-654.
- Bueler et al. (1996) Nature 356:577-582.
- Chartier-Harlin et al. (1991) Nature 353:844-846.
- 5 Ferrell et al. (1996) FEBS Lett. 381:143-148.
- Fenteany et al. (1995) Science 268:726-731.
- Fischer and Lerman (1983) Proc. Natl. Acad. Sci. (USA) 80:1579-1583.
- Games et al. (1995) Nature 373:523-527.
- Gavrieli et al. (1992) J. Cell Biol. 119:493-501.
- 10 Goate et al. (1991) Nature 349:704-706.
- Gravina et al. (1995) J. Biol. Chem. 270:7013-7016.
- Greco et al. (1996) Genes & Dev. 10:313-324.
- Hilbich et al. (1991) J. Mol. Biol. 218:149-163.
- Hogan et al. (1986) Manipulating the Mouse Embryo, Cold Spring Harbor Laboratory
- 15 Press,
Cold Spring Harbor, New York.
- Hsiao et al. (1995) Neuron. (in press).
- Iwatsubo et al. (1995) Ann. Neurol. 37:294-299.
- Jacobson et al. (1993) Nature 361:365.
- 20 Janus et al. (1995). Neurobiology of Learning and Memory, 64:58-67.
- Johansson et al. (1995) J. Biol. Chem. 270:20615-20620.
- Kahn (1995) Science 270:369-370.
- Karlinsky et al. (1992) Neurology 42:1445-1453.
- Katzman (1986) N. Eng. J. Med. 314:964-973.
- 25 Kikuchi et al. (1992) Oncogene 7:289-293.
- Klafki et al. (1996) J. Biol. Chem. 271:28655-28659.
- Kosik and Greenberg (1994) Alzheimer Disease. New York, Raven Press. 335-344.
- Krause and Aaronson (1991) Methods in Enzymology, 200:546-556.
- Lamb et al. (1993) Nature Genetics 5:22-29
- 30 Lassmann et al. (1995) Acta Neuropathol. 89:35.
- Levy-Lehad et al. (1995) Science 269:970-973.

-95-

- Liu and Sommer (1995) Biotechniques 18:470-477.
- Morris (1990) Cold Spring Harbor Symposia on Quantitative Biology, 55:161-173.
- Mullan et al. (1992) Nature Genetics 1:345-347.
- Murrell et al. (1991) Science 254:97-99.
- 5 Nowak (1995) Science 270:368-371.
- Okamoto, et al. (1995) J. Biol. Chem. 270:4205-4208.
- Phizicky and Fields (1994) Microbiol. Reviews 59:94-123.
- Pike et al. (1993) J. Neurosci. 13:1676-1678.
- Podlisny et al. (1995) J. Biol. Chem. 270:9564-9570.
- 10 Rock et al. (1994) Cell 78:761-771.
- Rogaev et al. (1995) Nature 376:775-778.
- Saleeba and Cotton (1993) Methods in Enzymology 217:286-295.
- Scheuner et al. (1995) Soc. Neurosci. Abstr. 21:1500.
- Scott et al. (1992) Protein Sci. 1:986-997.
- 15 Sherrington et al. (1995) Nature 375:754-760.
- Suzuki et al. (1994) Science 264:1336-1340.
- Takada et al. (1994) Genes & Dev. 8:174-189.
- Tamaoka et al. (1994) J. Biol. Chem. 269:32721-32724.
- Tamaoka et al. (1995) Brain Res. 679:151-156.
- 20 Vito et al. (1996) Science 271:521-525.
- Wolozin et al. (1996) Science 274:1710-1713.
- Wong et al. (1996) Neuroscience 22:728.
- Yamatsuji et al. (1996) Science 272:1349-1352.
- Zheng et al. (1995) Cell 81:525-531

-96-

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: ST. GEORGE-HYSLOP, PETER H.
ROMMENS, JOHANNA M.
FRASER, PAUL E.
- (ii) TITLE OF INVENTION: NUCLEIC ACIDS AND PROTEINS RELATED TO
ALZHEIMER'S DISEASE, AND USES THEREFOR
- (iii) NUMBER OF SEQUENCES: 12
- (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Sim & McBurney
(B) STREET: 330 University Avenue, 6TH Floor
(C) CITY: Toronto
(D) STATE: Ontario
(E) COUNTRY: Canada
(F) ZIP: M5G 1R7
- (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE: 27-JAN-1997
(C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: US 08/592,541
(B) FILING DATE: 26-JAN-1996
- (vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: US 60/021,673
(B) FILING DATE: 05-JUL-1996
- (vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: US 60/021,700
(B) FILING DATE: 12-JUL-1996
- (vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: US 60/029,895
(B) FILING DATE: 08-NOV-1996
- (vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: DOCKET# CAN-006PR(d)
(B) FILING DATE: 02-JAN-1997
- (viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: RAE, Patricia A.
- (ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (416) 595-1155
(B) TELEFAX: (416) 595-1163

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1330 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 145..1275
- (D) OTHER INFORMATION: /product= "S5a"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```

AATTCCCAAA TGACCTTTTA TTTCATACAG AGATACAAAG GCAACTATGT GCAGCAACAA      60
TCTGATGGGC AGTCCAAACT CTTGGGAGGA AGTAAATTCA TGGTAAATGT CATGATGGCG      120
GTCGGGAGGG AGGAAGGTGG CAAG ATG GTG TTG GAA AGC ACT ATG GTG TGT      171
                               Met Val Leu Glu Ser Thr Met Val Cys
                               1           5
GTG GAC AAC AGT GAG TAT ATG CGG AAT GGA GAC TTC TTA CCC ACC AGG      219
Val Asp Asn Ser Glu Tyr Met Arg Asn Gly Asp Phe Leu Pro Thr Arg
10           15           20           25
CTG CAG GCC CAG CAG GAT GCT GTC AAC ATA GTT TGT CAT TCA AAG ACC      267
Leu Gln Ala Gln Gln Asp Ala Val Asn Ile Val Cys His Ser Lys Thr
30           35           40

```

-97-

CGC	AGC	AAC	CCT	GAG	AAC	AAC	GTG	GGC	CTT	ATC	ACA	CTG	GCT	AAT	GAC	315
Arg	Ser	Asn	Pro	Glu	Asn	Asn	Val	Gly	Leu	Ile	Thr	Leu	Ala	Asn	Asp	
			45					50					55			
TGT	GAA	GTG	CTG	ACC	ACA	CTC	ACC	CCA	GAC	ACT	GGC	CGT	ATC	CTG	TCC	363
Cys	Glu	Val	Leu	Thr	Thr	Leu	Thr	Pro	Asp	Thr	Gly	Arg	Ile	Leu	Ser	
		60					65					70				
AAG	CTA	CAT	ACT	GTC	CAA	CCC	AAG	GGC	AAG	ATC	ACC	TTC	TGC	ACG	GGC	411
Lys	Leu	His	Thr	Val	Gln	Pro	Lys	Gly	Lys	Ile	Thr	Phe	Cys	Thr	Gly	
	75					80					85					
ATC	CGC	GTG	GCC	CAT	CTG	GCT	CTG	AAG	CAC	CGA	CAA	GGC	AAG	AAT	CAC	459
Ile	Arg	Val	Ala	His	Leu	Ala	Leu	Lys	His	Arg	Gln	Gly	Lys	Asn	His	
	90				95					100					105	
AAG	ATG	CGC	ATC	ATT	GCC	TTT	GTG	GGA	AGC	CCA	GTG	GAG	GAC	AAT	GAG	507
Lys	Met	Arg	Ile	Ile	Ala	Phe	Val	Gly	Ser	Pro	Val	Glu	Asp	Asn	Glu	
				110					115					120		
AAG	GAT	CTG	GTG	AAA	CTG	GCT	AAA	CGC	CTC	AAG	AAG	GAG	AAA	GTA	AAT	555
Lys	Asp	Leu	Val	Lys	Leu	Ala	Lys	Arg	Leu	Lys	Lys	Glu	Lys	Val	Asn	
			125					130					135			
GTT	GAC	ATT	ATC	AAT	TTT	GGG	GAA	GAG	GAG	GTG	AAC	ACA	GAA	AAG	CTG	603
Val	Asp	Ile	Ile	Asn	Phe	Gly	Glu	Glu	Glu	Val	Asn	Thr	Glu	Lys	Leu	
		140				145						150				
ACA	GCC	TTT	GTA	AAC	ACG	TTG	AAT	GGC	AAA	GAT	GGA	ACC	GGT	TCT	CAT	651
Thr	Ala	Phe	Val	Asn	Thr	Leu	Asn	Gly	Lys	Asp	Gly	Thr	Gly	Ser	His	
	155					160					165					
CTG	GTG	ACA	GTG	CCT	CCT	GGG	CCC	AGT	TTG	GCT	GAT	GCT	CTC	ATC	AGT	699
Leu	Val	Thr	Val	Pro	Pro	Gly	Pro	Ser	Leu	Ala	Asp	Ala	Leu	Ile	Ser	
	170				175					180					185	
TCT	CCG	ATT	TTG	GCT	GGT	GAA	GGT	GGT	GCC	ATG	CTG	GGT	CTT	GGT	GCC	747
Ser	Pro	Ile	Leu	Ala	Gly	Glu	Gly	Gly	Ala	Met	Leu	Gly	Leu	Gly	Ala	
				190					195					200		
AGT	GAC	TTT	GAA	TTT	GGA	GTA	GAT	CCC	AGT	GCT	GAT	CCT	GAG	CTG	GCC	795
Ser	Asp	Phe	Glu	Phe	Gly	Val	Asp	Pro	Ser	Ala	Asp	Pro	Glu	Leu	Ala	
			205					210					215			
TTG	GCC	CTT	CGT	GTA	TCT	ATG	GAA	GAG	CAG	CGG	CAG	CGG	CAG	GAG	GAG	843
Leu	Ala	Leu	Arg	Val	Ser	Met	Glu	Glu	Gln	Arg	Gln	Arg	Gln	Glu	Glu	
			220				225					230				
GAG	GCC	CGG	CGG	GCA	GCT	GCA	GCT	TCT	GCT	GCT	GAG	GCC	GGG	ATT	GCT	891
Glu	Ala	Arg	Arg	Ala	Ala	Ala	Ala	Ser	Ala	Ala	Glu	Ala	Gly	Ile	Ala	
	235					240					245					
ACG	ACT	GGG	ACT	GAA	GAC	TCA	GAC	GAT	GCC	CTG	CTG	AAG	ATG	ACC	ATC	939
Thr	Thr	Gly	Thr	Glu	Asp	Ser	Asp	Asp	Ala	Leu	Leu	Lys	Met	Thr	Ile	
	250				255					260					265	
AGC	CAG	CAA	GAG	TTT	GGC	CGC	ACT	GGG	CTT	CCT	GAC	CTA	AGC	AGT	ATG	987
Ser	Gln	Gln	Glu	Phe	Gly	Arg	Thr	Gly	Leu	Pro	Asp	Leu	Ser	Ser	Met	
				270					275					280		
ACT	GAG	GAA	GAG	CAG	ATT	GCT	TAT	GCC	ATG	CAG	ATG	TCC	CTG	CAG	GGA	1035
Thr	Glu	Glu	Glu	Gln	Ile	Ala	Tyr	Ala	Met	Gln	Met	Ser	Leu	Gln	Gly	
			285					290					295			
GCA	GAG	TTT	GGC	CAG	GCG	GAA	TCA	GCA	GAC	ATT	GAT	GCC	AGC	TCA	GCT	1083
Ala	Glu	Phe	Gly	Gln	Ala	Glu	Ser	Ala	Asp	Ile	Asp	Ala	Ser	Ser	Ala	
		300					305					310				
ATG	GAC	ACA	TCC	GAG	CCA	GCC	AAG	GAG	GAG	GAT	GAT	TAC	GAC	GTG	ATG	1131
Met	Asp	Thr	Ser	Glu	Pro	Ala	Lys	Glu	Glu	Asp	Asp	Tyr	Asp	Val	Met	
	315					320					325					
CAG	GAC	CCC	GAG	TTC	CTT	CAG	AGT	GTC	CTA	GAG	AAC	CTC	CCA	GGT	GTG	1179
Gln	Asp	Pro	Glu	Phe		Gln	Ser	Val	Leu	Glu	Asn	Leu	Pro	Gly	Val	
	330				335					340					345	
GAT	CCC	AAC	AAT	GAA	GCC	ATT	CGA	AAT	GCT	ATG	GGC	TCC	CTG	GCC	TCC	1227
Asp	Pro	Asn	Asn	Glu	Ala	Ile	Arg	Asn	Ala	Met	Gly	Ser	Leu	Ala	Ser	
				350					355					360		
CAG	GCC	ACC	AAG	GAC	GGC	AAG	AAG	GAC	AAG	AAG	GAG	GAA	GAC	AAG	AAG	1275
Gln	Ala	Thr	Lys	Asp	Gly	Lys	Lys	Asp	Lys	Lys	Glu	Glu	Asp	Lys	Lys	
			365					370					375			
TTGAGACTGGA	GGGAAAGGGT	AGCTGAGTCT	GCTTAGGGAC	TGCATGGGGG	AATTC											1330

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 377 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

SUBSTITUTE SHEET (RULE 26)

-98-

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```

Met Val Leu Glu Ser Thr Met Val Cys Val Asp Asn Ser Glu Tyr Met
 1      5      10      15
Arg Asn Gly Asp Phe Leu Pro Thr Arg Leu Gln Ala Gln Asp Ala
 20      25      30
Val Asn Ile Val Cys His Ser Lys Thr Arg Ser Asn Pro Glu Asn Asn
 35      40      45
Val Gly Leu Ile Thr Leu Ala Asn Asp Cys Glu Val Leu Thr Thr Leu
 50      55      60
Thr Pro Asp Thr Gly Arg Ile Leu Ser Lys Leu His Thr Val Gln Pro
 65      70      75      80
Lys Gly Lys Ile Thr Phe Cys Thr Gly Ile Arg Val Ala His Leu Ala
 85      90      95
Leu Lys His Arg Gln Gly Lys Asn His Lys Met Arg Ile Ile Ala Phe
100      105      110
Val Gly Ser Pro Val Glu Asp Asn Glu Lys Asp Leu Val Lys Leu Ala
115      120      125
Lys Arg Leu Lys Lys Glu Lys Val Asn Val Asp Ile Ile Asn Phe Gly
130      135      140
Glu Glu Glu Val Asn Thr Glu Lys Leu Thr Ala Phe Val Asn Thr Leu
145      150      155      160
Asn Gly Lys Asp Gly Thr Gly Ser His Leu Val Thr Val Pro Pro Gly
165      170      175
Pro Ser Leu Ala Asp Ala Leu Ile Ser Ser Pro Ile Leu Ala Gly Glu
180      185      190
Gly Gly Ala Met Leu Gly Leu Gly Ala Ser Asp Phe Glu Phe Gly Val
195      200      205
Asp Pro Ser Ala Asp Pro Glu Leu Ala Leu Ala Leu Arg Val Ser Met
210      215      220
Glu Glu Gln Arg Gln Arg Gln Glu Glu Glu Ala Arg Arg Ala Ala Ala
225      230      235
Ala Ser Ala Ala Glu Ala Gly Ile Ala Thr Thr Gly Thr Glu Asp Ser
245      250      255
Asp Asp Ala Leu Leu Lys Met Thr Ile Ser Gln Gln Glu Phe Gly Arg
260      265      270
Thr Gly Leu Pro Asp Leu Ser Ser Met Thr Glu Glu Glu Gln Ile Ala
275      280      285
Tyr Ala Met Gln Met Ser Leu Gln Gly Ala Glu Phe Gly Gln Ala Glu
290      295      300
Ser Ala Asp Ile Asp Ala Ser Ser Ala Met Asp Thr Ser Glu Pro Ala
305      310      315
Lys Glu Glu Asp Asp Tyr Asp Val Met Gln Asp Pro Glu Phe Leu Gln
325      330      335
Ser Val Leu Glu Asn Leu Pro Gly Val Asp Pro Asn Asn Glu Ala Ile
340      345      350
Arg Asn Ala Met Gly Ser Leu Ala Ser Gln Ala Thr Lys Asp Gly Lys
355      360      365
Lys Asp Lys Lys Glu Glu Asp Lys Lys
370      375

```

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 3841 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: CDS
 (B) LOCATION: 2..3121

(ix) FEATURE:

- (A) NAME/KEY: misc feature
 (B) LOCATION: 1..3841
 (D) OTHER INFORMATION: /note= "GT24"

-99-

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

T TCA CAG CTC CCG GCC CGA GGC ACA CAA GCC CGA GST ACG GGC CAG Ser Gln Leu Pro Ala Arg Gly Thr Gln Ala Arg Xaa Thr Gly Gln	46
AGC TTC AGC CAG GGC ACG ACC AGC CGC GCC GGC CAC CTG GCG GGG CCC Ser Phe Ser Gln Gly Thr Thr Ser Arg Ala Gly His Leu Ala Gly Pro	94
GAG CCC GCG CCG CCG CCG CCG CCG CCR CCG CGG GAG CCG TTC GCG CCC Glu Pro Ala Pro Pro Pro Pro Pro Xaa Pro Arg Glu Pro Phe Ala Pro	142
AGC CTG GGC AGC GCC TTC CAC CTG CCC GAC GCG CCG CCC GCC GCC GCC Ser Leu Gly Ser Ala Phe His Leu Pro Asp Ala Pro Ala Ala Ala	190
GCC GCC GCG CTC TAC TAC TCC AKC TCC ACG CTG CCC GCG CCG CCG CGC Ala Ala Ala Leu Tyr Tyr Ser Xaa Ser Thr Leu Pro Ala Pro Pro Arg	238
GGG GGC TCC CCG CTG GCC GCG CCC CAG GGC GGT TCG CCC ACC AAG CTG Gly Gly Ser Pro Leu Ala Ala Pro Gln Gly Ser Pro Thr Lys Leu	286
CAG CGC GGC GGC TCG GCC CCC GAG GGC GCC ACC TAC GCC GCG CCG CGC Gln Arg Gly Gly Ser Ala Pro Glu Gly Ala Thr Tyr Ala Ala Pro Arg	334
GGC TCC TCG CCC AAG CAG TCG CCC AGC CGC CTG GCC AAG TCC TAC AGC Gly Ser Ser Pro Lys Gln Ser Pro Ser Arg Leu Ala Lys Ser Tyr Ser	382
ACC AGC TCG CCC ATC AAC ATC GTC GTG TCC TCG GCC GGC CTG TCC CCG Thr Ser Ser Pro Ile Asn Ile Val Ser Ser Ala Gly Leu Ser Pro	430
ATC CGC GTG ACC TCG CCC CCC ACC GTG CAG TCC ACC ATC TCC TCC TCG Ile Arg Val Thr Ser Pro Thr Val Gln Ser Thr Ile Ser Ser Ser	478
CCC ATC CAC CAG CTG AGC TCC ACC ATC GGC ACG TAC GCC ACC CTG TCG Pro Ile His Gln Leu Ser Thr Ile Gly Thr Tyr Ala Thr Leu Ser	526
CCC ACC AAG CGC CTG GTC CAC GCG TCC GAG CAG TAC AGC AAG CAC TCG Pro Thr Lys Arg Leu Val His Ala Ser Glu Gln Tyr Ser Lys His Ser	574
CAG GAG CTG TAT GCC ACG GCC ACC CTC CAG AGG CCG GGC AGC CTG GCA Gln Glu Leu Tyr Ala Thr Ala Thr Leu Gln Arg Pro Gly Ser Leu Ala	622
GCT GGT TCC CGA GCC TCA TAC AGC AGC CAG CAT GGG CAC CTG GGC CCA Ala Gly Ser Arg Ala Ser Tyr Ser Ser Gln His Gly His Leu Gly Pro	670
GAG TTG CCG GCC CTG CAG TCC CCA GAA CAC CAC ATA GAT CCC ATC TAT Glu Leu Arg Ala Leu Gln Ser Pro Glu His His Ile Asp Pro Ile Tyr	718
GAA GAC CGC GTC TAT CAG AAG CCC CCT ATG AGG AGT CTC AGC CAG AGC Glu Asp Arg Val Tyr Gln Lys Pro Pro Met Arg Ser Leu Ser Gln Ser	766
CAG GGG GAC CCT CTG CCG CCA GCA CAC ACC GGC ACC TAC CCG ACG AGC Gln Gly Asp Pro Pro Pro Ala His Thr Gly Thr Tyr Arg Thr Ser	814
ACA GCC CCA TCT TCC CCT GGT GTC GAC TCC GTC CCC TTG CAG CGC ACA Thr Ala Pro Ser Ser Pro Gly Val Asp Ser Val Pro Leu Gln Arg Thr	862
GGC AGC CAG CAC GGC CCA CAG AAT GCC GCC GCG GCC ACC TTC CAG AGG Gly Ser Gln His Gly Pro Gln Asn Ala Ala Ala Ala Thr Phe Gln Arg	910
GCC AGC TAT GCC GCC GGC CCA GCC TCC AAT TAC GCG GAC CCC TAC CGA Ala Ser Tyr Ala Ala Gly Pro Ala Ser Asn Tyr Ala Asp Pro Tyr Arg	958
CAG CTG CAG TAT TGT CCC TCT GTT GAG TCT CCA TAC AGC AAA TCC GGC Gln Leu Gln Tyr Cys Ser Ser Val Glu Ser Pro Tyr Ser Lys Ser Gly	1006
CCT GCT CTC CCG CCT GAA GGC ACC TTG GCC AGG TCC CCG TCC ATT GAT Pro Ala Leu Pro Pro Glu Gly Thr Leu Ala Arg Ser Pro Ser Ile Asp	1054
AGC ATT CAG AAA GAT CCC AGA GAA TTT GGA TGG AGA GAC CCG GAA CTG Ser Ile Gln Lys Asp Pro Arg Glu Phe Gly Trp Arg Asp Pro Glu Leu	1102
CCG GAA GTG ATT CAG ATG TTG CAG CAC CAG TTT CCC TCG GTC CAG TCT	1150

SUBSTITUTE SHEET (RULE 26)

-100-

Pro	Glu	Val	Ile	Gln	Met	Leu	Gln	His	Gln	Phe	Pro	Ser	Val	Gln	Ser	
		370					375					380				
AAC	GCG	GCA	GCC	TAC	TTG	CAA	CAC	CTC	TGT	TTT	GGA	GAC	AAC	AAA	ATT	1198
Asn	Ala	Ala	Ala	Tyr	Leu	Gln	His	Leu	Cys	Phe	Gly	Asp	Asn	Lys	Ile	
	385					390					395					
AAA	GCC	GAG	ATA	AGG	AGA	CAA	GGA	GGC	ATC	CAG	CTC	CTG	GTG	GAC	CTG	1246
Lys	Ala	Glu	Ile	Arg	Arg	Gln	Gly	Gly	Ile	Gln	Leu	Leu	Val	Asp	Leu	
	400			405						410					415	
TTG	GAT	CAT	CGG	ATG	ACC	GAA	GTC	CAC	CGT	AGT	GCC	TGT	GGA	GCT	CTG	1294
Leu	Asp	His	Arg	Met	Thr	Glu	Val	His	Arg	Ser	Ala	Cys	Gly	GCT	Ala	
				420					425				430			
AGA	AAC	CTG	GTG	TAT	GGG	AAG	GCC	AAC	GAT	GAT	AAC	AAA	ATT	GCC	CTG	1342
Arg	Asn	Leu	Val	Tyr	Gly	Lys	Ala	Asn	Asp	Asp	Asn	Lys	Ile	Ala	Leu	
			435					440					445			
AAA	AAC	TGT	GGT	GGC	ATC	CCA	GCA	CTG	GTG	AGG	TTA	CTC	CGC	AAG	ACG	1390
Lys	Asn	Cys	Gly	Gly	Ile	Pro	Ala	Leu	Val	Arg	Leu	Leu	Arg	Lys	Thr	
		450				455						460				
ACT	GAC	CTG	GAG	ATC	CGG	GAG	CTG	GTC	ACA	GGA	GTC	CTT	TGG	AAC	CTC	1438
Thr	Asp	Leu	Glu	Ile	Arg	Glu	Leu	Val	Thr	Gly	Val	Leu	Trp	Asn	Leu	
	465					470					475					
TCC	TCA	TGC	GAT	GCA	CTC	AAA	ATG	CCA	ATC	ATC	CAG	GAT	GCC	CTA	GCA	1486
Ser	Ser	Cys	Asp	Ala	Leu	Lys	Met	Pro	Ile	Ile	Gln	Asp	Ala	Leu	Ala	
	480				485					490					495	
GTA	CTG	ACC	AAC	GCG	GTG	ATT	ATC	CCC	CAC	TCA	GGC	TGG	GAA	AAT	TCG	1534
Val	Leu	Thr	Asn	Ala	Val	Ile	Ile	Pro	His	Ser	Gly	Trp	Glu	Asn	Ser	
				500					505					510		
CCT	CTT	CAG	GAT	GAT	CGG	AAA	ATA	CAG	CTG	CAT	TCA	TCA	CAG	GTG	CTG	1582
Pro	Leu	Gln	Asp	Asp	Arg	Lys	Ile	Gln	Leu	His	Ser	Ser	Gln	Val	Leu	
			515					520					525			
CGT	AAC	GCC	ACC	GGG	TGC	CTA	AGG	AAT	GTT	AGT	TCG	GCC	GGA	GAG	GAG	1630
Arg	Asn	Ala	Thr	Gly	Cys	Leu	Arg	Asn	Val	Ser	Ser	Ala	Gly	Glu	Glu	
		530					535					540				
GCC	CGC	AGA	AGG	ATG	AGA	GAG	TGT	GAT	GGG	CTT	ACG	GAT	GCC	TTG	CTG	1678
Ala	Arg	Arg	Arg	Met	Arg	Glu	Cys	Asp	Gly	Leu	Thr	Asp	Ala	Leu	Leu	
	545					550					555					
TAC	GTG	ATC	CAG	TCT	GCG	CTG	GGG	AGC	AGT	GAG	ATC	GAT	AGC	AAG	ACC	1726
Tyr	Val	Ile	Gln	Ser	Ala	Leu	Gly	Ser	Ser	Glu	Ile	Asp	Ser	Lys	Thr	
	560				565					570				575		
GTT	GAA	AAC	TGT	GTG	TGC	ATT	TTA	AGG	AAC	CTC	TCG	TAC	CGG	CTG	GCG	1774
Val	Glu	Asn	Cys	Val	Cys	Ile	Leu	Arg	Asn	Leu	Ser	Tyr	Arg	Leu	Ala	
				580					585					590		
GCA	GAA	ACG	TCT	CAG	GGA	CAG	CAC	ATG	GGC	ACG	GAC	GAG	CTG	GAC	GGG	1822
Ala	Glu	Thr	Ser	Gln	Gly	Gln	His	Met	Gly	Thr	Asp	Glu	Leu	Asp	Gly	
			595					600					605			
CTA	CTC	TGT	GGC	GAG	GCC	AAT	GGC	AAG	GAT	GCT	GAG	AGC	TCT	GGG	TGC	1870
Leu	Leu	Cys	Gly	Glu	Ala	Asn	Gly	Lys	Asp	Ala	Glu	Ser	Ser	Gly	Cys	
		610					615					620				
TGG	GGC	AAG	AAG	AAG	AAG	AAA	AAG	AAA	TCC	CAA	GAT	CAG	TGG	GAT	GGA	1918
Trp	Gly	Lys	Lys	Lys	Lys	Lys	Lys	Lys	Ser	Gln	Asp	Gln	Trp	Asp	Gly	
	625					630					635					
GTA	GGA	CCT	CTT	CCA	GAC	TGT	GCT	GAA	CCA	CCA	AAA	GGG	ATC	CAG	ATG	1966
Val	Gly	Pro	Leu	Pro	Asp	Cys	Ala	Glu	Pro	Pro	Lys	Gly	Ile	Gln	Met	
	640				645					650					655	
CTG	TGG	CAC	CCA	TCA	ATA	GTC	AAA	CCC	TAC	CTC	ACA	CTG	CTC	TCT	GAG	2014
Leu	Trp	His	Pro	Ser	Ile	Val	Lys	Pro	Tyr	Leu	Thr	Leu	Leu	Glu	Glu	
					660				665					670		
TGC	TCA	AAT	CCA	GAC	ACG	CTG	GAA	GGG	GCG	GCA	GGC	GCC	CTG	CAG	AAC	2062
Cys	Ser	Asn	Pro	Asp	Thr	Leu	Glu	Gly	Ala	Ala	Gly	Ala	Leu	Gln	Asn	
			675					680					685			
TTG	GCT	GCA	GGG	AGC	TGG	AAG	TGG	TCA	GTA	TAT	ATC	CGA	GCC	GCT	GTC	2110
Leu	Ala	Ala	Gly	Ser	Trp	Lys	Trp	Ser	Val	Tyr	Ile	Arg	Ala	Ala	Val	
			690				695					700				
CGA	AAA	GAG	AAA	GGC	CTG	CCC	ATC	CTC	GTG	GAG	CTG	CTC	CGA	ATA	GAC	2158
Arg	Lys	Glu	Lys	Gly	Leu	Pro	Ile	Leu	Val	Glu	Leu	Leu	Arg	Ile	Asp	
	705					710					715					
AAT	GAC	CGT	GTG	GTG	TGC	GCG	GTG	GCC	ACT	GCG	CTG	CGG	AAC	ATG	GCC	2206
Asn	Asp	Arg	Val	Val	Cys	Ala	Val	Ala	Thr	Ala	Leu	Arg	Asn	Met	Ala	
					725					730					735	
TTG	GAC	GTC	AGA	AAT	AAG	GAG	CTC	ATC	GGC	AAA	TAC	GCC	ATG	CGA	GAC	2254
Leu	Asp	Val	Arg	Asn	Lys	Glu	Leu	Ile	Gly	Lys	Tyr	Ala	Met	Arg	Asp	
					740				745					750		

SUBSTITUTE SHEET (RULE 26)

-101-

CTA GTC CAC AGG CTT CCA GGA GGG AAC AAC AGC AAC AAC ACT GCA AGC Leu Val His Arg 755 Leu Pro Gly Gly Asn Asn Ser Asn Asn Thr Ala Ser	2302
AAG GCC ATG TCG GAT GAC ACA GTG ACA GCT GTC TGC TGC ACA CTG CAC Lys Ala Met 770 Ser Asp Asp Thr Val Thr Ala Val Cys Cys 780 Thr Leu His	2350
GAA GTG ATT ACC AAG AAC ATG GAG AAC GCC AAG GCC TTA CGG GAT GCC Glu Val Ile Thr Lys Asn Met 790 Glu Asn Ala Lys Ala Leu Arg Asp Ala	2398
GGT GGC ATC GAG AAG TTG GTC GGC ATC TCC AAA AGC AAA GGA GAT AAA Gly Gly Ile Glu Lys Leu Val Gly Ile Ser Lys Ser Lys Gly Asp Lys	2446
CAC TCT CCA AAA GTG GTC AAG GCT GCA TCT CAG GTC CTC AAC AGC ATG His Ser Pro Lys Val Lys Ala Ala Ser Gln Val Leu Asn Ser Met	2494
TGG CAG TAC CGA GAT CTG AGG AGT CTC TAC AAA AAG GAT GGA TGG TCA Trp Gln Tyr Arg 835 Asp Leu Arg Ser Leu Tyr Lys Lys Asp 845 Trp Ser	2542
CAA TAC CAC TTT GTA GCC TCG TCT TCA ACC ATC GAG AGG GAC CGG CAA Gln Tyr His 850 Phe Val Ala Ser 855 Ser Thr Ile Glu Arg 860 Asp Arg Gln	2590
AGG CCC TAC TCC TCC TCC CGC ACG CCC TCC ATC TCC CCT GTG CGC GTG Arg Pro Tyr Ser Ser Ser 870 Thr Pro Ser Ile Ser Pro Val Arg Val	2638
TCT CCC AAC AAC CGC TCA GCA AGT GCC CCA GCT TCA CCT CGG GAA ATG Ser Pro Asn Asn Arg Ser 885 Ala Ser Ala Pro Ala Ser Pro Arg Glu Met	2686
ATC AGC CTC AAA GAA AGG AAA ACA GAC TAC GAG TGC ACC GGC AGC AAC Ile Ser Leu Lys Glu Arg Lys Thr Asp Tyr 905 Glu Cys Thr Gly Ser Asn	2734
GCC ACC TAC CAC GGA GGT AAA GGC GAA CAC ACT TCC AGG AAA GAT GCC Ala Thr Tyr His 915 Gly Gly Lys Gly Glu His Thr Ser Arg Lys Asp Ala	2782
ATG ACA GCT CAA AAC ACT GGA ATT TCA ACT TTG TAT AGG AAT TCT TAT Met Thr Ala Gln Asn Thr Gly Ile 935 Ser Thr Leu Tyr Arg Asn Ser Tyr	2830
GGT GCG CCC GCT GAA GAC ATC AAA CAC AAC CAG GTT TCA GCA CAG CCA Gly Ala Pro Ala Glu Asp Ile 950 Lys His Asn Gln Val Ser Ala Gln Pro	2878
GTC CCA CAG GAG CCC AGC AGA AAA GAT TAC GAG ACC TAC CAG CCA TTT Val Pro Gln Glu Pro Ser 965 Arg Lys Asp Tyr Glu Thr Tyr Gln Pro Phe	2926
CAG AAT TCC ACA AGA AAT TAC GAT GAG TCC TTC TTC GAG GAC CAG GTC Gln Asn Ser Thr Arg 980 Asn Tyr Asp Glu Ser Phe Phe Glu Asp Gln Val	2974
CAC CAT CGC CCT CCC GCC AGC GAG TAC ACC ATG CAC CTG GGT CTC AAG His His Arg Pro 995 Pro Ala Ser Glu Tyr Thr Met His Leu Gly Leu Lys	3022
TCC ACC GGC AAC TAC GTT GAC TTC TAC TCA GCT GCC CGT CCC TAC AGT Ser Thr Gly Asn Tyr Val Asp Phe Tyr Ser Ala Ala Arg Pro Tyr Ser	3070
GAA CTG AAC TAT GAA ACG AGC CAC TAC CCG GCC TCC CCC GAC TCC TGG Glu Leu Asn Tyr Glu Thr Ser His Tyr Pro Ala Ser Pro Asp Ser Trp	3118
GTG TGAGGAGCAG GGCACAGGCG CTCCGGGAAA CAGTGCATGT GCATGCATAC Val 1040	3171
CACAAGACAT TTCTTTCTGT TTTGGTTTTT TTCTCCTGCA AATTIAGTTT GTTAAAGCCT	3231
GTTCCATAGG AAGGCTGTGA TAACCAGTAA GGGAAATATT AAGAGCTATT TTAGAAAGCT	3291
AAATGAATCG CAAGTTAACT TGGAAATCAG TAGAAAGCTA AAGTGATCCT AAATATGACA	3351
GTGGGCAGCA CCTTTCCTAG CGTGTTNTGT TAGGAGTAAC GAGAAGTGCT TTATACTGAA	3411
CGTGGGTTGN TTGGTAGGGT GGAGNCGAGG CATTCGGGCC GGTGGGGCGT AAGGGTTATC	3471
GTTAAGCACA AGACACAGAA TAGTTTACAC ACTGTGTGGG GGACGGCTTC TCACGCTTTG	3531
TTTACTCTCT TCATCCGTTG TGA CTCTAGG CTTCAGGTTG CATTGGGGTT CCTCTGTACA	3591
GCAAGATGTT TCTTGCCCTTT TGTTAATGCA TTGTTGTAAG GTATTTGATG TACATTACAG	3651
ATTAAGAAG NAAAGCGCGT TGTGTATATT ACACCAATNC CGCCGTGTTT CCTCATCTAT	3711
GTTTCTAAAT ATTGCTTCAA TTTCAACTT TTGAAAGATG TATGGATTTC CAGTTTTTCT	3771

SUBSTITUTE SHEET (RULE 26)

-102-

TTACTTTCTC CCAGTATGTT TTAACCNMMN AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 3831
 AAAACTCGAG 3841

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1040 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Ser₁ Gln Leu Pro Ala₅ Arg Gly Thr Gln Ala₁₀ Arg Xaa Thr Gly Gln Ser₁₅
 Phe Ser Gln Gly₂₀ Thr Thr Ser Arg Ala₂₅ Gly His Leu Ala Gly₃₀ Pro Glu
 Pro Ala Pro₃₅ Pro Pro Pro Pro Xaa₄₀ Pro Arg Glu Pro Phe₄₅ Ala Pro Ser
 Leu Gly₅₀ Ser Ala Phe His Leu₅₅ Pro Asp Ala Pro Pro₆₀ Ala Ala Ala Ala
 Ala₆₅ Ala Leu Tyr Tyr Ser₇₀ Xaa Ser Thr Leu Pro₇₅ Ala Pro Pro Arg Gly₈₀
 Gly Ser Pro Leu₈₅ Ala Pro Gln Gly Gly₉₀ Ser Pro Thr Lys Leu₉₅ Gln
 Arg Gly Gly Ser₁₀₀ Ala Pro Glu Gly Ala₁₀₅ Thr Tyr Ala Ala Pro₁₁₀ Arg Gly
 Ser Ser Pro₁₁₅ Lys Gln Ser Pro Ser₁₂₀ Arg Leu Ala Lys Ser₁₂₅ Tyr Ser Thr
 Ser Ser₁₃₀ Pro Ile Asn Ile Val₁₃₅ Val Ser Ser Ala Gly₁₄₀ Leu Ser Pro Ile
 Arg₁₄₅ Val Thr Ser Pro₁₅₀ Thr Val Gln Ser Thr₁₅₅ Ile Ser Ser Ser Pro₁₆₀
 Ile His Gln Leu Ser₁₆₅ Ser Thr Ile Gly Thr₁₇₀ Tyr Ala Thr Leu Ser₁₇₅ Pro
 Thr Lys Arg Leu₁₈₀ Val His Ala Ser Glu₁₈₅ Gln Tyr Ser Lys His₁₉₀ Ser Gln
 Glu Leu Tyr₁₉₅ Ala Thr Ala Thr Leu₂₀₀ Gln Arg Pro Gly Ser₂₀₅ Leu Ala Ala
 Gly Ser₂₁₀ Arg Ala Ser Tyr Ser₂₁₅ Ser Gln His Gly His₂₂₀ Leu Gly Pro Glu
 Leu₂₂₅ Arg Ala Leu Gln Ser₂₃₀ Pro Glu His His Ile₂₃₅ Asp Pro Ile Tyr Glu₂₄₀
 Asp Arg Val Tyr Gln₂₄₅ Lys Pro Pro Met Arg₂₅₀ Ser Leu Ser Gln Ser₂₅₅ Gln
 Gly Asp Pro Leu₂₆₀ Pro Pro Ala His Thr₂₆₅ Gly Thr Tyr Arg Thr₂₇₀ Ser Thr
 Ala Pro Ser₂₇₅ Ser Pro Gly Val Asp₂₈₀ Ser Val Pro Leu Gln₂₈₅ Arg Thr Gly
 Ser Gln₂₉₀ His Gly Pro Gln Asn₂₉₅ Ala Ala Ala Ala Thr₃₀₀ Phe Gln Arg Ala
 Ser Tyr Ala Ala Gly Pro₃₁₀ Ala Ser Asn Tyr Ala₃₁₅ Asp Pro Tyr Arg Gln₃₂₀
 Leu Gln Tyr Cys Pro₃₂₅ Ser Val Glu Ser Pro₃₃₀ Tyr Ser Lys Ser Gly₃₃₅ Pro
 Ala Leu Pro Pro₃₄₀ Glu Gly Thr Leu Ala₃₄₅ Arg Ser Pro Ser Ile₃₅₀ Asp Ser
 Ile Gln Lys₃₅₅ Asp Pro Arg Glu Phe₃₆₀ Gly Trp Arg Asp Pro₃₆₅ Glu Leu Pro
 Glu Val₃₇₀ Ile Gln Met Leu Gln₃₇₅ His Gln Phe Pro Ser₃₈₀ Val Gln Ser Asn
 Ala₃₈₅ Ala Ala Tyr Leu Gln₃₉₀ His Leu Cys Phe Gly₃₉₅ Asp Asn Lys Ile Lys₄₀₀
 Ala Glu Ile Arg Arg₄₀₅ Gln Gly Gly Ile Gln₄₁₀ Leu Leu Val Asp Leu₄₁₅ Leu

SUBSTITUTE SHEET (RULE 26)

-103-

Asp His Arg Met Thr Glu Val His Arg Ser Ala Cys Gly Ala Leu Arg
 420 425 430
 Asn Leu Val Tyr Gly Lys Ala Asn Asp Asp Asn Lys Ile Ala Leu Lys
 435 440 445
 Asn Cys Gly Gly Ile Pro Ala Leu Val Arg Leu Leu Arg Lys Thr Thr
 450 455 460
 Asp Leu Glu Ile Arg Glu Leu Val Thr Gly Val Leu Trp Asn Leu Ser
 465 470 475 480
 Ser Cys Asp Ala Leu Lys Met Pro Ile Ile Gln Asp Ala Leu Ala Val
 485 490 495
 Leu Thr Asn Ala Val Ile Ile Pro His Ser Gly Trp Glu Asn Ser Pro
 500 505 510
 Leu Gln Asp Asp Arg Lys Ile Gln Leu His Ser Ser Gln Val Leu Arg
 515 520 525
 Asn Ala Thr Gly Cys Leu Arg Asn Val Ser Ser Ala Gly Glu Glu Ala
 530 535 540
 Arg Arg Arg Met Arg Glu Cys Asp Gly Leu Thr Asp Ala Leu Leu Tyr
 545 550 555 560
 Val Ile Gln Ser Ala Leu Gly Ser Ser Glu Ile Asp Ser Lys Thr Val
 565 570 575
 Glu Asn Cys Val Cys Ile Leu Arg Asn Leu Ser Tyr Arg Leu Ala Ala
 580 585 590
 Glu Thr Ser Gln Gly Gln His Met Gly Thr Asp Glu Leu Asp Gly Leu
 595 600 605
 Leu Cys Gly Glu Ala Asn Gly Lys Asp Ala Glu Ser Ser Gly Cys Trp
 610 615 620
 Gly Lys Lys Lys Lys Lys Lys Ser Gln Asp Gln Trp Asp Gly Val
 625 630 635 640
 Gly Pro Leu Pro Asp Cys Ala Glu Pro Pro Lys Gly Ile Gln Met Leu
 645 650 655
 Trp His Pro Ser Ile Val Lys Pro Tyr Leu Thr Leu Leu Ser Glu Cys
 660 665 670
 Ser Asn Pro Asp Thr Leu Glu Gly Ala Ala Gly Ala Leu Gln Asn Leu
 675 680 685
 Ala Ala Gly Ser Trp Lys Trp Ser Val Tyr Ile Arg Ala Ala Val Arg
 690 695 700
 Lys Glu Lys Gly Leu Pro Ile Leu Val Glu Leu Leu Arg Ile Asp Asn
 705 710 715 720
 Asp Arg Val Val Cys Ala Val Ala Thr Ala Leu Arg Asn Met Ala Leu
 725 730 735
 Asp Val Arg Asn Lys Glu Leu Ile Gly Lys Tyr Ala Met Arg Asp Leu
 740 745 750
 Val His Arg Leu Pro Gly Gly Asn Asn Ser Asn Asn Thr Ala Ser Lys
 755 760 765
 Ala Met Ser Asp Asp Thr Val Thr Ala Val Cys Cys Thr Leu His Glu
 770 775 780
 Val Ile Thr Lys Asn Met Glu Asn Ala Lys Ala Leu Arg Asp Ala Gly
 785 790 795 800
 Gly Ile Glu Lys Leu Val Gly Ile Ser Lys Ser Lys Gly Asp Lys His
 805 810 815
 Ser Pro Lys Val Val Lys Ala Ala Ser Gln Val Leu Asn Ser Met Trp
 820 825 830
 Gln Tyr Arg Asp Leu Arg Ser Leu Tyr Lys Lys Asp Gly Trp Ser Gln
 835 840 845
 Tyr His Phe Val Ala Ser Ser Ser Thr Ile Glu Arg Asp Arg Gln Arg
 850 855 860
 Pro Tyr Ser Ser Ser Arg Thr Pro Ser Ile Ser Pro Val Arg Val Ser
 865 870 875 880
 Pro Asn Asn Arg Ser Ala Ser Ala Pro Ala Ser Pro Arg Glu Met Ile
 885 890 895
 Ser Leu Lys Glu Arg Lys Thr Asp Tyr Glu Cys Thr Gly Ser Asn Ala
 900 905 910
 Thr Tyr His Gly Gly Lys Gly Glu His Thr Ser Arg Lys Asp Ala Met
 915 920 925

SUBSTITUTE SHEET (RULE 26)

-104-

Thr Ala Gln Asn Thr Gly Ile Ser Thr Leu Tyr Arg Asn Ser Tyr Gly
 930 935 940
 Ala Pro Ala Glu Asp Ile Lys His Asn Gln Val Ser Ala Gln Pro Val
 945 950 955 960
 Pro Gln Glu Pro Ser Arg Lys Asp Tyr Glu Thr Tyr Gln Pro Phe Gln
 965 970 975
 Asn Ser Thr Arg Asn Tyr Asp Glu Ser Phe Phe Glu Asp Gln Val His
 980 985 990
 His Arg Pro Ala Ser Glu Tyr Thr Met His Leu Gly Leu Lys Ser
 995 1000 1005
 Thr Gly Asn Tyr Val Asp Phe Tyr Ser Ala Ala Arg Pro Tyr Ser Glu
 1010 1015 1020
 Leu Asn Tyr Glu Thr Ser His Tyr Pro Ala Ser Pro Asp Ser Trp Val
 1025 1030 1035 1040

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 3907 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: CDS
 (B) LOCATION: 142..3777
 (D) OTHER INFORMATION: /note= "p0071"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

CTACTGTTGT TTTTGAGGGG CGGGCAGCCG CGCCGCCGCG GCACTTTTTT AATTTTTTCG 60
 GGTGCCG CAG CAGCGACCCC TCGGCGCCGA TGTCCTGAT CCCTGGAGCG ACGACGGCCG 120
 CTGCCTAAGC TGGGAAGAGG A ATG CCA GCT CCT GAG CAG GCC TCA TTG GTG 171
 Met Pro Ala Pro Glu Gln Ala Ser Leu Val 10
 GAG GAG GGG CAA CCA CAG ACC CGC CAG GAA GCT GCC TCC ACT GGC CCA 219
 Glu Glu Gly Gln Pro Gln Thr Arg Gln Glu Ala Ala Ser Thr Gly Pro 25
 GGC ATG GAA CCC GAG ACC ACA GCC ACC ACT ATT CTA GCA TCC GTG AAG 267
 Gly Met Glu Pro Glu Thr Thr Ala Thr Thr Ile Leu Ala Ser Val Lys 40
 GAG CAG GAG CTT CAG TTT CAG CGA CTC ACC CGA GAA CTG GAA GTG GAA 315
 Glu Gln Glu Leu Gln Phe Gln Arg Leu Thr Arg Glu Leu Glu Val Glu 55
 AGG CAG ATT GTT GCC AGT CAG CTA GAA AGA TGT AGG CTT GGA GCA GAA 363
 Arg Gln Ile Val Ala Ser Gln Leu Glu Arg Cys Arg Leu Gly Ala Glu 70
 TCA CCA AGC ATC GCC AGC ACC AGC TCA ACT GAG AAG TCA TTT CCT TGG 411
 Ser Pro Ser Ile Ala Ser Thr Ser Ser Thr Glu Lys Ser Phe Pro Trp 85 90
 AGA TCA ACA GAC GTG CCA AAT ACT GGT GTA AGC AAA CCT AGA GTT TCT 459
 Arg Ser Thr Asp Val Pro Asn Thr Gly Val Ser Lys Pro Arg Val Ser 95 105
 GAC GCT GTC CAG CCC AAC AAC TAT CTC ATC AGG ACA GAG CCA GAA CAA 507
 Asp Ala Val Gln Pro Asn Asn Tyr Leu Ile Arg Thr Glu Pro Glu Gln 110 120
 GGA ACC CTC TAT TCA CCA GAA CAG ACA TCT CTC CAT GAA AGT GAG GGA 555
 Gly Thr Leu Tyr Ser Pro Glu Gln Thr Ser Leu His Glu Ser Glu Gly 125 135
 TCA TTG GGT AAC TCA AGA AGT TCA ACA CAA ATG AAT TCT TAT TCC GAC 603
 Ser Leu Gly Asn Ser Arg Ser Ser Thr Gln Met Asn Ser Tyr Ser Asp 140 145 150
 AGT GGA TAC CAG GAA GCA GGG AGT TTC CAC AAC AGC CAG AAC GTG AGC 651
 Ser Gly Tyr Gln Glu Ala Gly Ser Phe His Asn Ser Gln Asn Val Ser 155 160 165 170
 AAG GCA GAC AAC AGA CAG CAG CAT TCA TTC ATA GGA TCA ACT AAC AAC 699
 Lys Ala Asp Asn Arg Gln Gln His Ser Phe Ile Gly Ser Thr Asn Asn 175 180 185
 CAT GTG GTG AGG AAT TCA AGA GCT GAA GGA CAA ACA CTG GTT CAG CCA 747
 His Val Val Arg Asn Ser Arg Ala Glu Gly Gln Thr Leu Val Gln Pro

SUBSTITUTE SHEET (RULE 26)

-105-

190							195					200					
TCA	GTA	GCC	AAT	CGG	GCC	ATG	AGA	AGA	GTT	AGT	TCA	GTT	CCA	TCT	AGA	795	
Ser	Val	Ala	Asn	Arg	Ala	Met	Arg	Arg	Val	Ser	Ser	Val	Pro	Ser	Arg		
		205					210					215					
GCA	CAG	TCT	CCT	TCT	TAT	GTT	ATC	AGC	ACA	GGC	GTG	TCT	CCT	TCA	AGG	843	
Ala	Gln	Ser	Pro	Ser	Tyr	Val	Ile	Ser	Thr	Gly	Val	Ser	Pro	Ser	Arg		
	220					225					230						
GGG	TCT	CTG	AGA	ACT	TCT	CTG	GGT	AGT	GGA	TTT	GGC	TCT	CCG	TCA	GTG	891	
Gly	Ser	Leu	Arg	Thr	Ser	Leu	Gly	Ser	Gly	Phe	Gly	Ser	Pro	Ser	Val		
	235				240					245					250		
ACC	GAC	CCC	CGA	CCT	CTG	AAC	CCC	AGT	GCA	TAT	TCC	TCC	ACC	ACA	TTA	939	
Thr	Asp	Pro	Arg	Pro	Leu	Asn	Pro	Ser	Ala	Tyr	Ser	Ser	Thr	Thr	Leu		
				255					260					265			
CCT	GCT	GCA	CGG	GCA	GCC	TCT	CCG	TAC	TCA	CAG	AGA	CCC	GCC	TCC	CCA	987	
Pro	Ala	Ala	Arg	Ala	Ala	Ser	Pro	Tyr	Ser	Gln	Arg	Pro	Ala	Ser	Pro		
			270					275					280				
ACA	GCT	ATA	CGG	CGG	ATT	GGG	TCA	GTC	ACC	TCC	CGG	CAG	ACC	TCC	AAT	1035	
Thr	Ala	Ile	Arg	Arg	Ile	Gly	Ser	Val	Thr	Ser	Arg	Gln	Thr	Ser	Asn		
		285					290						295				
CCC	AAC	GGA	CCA	ACC	CCT	CAA	TAC	CAA	ACC	ACC	GCC	AGA	GTG	GGG	TCC	1083	
Pro	Asn	Gly	Pro	Thr	Pro	Gln	Tyr	Gln	Thr	Thr	Ala	Arg	Val	Gly	Ser		
	300					305					310						
CCA	CTG	ACC	CTG	ACG	GAT	GCA	CAG	ACT	CGA	GTA	GCT	TCC	CCA	TCC	CAA	1131	
Pro	Leu	Thr	Leu	Thr	Asp	Ala	Gln	Thr	Arg	Val	Ala	Ser	Pro	Ser	Gln		
	315				320					325					330		
GGC	CAG	GTG	GGG	TCG	TCG	TCC	CCC	AAA	CGC	TCA	GGG	ATG	ACC	GCC	GTA	1179	
Gly	Gln	Val	Gly	Ser	Ser	Ser	Pro	Lys	Arg	Ser	Gly	Met	Thr	Ala	Val		
			335					340						345			
CCA	CAG	CAT	CTG	GGA	CCT	TCA	CTG	CAA	AGG	ACT	GTT	CAT	GAC	ATG	GAG	1227	
Pro	Gln	His	Gly	Gly	Pro	Ser	Leu	Gln	Arg	Thr	Val	His	Asp	Met	Glu		
			350					355					360				
CAA	TTC	GGA	CAG	CAG	CAG	TAT	GAC	ATT	TAT	GAG	AGG	ATG	GTT	CCA	CCC	1275	
Gln	Phe	Gly	Gln	Gln	Gln	Tyr	Asp	Ile	Tyr	Glu	Arg	Met	Val	Pro	Pro		
		365					370					375					
AGG	CCA	GAC	AGC	CTG	ACA	GGC	TTA	CGG	AGT	TCC	TAT	GCT	AGT	CAG	CAT	1323	
Arg	Pro	Asp	Ser	Leu	Thr	Gly	Leu	Arg	Ser	Ser	Tyr	Ala	Ser	Gln	His		
		380				385					390						
AGT	CAG	CTT	GGG	CAA	GAC	CTT	CGT	TCT	GCC	GTG	TCT	CCC	GAC	TTG	CAC	1371	
Ser	Gln	Leu	Gly	Gln	Asp	Leu	Arg	Ser	Ala	Val	Ser	Pro	Asp	Leu	His		
		395			400					405				410			
ATT	ACT	CCT	ATA	TAT	GAG	GGG	AGG	ACC	TAT	TAC	AGC	CCA	GTG	TAC	CGC	1419	
Ile	Thr	Pro	Ile	Tyr	Glu	Gly	Arg	Thr	Tyr	Tyr	Ser	Pro	Val	Tyr	Arg		
				415					420					425			
AGC	CCA	AAC	CAT	GGA	ACT	GTG	GAG	CTC	CAA	GGA	TCG	CAG	ACG	GCG	TTG	1467	
Ser	Pro	Asn	His	Gly	Thr	Val	Glu	Leu	Gln	Gly	Ser	Gln	Thr	Ala	Leu		
			430					435					440				
TAT	CGC	ACA	GGT	GTA	TCA	GGT	ATT	GGA	AAT	CTA	CAA	AGG	ACA	TCC	AGC	1515	
Tyr	Arg	Thr	Gly	Val	Ser	Gly	Ile	Gly	Asn	Leu	Gln	Arg	Thr	Ser	Ser		
		445				450						455					
CAA	CGA	AGT	ACC	CTT	ACA	TAC	CAA	AGA	AAT	AAT	TAT	GCT	CTG	AAC	ACA	1563	
Gln	Arg	Ser	Thr	Leu	Thr	Tyr	Gln	Arg	Asn	Asn	Tyr	Ala	Leu	Asn	Thr		
		460				465					470						
ACA	GCT	ACC	TAC	GCG	GAG	CCC	TAC	AGG	CCT	ATA	CAA	TAC	CGA	GTG	CAA	1611	
Thr	Ala	Thr	Tyr	Ala	Glu	Pro	Tyr	Arg	Pro	Ile	Gln	Tyr	Arg	Val	Gln		
		475				480				485				490			
GAG	TGC	AAT	TAT	AAC	AGG	CTT	CAG	CAT	GCA	GTG	CCG	GCT	GAT	GAT	GGC	1659	
Glu	Cys	Asn	Tyr	Asn	Arg	Leu	Gln	His	Ala	Val	Pro	Ala	Asp	Asp	Gly		
				495					500					505			
ACC	ACA	AGA	TCC	CCA	TCA	ATA	GAC	AGC	ATT	CAG	AAG	GAC	CCC	AGG	GAG	1707	
Thr	Thr	Arg	Ser	Pro	Ser	Ile	Asp	Ser	Ile	Gln	Lys	Asp	Pro	Arg	Glu		
			510					515					520				
TTT	GCC	TGG	CGT	GAT	CCT	GAG	TTG	CCT	GAG	GTC	ATT	CAC	ATG	CTT	GAG	1755	
Phe	Ala	Trp	Arg	Asp	Pro	Glu	Leu	Pro	Glu	Val	Ile	His	Met	Leu	Glu		
		525					530					535					
CAC	CAG	TTC	CCA	TCT	GTT	CAG	GCA	AAT	GCA	GCG	GCC	TAC	CTG	CAG	CAC	1803	
His	Gln	Phe	Pro	Ser	Val	Gln	Ala	Asn	Ala	Ala	Ala	Tyr	Leu	Gln	His		
		540				545					550						
CTG	TGC	TTT	GGT	GAC	AAC	AAA	GTG	AAG	ATG	GAG	GTG	TGT	AGG	TTA	GGG	1851	
Leu	Cys	Phe	Gly	Asp	Asn	Lys	Val	Lys	Met	Glu	Val	Cys	Arg	Leu	Gly		
				560						565					570		
GGA	ATC	AAG	CAT	CTG	GTT	GAC	CTT	CTG	GAC	CAC	AGA	GTT	TTG	GAA	GTT	1899	

SUBSTITUTE SHEET (RULE 26)

-106-

Gly	Ile	Lys	His	Leu	Val	Asp	Leu	Leu	Asp	His	Arg	Val	Leu	Glu	Val	
				575					580					585		
CAG	AAG	AAT	GCT	TGT	GGT	GCC	CTT	CGA	AAC	CTC	GTT	TTT	GGC	AAG	TCT	1947
Gln	Lys	Asn	Ala	Cys	Gly	Ala	Leu	Arg	Asn	Leu	Val	Phe	Gly	Lys	Ser	
			590					595					600			
ACA	GAT	GAA	AAT	AAA	ATA	GCA	ATG	AAG	AAT	GTT	GGT	GGG	ATA	CCT	GCC	1995
Thr	Asp	Glu	Asn	Lys	Ile	Ala	Met	Lys	Asn	Val	Gly	Gly	Ile	Pro	Ala	
		605					610					615				
TTG	TTG	CGA	CTG	TTG	AGA	AAA	TCT	ATT	GAT	GCA	GAA	GTA	AGG	GAG	CTT	2043
Leu	Leu	Arg	Leu	Leu	Arg	Lys	Ser	Ile	Asp	Ala	Glu	Val	Arg	Glu	Leu	
		620				625					630					
GTT	ACA	GGA	GTT	CTT	TGG	AAT	TTA	TCC	TCA	TGT	GAT	GCT	GTA	AAA	ATG	2091
Val	Thr	Gly	Val	Leu	Trp	Asn	Leu	Ser	Ser	Cys	Asp	Ala	Val	Lys	Met	
		635			640					645					650	
ACA	ATC	ATT	CGA	GAT	GCT	CTC	TCA	ACC	TTA	ACA	AAC	ACT	GTG	ATT	GTT	2139
Thr	Ile	Ile	Arg	Asp	Ala	Leu	Ser	Thr	Leu	Thr	Asn	Thr	Val	Ile	Val	
				655					660					665		
CCA	CAT	TCT	GGA	TGG	AAT	AAC	TCT	TCT	TTT	GAT	GAT	GAT	CAT	AAA	ATT	2187
Pro	His	Ser	Gly	Trp	Asn	Asn	Ser	Ser	Phe	Asp	Asp	Asp	His	Lys	Ile	
			670					675					680			
AAA	TTT	CAG	ACT	TCA	CTA	GTT	CTG	CGT	AAC	ACG	ACA	GGT	TGC	CTA	AGG	2235
Lys	Phe	Gln	Thr	Ser	Leu	Val	Leu	Arg	Asn	Thr	Thr	Gly	Cys	Leu	Arg	
		685					690					695				
AAC	CTC	ACG	TCC	GCG	GGG	GAA	GAA	GCT	CGG	AAG	CAA	ATG	CGG	TCC	TGC	2283
Asn	Leu	Thr	Ser	Ala	Gly	Glu	Glu	Ala	Arg	Lys	Gln	Met	Arg	Ser	Cys	
		700				705					710					
GAG	GGG	CTG	GTA	GAC	TCA	CTG	TTG	TAT	GTG	ATC	CAC	ACG	TGT	GTG	AAC	2331
Glu	Gly	Leu	Val	Asp	Ser	Leu	Leu	Tyr	Val	Ile	His	Thr	Cys	Val	Asn	
		715			720				725						730	
ACA	TCC	GAT	TAC	GAC	AGC	AAG	ACG	GTG	GAG	AAC	TGC	GTG	TGC	ACC	CTG	2379
Thr	Ser	Asp	Tyr	Asp	Ser	Lys	Thr	Val	Glu	Asn	Cys	Val	Cys	Thr	Leu	
				735				740						745		
AGG	AAC	CTG	TCC	TAT	CGG	CTG	GAG	CTG	GAG	GTG	CCC	CAG	GCC	CGG	TTA	2427
Arg	Asn	Leu	Ser	Tyr	Arg	Leu	Glu	Glu	Glu	Val	Pro	Gln	Ala	Arg	Leu	
			750					755					760			
CTG	GGA	CTG	AAC	GAA	TTG	GAT	GAC	TTA	CTA	GGA	AAA	GAG	TCT	CCC	AGC	2475
Leu	Gly	Leu	Asn	Glu	Leu	Asp	Asp	Leu	Leu	Gly	Lys	Glu	Ser	Pro	Ser	
		765				770						775				
AAA	GAC	TCT	GAG	CCA	AGT	TGC	TGG	GGG	AAG	AAG	AAG	AAA	AAG	AAA	AAG	2523
Lys	Asp	Ser	Glu	Pro	Ser	Cys	Trp	Gly	Lys	Lys	Lys	Lys	Lys	Lys	Lys	
		780				785					790					
AGG	ACT	CCG	CAA	GAA	GAT	CAA	TGG	GAT	GGA	GTT	GGT	CCT	ATC	CCA	GGA	2571
Arg	Thr	Pro	Gln	Glu	Asp	Gln	Trp	Asp	Gly	Val	Gly	Pro	Ile	Pro	Gly	
				800						805					810	
CTG	TCG	AAG	TCC	CCC	AAA	GGG	GTT	GAG	ATG	CTG	TGG	CAC	CCA	TCG	GTG	2619
Leu	Ser	Lys	Ser	Pro	Lys	Gly	Val	Glu	Met	Leu	Trp	His	Pro	Ser	Val	
				815					820					825		
GTA	AAA	CCA	TAT	CTG	ACT	CTT	CTA	GCA	GAA	AGT	TCC	AAC	CCA	GCC	ACC	2667
Val	Lys	Pro	Tyr	Leu	Thr	Leu	Leu	Ala	Glu	Ser	Ser	Asn	Pro	Ala	Thr	
			830					835					840			
TTG	GAA	GGC	TCT	GCA	GGG	TCT	CTC	CAG	AAC	CTC	TCT	GCT	AGC	AAC	TGG	2715
Leu	Glu	Gly	Ser	Ala	Gly	Ser	Leu	Gln	Asn	Leu	Ser	Ala	Ser	Asn	Trp	
		845					850					855				
AAG	TTT	GCA	GCA	TAT	ATC	CGG	GGC	GGC	CGT	CCG	AAA	AGA	AAA	GGG	CTC	2763
Lys	Phe	Ala	Ala	Tyr	Ile	Arg	Gly	Gly	Arg	Pro	Lys	Arg	Lys	Gly	Leu	
		860				865					870					
CCC	ATC	CTT	GTG	GAG	CTT	CTG	AGA	ATG	GAT	AAC	GAT	AGA	GTT	GTT	TCT	2811
Pro	Ile	Leu	Val	Glu	Leu	Leu	Arg	Met	Asp	Asn	Asp	Arg	Val	Val	Ser	
				880						885					890	
TCC	GGT	GCA	ACA	GCC	TTG	AGG	AAT	ATG	GCA	CTA	GAT	GTT	CGC	AAC	AAG	2859
Ser	Gly	Ala	Thr	Ala	Leu	Arg	Asn	Met	Ala	Leu	Asp	Val	Arg	Asn	Lys	
				895					900					905		
GAG	CTC	ATA	GGC	AAA	TAC	GCC	ATG	CGA	GAC	CTG	GTC	AAC	CGG	CTC	CCC	2907
Glu	Leu	Ile	Gly	Lys	Tyr	Ala	Met	Arg	Asp	Leu	Val	Asn	Arg	Leu	Pro	
		910						915					920			
GGC	GGC	AAT	GGC	CCC	AGT	GTC	TTG	TCT	GAT	GAG	ACC	ATG	GCA	GCC	ATC	2955
Gly	Gly	Asn	Gly	Pro	Ser	Val	Leu	Ser	Asp	Glu	Thr	Met	Ala	Ala	Ile	
		925					930					935				
TGC	TGT	GCT	CTG	CAC	GAG	GTC	ACC	AGC	AAA	AAC	ATG	GAG	AAC	GCA	AAA	3003
Cys	Cys	Ala	Leu	His	Glu	Val	Thr	Ser	Lys	Asn	Met	Glu	Asn	Ala	Lys	
		940				945					950					

SUBSTITUTE SHEET (RULE 26)

-107-

GCC CTG GCC GAC TCA GGA GGC ATA GAG AAG CTG GTG AAC ATA ACC AAA Ala Leu Ala Asp Ser Gly Gly Ile Glu Lys Leu Val Asn Ile Thr Lys 955 960 965 970	3051
GGC AGG GGC GAC AGA TCA TCT CTG AAA GTG GTG AAG GCA GCA GCC CAG Gly Arg Gly Asp Arg Ser Ser Leu Lys Val Val Lys Ala Ala Ala Gln 975 980 985	3099
GTC TTG AAT ACA TTA TGG CAA TAT CGG GAC CTC CGG AGC ATT TAT AAA Val Leu Asn Thr Leu Trp Gln Tyr Arg Asp Leu Arg Ser Ile Tyr Lys 990 995 1000	3147
AAG GAT GGG TGG AAT CAG AAC CAT TTT ATT ACA CCT GTG TCG ACA TTG Lys Asp Gly Trp Asn Gln Asn His Phe Ile Thr Pro Val Ser Thr Leu 1005 1010 1015	3195
GAG CGA GAC CGA TTC AAA TCA CAT CCT TCC TTG TCT ACC ACC AAC CAA Glu Arg Asp Arg Phe Lys Ile Gln Ser His Pro Ser Leu Ser Thr Thr Asn Gln 1020 1025 1030	3243
CAG ATG TCA CCC ATC ATT CAG TCA GTC GGC AGC ACC TCT TCC TCA CCA Gln Met Ser Pro Ile Ile Gln Ser Val Gly Ser Thr Ser Ser Ser Pro 1035 1040 1045 1050	3291
GCA CTG TTA GGA ATC AGA GAC CCT CGC TCT GAA TAC GAT AGG ACC CAG Ala Leu Leu Gly Ile Arg Asp Pro Arg Ser Glu Tyr Asp Arg Thr Gln 1055 1060 1065	3339
CCA CCT ATG CAG TAT TAC AAT AGC CAA GGG GAT GCC ACA CAT AAA GGC Pro Pro Met Gln Tyr Tyr Asn Ser Gln Gly Asp Ala Thr His Lys Gly 1070 1075 1080	3387
CTG TAC CCT GGC TCC AGC AAA CCT TCA CCA ATT TAC ATC AGT TCC TAT Leu Tyr Pro Gly Ser Ser Lys Pro Ser Pro Ile Tyr Ile Ser Ser Tyr 1085 1090 1095	3435
TCC TCA CCA GCA AGA GAA CAA AAT AGA CGG CTA CAG CAT CAA CAG CTG Ser Ser Pro Ala Arg Glu Gln Asn Arg Arg Leu Gln His Gln Gln Leu 1100 1105 1110	3483
TAT TAT AGT CAA GAT GAC TCC AAC AGA AAG AAC TTT GAT GCA TAC AGA Tyr Tyr Ser Gln Asp Asp Ser Asn Arg Lys Asn Phe Asp Ala Tyr Arg 1115 1120 1125 1130	3531
TTG TAT TTG CAG TCT CCT CAT AGC TAT GAA GAT CCT TAT TTT GAT GAC Leu Tyr Leu Gln Ser Pro His Ser Tyr Glu Asp Pro Tyr Phe Asp Asp 1135 1140 1145	3579
CGA GTT CAC TTT CCA GCT TCT ACT GAT TAC TCA ACA CAG TAT GGA CTG Arg Val His Phe Pro Ala Ser Thr Asp Tyr Ser Thr Gln Tyr Gly Leu 1150 1155 1160	3627
AAA TCG ACC ACA AAT TAT GTA GAC TTT TAT TCC ACT AAA CGA CCT TCT Lys Ser Thr Thr Asn Tyr Val Asp Phe Tyr Ser Thr Lys Arg Pro Ser 1165 1170 1175	3675
TAT AGA GCA GAA CAG TAC CCA GGG TCC CCA GAC TCA TGG GTG TAC GAT Tyr Arg Ala Glu Gln Tyr Pro Gly Ser Pro Asp Ser Trp Val Tyr Asp 1180 1185 1190	3723
CAA GAT GCC CAA CAG AGG AAC TCT TTC TTT CTA ACC TTG TTC AGA TTG Gln Asp Ala Gln Gln Arg Asn Ser Phe Phe Leu Thr Leu Phe Arg Leu 1195 1200 1205 1210 1215 1220	3771
AGG TGA AAAGTCCATC TTGCTGATTT CATGATTGAA ATGTGAAAGT GAAGTGGAAAG Arg	3827
GAATGAATGA AGTGTGTTTT TTTTCCTTT TTGAGGAATT ATCAGGGGAA TTCGATATCA AGCTTATCGA TACCGTCGAC	3887
	3907

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1212 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Met Pro Ala Pro Glu Gln Ala Ser Leu Val Glu Glu Gly Gln Pro Gln
 1 5 10 15
 Thr Arg Gln Glu Ala Ala Ser Thr Gly Pro Gly Met Glu Pro Glu Thr
 20 25 30
 Thr Ala Thr Thr Ile Leu Ala Ser Val Lys Glu Gln Glu Leu Gln Phe
 35 40 45
 Gln Arg Leu Thr Arg Glu Leu Glu Val Glu Arg Gln Ile Val Ala Ser
 50 55 60

SUBSTITUTE SHEET (RULE 26)

-108-

Gln₆₅ Leu Glu Arg Cys Arg₇₀ Leu Gly Ala Glu Ser₇₅ Pro Ser Ile Ala Ser₈₀
 Thr Ser Ser Thr Glu₈₅ Lys Ser Phe Pro Trp₉₀ Arg Ser Thr Asp Val₉₅ Pro
 Asn Thr Gly Val₁₀₀ Ser Lys Pro Arg Val₁₀₅ Ser Asp Ala Val Gln₁₁₀ Pro Asn
 Asn Tyr Leu₁₁₅ Ile Arg Thr Glu Pro₁₂₀ Glu Gln Gly Thr Leu₁₂₅ Tyr Ser Pro
 Glu Gln₁₃₀ Thr Ser Leu His Glu₁₃₅ Ser Glu Gly Ser Leu₁₄₀ Gly Asn Ser Arg
 Ser₁₄₅ Ser Thr Gln Met Asn₁₅₀ Ser Tyr Ser Asp Ser₁₅₅ Gly Tyr Gln Glu Ala₁₆₀
 Gly Ser Phe His Asn₁₆₅ Ser Gln Asn Val Ser₁₇₀ Lys Ala Asp Asn Arg₁₇₅ Gln
 Gln His Ser Phe₁₈₀ Ile Gly Ser Thr Asn₁₈₅ Asn His Val Val Arg₁₉₀ Asn Ser
 Arg Ala Glu₁₉₅ Gly Gln Thr Leu Val₂₀₀ Gln Pro Ser Val Ala₂₀₅ Asn Arg Ala
 Met Arg₂₁₀ Arg Val Ser Ser Val₂₁₅ Pro Ser Arg Ala Gln₂₂₀ Ser Pro Ser Tyr
 Val₂₂₅ Ile Ser Thr Gly Val₂₃₀ Ser Pro Ser Arg Gly₂₃₅ Ser Leu Arg Thr Ser₂₄₀
 Leu Gly Ser Gly Phe₂₄₅ Gly Ser Pro Ser Val₂₅₀ Thr Asp Pro Arg Pro₂₅₅ Leu
 Asn Pro Ser Ala₂₆₀ Tyr Ser Ser Thr Thr₂₆₅ Leu Pro Ala Ala Arg₂₇₀ Ala Ala
 Ser Pro Tyr₂₇₅ Ser Gln Arg Pro Ala₂₈₀ Ser Pro Thr Ala Ile₂₈₅ Arg Arg Ile
 Gly Ser₂₉₀ Val Thr Ser Arg Gln₂₉₅ Thr Ser Asn Pro Asn₃₀₀ Gly Pro Thr Pro
 Gln₃₀₅ Tyr Gln Thr Thr Ala₃₁₀ Arg Val Gly Ser Pro₃₁₅ Leu Thr Leu Thr Asp₃₂₀
 Ala Gln Thr Arg Val₃₂₅ Ala Ser Pro Ser Gln₃₃₀ Gly Gln Val Gly Ser₃₃₅ Ser
 Ser Pro Lys Arg₃₄₀ Ser Gly Met Thr Ala₃₄₅ Val Pro Gln His Leu₃₅₀ Gly Pro
 Ser Leu Gln₃₅₅ Arg Thr Val His Asp₃₆₀ Met Glu Gln Phe Gly₃₆₅ Gln Gln Gln
 Tyr Asp₃₇₀ Ile Tyr Glu Arg Met₃₇₅ Val Pro Pro Arg Pro₃₈₀ Asp Ser Leu Thr
 Gly₃₈₅ Leu Arg Ser Ser Tyr₃₉₀ Ala Ser Gln His Ser₃₉₅ Gln Leu Gly Gln Asp₄₀₀
 Leu Arg Ser Ala Val₄₀₅ Ser Pro Asp Leu His₄₁₀ Ile Thr Pro Ile Tyr₄₁₅ Glu
 Gly Arg Thr Tyr₄₂₀ Tyr Ser Pro Val Tyr₄₂₅ Arg Ser Pro Asn His₄₃₀ Gly Thr
 Val Glu Leu₄₃₅ Gln Gly Ser Gln Thr Ala₄₄₀ Leu Tyr Arg Thr₄₄₅ Gly Val Ser
 Gly Ile₄₅₀ Gly Asn Leu Gln Arg₄₅₅ Thr Ser Ser Gln Arg₄₆₀ Ser Thr Leu Thr
 Tyr₄₆₅ Gln Arg Asn Asn Tyr₄₇₀ Ala Leu Asn Thr Thr₄₇₅ Ala Thr Tyr Ala Glu₄₈₀
 Pro Tyr Arg Pro Ile₄₈₅ Gln Tyr Arg Val Gln₄₉₀ Glu Cys Asn Tyr Asn₄₉₅ Arg
 Leu Gln His Ala₅₀₀ Val Pro Ala Asp Asp₅₀₅ Gly Thr Thr Arg Ser₅₁₀ Pro Ser
 Ile Asp Ser₅₁₅ Ile Gln Lys Asp Pro₅₂₀ Arg Glu Phe Ala Trp₅₂₅ Arg Asp Pro
 Glu Leu₅₃₀ Pro Glu Val Ile His₅₃₅ Met Leu Glu His Gln₅₄₀ Phe Pro Ser Val
 Gln₅₄₅ Ala Asn Ala Ala Ala₅₅₀ Tyr Leu Gln His Leu₅₅₅ Cys Phe Gly Asp Asn₅₆₀
 Lys Val Lys Met Glu Val Cys Arg Leu Gly Gly Ile Lys His Leu Val

SUBSTITUTE SHEET (RULE 26)

-109-

565
 Asp Leu Leu Asp His Arg Val Leu Glu Val Gln Lys Asn Ala Cys Gly
 580 585 590
 Ala Leu Arg Asn Leu Val Phe Gly Lys Ser Thr Asp Glu Asn Lys Ile
 595 600 605
 Ala Met Lys Asn Val Gly Gly Ile Pro Ala Leu Leu Arg Leu Leu Arg
 610 615 620
 Lys Ser Ile Asp Ala Glu Val Arg Glu Leu Val Thr Gly Val Leu Trp
 625 630 635 640
 Asn Leu Ser Ser Cys Asp Ala Val Lys Met Thr Ile Ile Arg Asp Ala
 645 650 655
 Leu Ser Thr Leu Thr Asn Thr Val Ile Val Pro His Ser Gly Trp Asn
 660 665 670
 Asn Ser Ser Phe Asp Asp Asp His Lys Ile Lys Phe Gln Thr Ser Leu
 675 680 685
 Val Leu Arg Asn Thr Thr Gly Cys Leu Arg Asn Leu Thr Ser Ala Gly
 690 695 700
 Glu Glu Ala Arg Lys Gln Met Arg Ser Cys Glu Gly Leu Val Asp Ser
 705 710 715 720
 Leu Leu Tyr Val Ile His Thr Cys Val Asn Thr Ser Asp Tyr Asp Ser
 725 730 735
 Lys Thr Val Glu Asn Cys Val Cys Thr Leu Arg Asn Leu Ser Tyr Arg
 740 745 750
 Leu Glu Leu Glu Val Pro Gln Ala Arg Leu Leu Gly Leu Asn Glu Leu
 755 760 765
 Asp Asp Leu Leu Gly Lys Glu Ser Pro Ser Lys Asp Ser Glu Pro Ser
 770 775 780
 Cys Trp Gly Lys Lys Lys Lys Lys Lys Arg Thr Pro Gln Glu Asp
 785 790 795 800
 Gln Trp Asp Gly Val Gly Pro Ile Pro Gly Leu Ser Lys Ser Pro Lys
 805 810 815
 Gly Val Glu Met Leu Trp His Pro Ser Val Val Lys Pro Tyr Leu Thr
 820 825 830
 Leu Leu Ala Glu Ser Ser Asn Pro Ala Thr Leu Glu Gly Ser Ala Gly
 835 840 845
 Ser Leu Gln Asn Leu Ser Ala Ser Asn Trp Lys Phe Ala Ala Tyr Ile
 850 855 860
 Arg Gly Gly Arg Pro Lys Arg Lys Gly Leu Pro Ile Leu Val Glu Leu
 865 870 875 880
 Leu Arg Met Asp Asn Asp Arg Val Val Ser Ser Gly Ala Thr Ala Leu
 885 890 895
 Arg Asn Met Ala Leu Asp Val Arg Asn Lys Glu Leu Ile Gly Lys Tyr
 900 905 910
 Ala Met Arg Asp Leu Val Asn Arg Leu Pro Gly Gly Asn Gly Pro Ser
 915 920 925
 Val Leu Ser Asp Glu Thr Met Ala Ala Ile Cys Cys Ala Leu His Glu
 930 935 940
 Val Thr Ser Lys Asn Met Glu Asn Ala Lys Ala Leu Ala Asp Ser Gly
 945 950 955 960
 Gly Ile Glu Lys Leu Val Asn Ile Thr Lys Gly Arg Gly Asp Arg Ser
 965 970 975
 Ser Leu Lys Val Val Lys Ala Ala Ala Gln Val Leu Asn Thr Leu Trp
 980 985 990
 Gln Tyr Arg Asp Leu Arg Ser Ile Tyr Lys Lys Asp Gly Trp Asn Gln
 995 1000 1005
 Asn His Phe Ile Thr Pro Val Ser Thr Leu Glu Arg Asp Arg Phe Lys
 1010 1015 1020
 Ser His Pro Ser Leu Ser Thr Thr Asn Gln Gln Met Ser Pro Ile Ile
 1025 1030 1035 1040
 Gln Ser Val Gly Ser Thr Ser Ser Ser Pro Ala Leu Leu Gly Ile Arg
 1045 1050 1055
 Asp Pro Arg Ser Glu Tyr Asp Arg Thr Gln Pro Pro Met Gln Tyr Tyr
 1060 1065 1070

SUBSTITUTE SHEET (RULE 26)

-110-

Asn Ser Gln Gly Asp Ala Thr His Lys Gly Leu Tyr Pro Gly Ser Ser
 1075 1080 1085
 Lys Pro Ser Pro Ile Tyr Ile Ser Ser Tyr Ser Ser Pro Ala Arg Glu
 1090 1095 1100
 Gln Asn Arg Arg Leu Gln His Gln Gln Leu Tyr Tyr Ser Gln Asp Asp
 1105 1110 1115 1120
 Ser Asn Arg Lys Asn Phe Asp Ala Tyr Arg Leu Tyr Leu Gln Ser Pro
 1125 1130 1135
 His Ser Tyr Glu Asp Pro Tyr Phe Asp Asp Arg Val His Phe Pro Ala
 1140 1145 1150
 Ser Thr Asp Tyr Ser Thr Gln Tyr Gly Leu Lys Ser Thr Thr Asn Tyr
 1155 1160 1165
 Val Asp Phe Tyr Ser Thr Lys Arg Pro Ser Tyr Arg Ala Glu Gln Tyr
 1170 1175 1180
 Pro Gly Ser Pro Asp Ser Trp Val Tyr Asp Gln Asp Ala Gln Gln Arg
 1185 1190 1195 1200
 Asn Ser Phe Phe Leu Thr Leu Phe Arg Leu Arg *
 1205 1210

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 970 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: misc feature
 (B) LOCATION: 1..970
 (D) OTHER INFORMATION: /note= "Y2H9"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

GAATCCCAC AGATACCACT GCTGCTCCCG CCCTTTCGCT CCTCGGCCGC GCAATGGGCA	60
CCCGCGACGA CGAGTACGAC TACCTCTTTA AAGTTGTCCT TATTGGAGAT TCTGGTGTG	120
GAAAGAGTAA TCTCCTGTCT CGATTACTC GAAATGAGTT TAATCTGGAA AGCAAGAGCA	180
CCATTGGAGT AGAGTTTGCA ACAAGAAGCA TCCAGGTTGA TGGAAAAACA ATAAAGGCAC	240
AGATATGGGA CACAGCAGGG CAAGAGCGAT ATCGAGCTAT AACATCAGCA TATTATCGTG	300
GAGCTGTAGG TGCCTTATTG GTTTATGACA TTGCTAAACA TCTCACATAT GAAAATGTAG	360
AGCGATGGCT GAAAGAACTG AGAGATCATG CTGATAGTAA CATTGTTATC ATGCTTGTGG	420
GCAATAAGAG TGATCTACGT CATCTCAGGG CAGTTCCTAC AGATGAAGCA AGAGCTTTTG	480
CAGAAAAGAA TGGTTTGTCA TTCATTGAAA CTTCGGCCCT AGACTCTACA AATGTAGAAG	540
CTGCTTTTCA GACAATTTTA ACAGAGATTT ACCGCATTGT TTCTCAGAAG CAAATGTCAG	600
ACAGACGCGA AAATGACATG TCTCCAAGCA ACAATGTGGT TCCTATTCAT GTTCCACCAA	660
CCACTGAAAA CAAGCCAAAG GTGCAGTGCT GTCAGAACAT CTAAGGCATT TCTCTTCTCC	720
CCTAGAAGGC TGTGTATAGT CCATTTCCTA GGTCTASAT TTAAATATAW TTGTAATTCT	780
TGTGTCACTT TTGTGTTTTA TTACTTCATA CTTATGAATT TTTCCATGTC CTAAGTCITT	840
TGATTTTGMT TTATAAAATC ATCCACTTGT NCCGAATGNC TGCAGCTTTT TTTTCATGCTA	900
TGGCTTCACT AGCCTTAGTT TNATAAACTG AATGTTTGGA TTCCTCCCCC CAAAAA	960
AAAACCTCGAG	970

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 264 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: misc feature
 (B) LOCATION: 1..264
 (D) OTHER INFORMATION: /note= "Y2H23b"

SUBSTITUTE SHEET (RULE 26)

-111-

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

GAATTCGCGG CCGNGTCGAC CCCCCACCCC CGATGCCACC ACCCCANTG GGNTCTCCCN	60
NCCCAAGTCAT CAGTTCTTCC ATGGNGTNCC CTGGTCTGCC CCCTCCAGCT CCCCCAGGCN	120
TTCTCCGGGT CTGNCAGCAG CCNCCAGATT AACTCAACAG TGCTACTCCC TGGGGGTGGG	180
TCTGGNCCCC CTGANGATGT GAAGCCACCA GTCTNAGNGG TCCGGGGTCT GTACTGTCCA	240
CCCCCTCCAG GTGGACCTGG CGCT	264

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 340 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: misc feature
- (B) LOCATION: 1..340
- (D) OTHER INFORMATION: /note= "Y2H27"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

GAATTCGCGG CCGCGTCGAC CGCGGTCGCG TCGACCTGTT GCCCAGGCCC TAGAGGTCAT	60
TCCTCGTACC CTGATCCAGA ACTGTGGGGC CAGCACCATC CGTCTACTTA CCTCCCTTCG	120
GGCCAAAGCAC ACCCAGGAGA ACTGTGAGAC CTGGGGTGTA AATGGTGAGA CGGGTACTTT	180
GGTGGACATG AAGGAAGTGG GCATATGGGA GCCATTGGCT GTGAAGCTGC AGACTTATAA	240
GACAGCAGTG GAGACGGCAG TTCTGCTACT GCGAATTGAT GACATCGTTT CAGGCCACAA	300
AAAGAAAGGC GATGACCAGA GCCGGCAAGG CGNGGCTCCT	340

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 404 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: misc feature
- (B) LOCATION: 1..404
- (D) OTHER INFORMATION: /note= "Y2H35"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

GAATTCGCGG TCGCGTCGAC GGTTAGTCCC ACTGGNCGCA TCGAGGGNTT CACCAACGTC	60
ATGGAGCTGT ATGGCANGAT CGCCGAGGTC TTCCNCCTGC CAACTGCCGA GGTGATGTTT	120
TGCACCTGA NCACCCACAA AGTGGACATN GACAAGCTCC TGGGGGGCCA GATCGGGCTG	180
GAGGACTTCA TCTTCGCCCA CGTGAAGGGG YAGCGCAAGG AGGTGGAGGT GTTCAWGTCTG	240
GAGGATGYAC TCGGKCTCAC CATCACGGAC AACGGGGCTG GCTACGCTTC CATCAAGCGC	300
ATCAAGGAGG GCAGCGTGAT CGACCACATC CACCTCATCA GCGTGGGCGA CATGATCGAG	360
GCCATTAACG GGCAGAGCTT CCTGGGCTGC CGGCATTACG AGGT	404

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 350 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: misc feature
- (B) LOCATION: 1..350
- (D) OTHER INFORMATION: /note= "Y2H171"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

GAATTCGCGG CCGCGTCGAC AAAAAAAGTA AAAGGAACTC GGCAAATCTT ACCCCGCCTG	60
TTTACCAAAA ACATCACCTC TAGCATCACC AGTATTAGAG GCACCGCCTG CCCAGTGACA	120

SUBSTITUTE SHEET (RULE 26)

-112-

CATGTTTAAC	GGCCGCGGTA	CCCTAACCGT	GCAAAGGTAG	CATAATCACT	TGTTCCCTTAA	180
GTAGGGACCT	GTATGAATGG	CTCCACGAGG	GTTCAGCTGT	CTCTTACTTT	TAACCARTGA	240
AATTGACCTG	CCCGTGAAGA	GGCGGGCATG	ACACAGCAAG	ACGAGAAGAC	CCTATGGAGC	300
TTTAATTTAT	TAATGCAAAC	AGTACCTAAC	AAACCCACAG	GGTCCTAAAC		350

(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 350 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: misc feature
(B) LOCATION: 1..350
(D) OTHER INFORMATION: /note= "Y2H41"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

GAATTCGCGG	NCGCGTCGAC	AGATAATGAA	AAAACCAGAG	GTTCCCTTCT	TTGGTCCCCCT	60
NNNNGATGGT	GCTATTGTGA	ATGGAAAGGT	TCTACCCATT	ATGGTTAGAG	CAACAGCTAT	120
AAATGCAAGC	CGTGCTCTGA	AATCTCTGAT	TCCATTGTAT	CAAAACTTCT	ATGAGGAGAG	180
AGCACGATAC	CTGCAAACAA	TTGTCCAGCA	CCACTTAGAA	CCAACAACAT	TTGAAGATTT	240
TGNAGCACAG	GTTTTTCTC	CAGCTCCCTA	CCACCATTTA	CCATCTGATG	CCGTTGGCTC	300
CTACCCAGAG	ATTCTACCCA	GTGAAAACTC	CCACAGCAAC	GCAGGTAGGA		350

-113-

CLAIMS

What is claimed is:

1. An isolated nucleic acid comprising a nucleotide sequence encoding at least a presenilin-interacting domain of a presenilin-interacting protein selected from the group consisting of a mammalian S5a (approximately residues 70-377 of SEQ ID NO: 2), GT24 (approximately residues 346-862 of SEQ ID NO: 4), p0071 (approximately residues 509-1022 of SEQ ID NO: 6), Rab11 (SEQ ID NO: 7), retinoid X receptor- β (SEQ ID NO: 8), cytoplasmic chaperonin (SEQ ID NO: 9), Y2H35 (SEQ ID NO: 10), Y2H171 (SEQ ID NO: 11), and a Y2H41 (SEQ ID NO: 12) presenilin-interacting domain.
2. An isolated nucleic acid comprising a nucleotide sequence of at least 10 consecutive nucleotides selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, GenBank Accession Numbers F08730, T18858, X81889, X56740, X53143, M84820, X63522, M81766, U17104, X74801, R12984, D55326, and T64843, and a sequence complementary to any of these sequences.
3. An isolated nucleic acid as in claim 2 comprising a nucleotide sequence of at least 15 consecutive nucleotides selected from said group.
4. An isolated nucleic acid as in claim 2 comprising a nucleotide sequence of at least 20 consecutive nucleotides selected from said group.

-114-

5. An isolated nucleic acid comprising a nucleotide sequence encoding an antigenic determinant of a presenilin-interacting protein selected from the group consisting of a mammalian S5a, GT24, p0071, Rab11, retinoid X receptor- β , cytoplasmic chaperonin, Y2H35, Y2H171, and Y2H41 protein.

5

6. A method for identifying allelic variants or heterospecific homologues of a human presenilin-interacting protein gene comprising

choosing a nucleic acid probe or primer capable of hybridizing to a human presenilin-interacting protein gene sequence under stringent hybridization conditions;

10 mixing said probe or primer with a sample of nucleic acids which may contain a nucleic acid corresponding to said variant or homologue;

detecting hybridization of said probe or primer to said nucleic acid corresponding to said variant or homologue.

15 7. A method as in claim 6 wherein said sample comprises a sample of nucleic acids selected from the group consisting of human genomic DNA, human mRNA, and human cDNA.

8. A method as in claim 6 wherein said sample comprises a sample of nucleic
20 acids selected from the group consisting of mammalian genomic DNA, mammalian mRNA, and mammalian cDNA.

9. A method as in claim 6 wherein said sample comprises a sample of nucleic
25 acids selected from the group consisting of invertebrate genomic DNA, invertebrate mRNA, and invertebrate cDNA.

-115-

10. A method as in claim 6 further comprising the step of isolating said nucleic acid corresponding to said variant or homologue.
- 5 11. A method as in claim 6 wherein said nucleic acid is identified by hybridization.
12. A method as in claim 6 wherein said nucleic acid is identified by PCR amplification.
- 10 13. A method for identifying allelic variants or heterospecific homologues of a human presenilin-interacting protein gene comprising
- choosing an antibody capable of selectively binding to a human presenilin-interacting protein;
- 15 mixing said antibody with a sample of proteins which may contain a protein corresponding to said variant or homologue;
- detecting binding of said antibody to said protein corresponding to said variant or homologue.
- 20 14. A method as in claim 13 wherein said sample comprises a sample of proteins selected from the group consisting of human proteins, human fusion proteins, and proteolytic fragments thereof.

-116-

15. A method as in claim 13 wherein said sample comprises a sample of proteins selected from the group consisting of mammalian proteins, mammalian fusion proteins, and proteolytic fragments thereof.
- 5 16. A method as in claim 13 wherein said sample comprises a sample of proteins selected from the group consisting of invertebrate proteins, invertebrate fusion proteins, and proteolytic fragments thereof.
- 10 17. A method as in claim 13 further comprising the step of substantially purifying said protein corresponding to said variant or homologue.
18. An isolated nucleic acid comprising an allelic variant or a heterospecific homologue of a human presenilin-interacting protein gene.
- 15 19. An isolated nucleic acid encoding an allelic variant or heterospecific homologue of a human presenilin-interacting protein.
20. An isolated nucleic acid comprising a recombinant vector including a nucleotide sequence of any one of claims 1-19.
- 20 21. An isolated nucleic acid as in claim 20 wherein said vector is an expression vector and said presenilin-interacting protein nucleotide sequence is operably joined to a regulatory region.

-117-

22. An isolated nucleic acid as in claim 21 wherein said expression vector may express said presenilin-interacting protein sequence in mammalian cells.
- 5 23. An isolated nucleic acid as in claim 22 wherein said cells are selected from the group consisting of fibroblast, liver, kidney, spleen, bone marrow and neurological cells.
24. An isolated nucleic acid as in claim 21 wherein said vector is selected from
10 the group consisting of vaccinia virus, adenovirus, retrovirus, neurotropic viruses and Herpes simplex.
25. An isolated nucleic acid as in claim 21 wherein said expression vector encodes at least a presenilin-interacting domain of a presenilin-interacting protein
15 selected from the group consisting of a mammalian S5a, GT24, p0071, Rab11, retinoid X receptor- β , cytoplasmic chaperonin, Y2H35, Y2H171, and Y2H41 protein.
26. An isolated nucleic acid as in claim 21 wherein said vector further comprises sequences encoding an exogenous protein operably joined to said
20 presenilin-interacting protein sequence and whereby said vector encodes a presenilin-interacting protein fusion protein.
27. An isolated nucleic acid as in claim 26 wherein said exogenous protein is selected from the group consisting of lacZ, trpE, maltose-binding protein, a poly-His

-118-

tag, glutathione-S-transferase, a GAL4-DNA binding domain, and a GAL4 activation domain.

28. An isolated nucleic acid comprising a recombinant expression vector
5 including nucleotide sequences corresponding to an endogenous regulatory region of a presenilin-interacting protein gene.

29. An isolated nucleic acid as in claim 28 wherein said endogenous regulatory region is operably joined to a marker gene.

10

30. A host cell transformed with an expression vector of any one of claims 20-29, or a descendant thereof.

31. A host cell as in claim 30 wherein said host cell is selected from the group
15 consisting of bacterial cells and yeast cells.

32. A host cell as in claim 30 wherein said host cell is selected from the group consisting of fetal cells, embryonic stem cells, zygotes, gametes, and germ line cells.

20 33. A host cell as in claim 30 wherein said cell is selected from the group consisting of fibroblast, liver, kidney, spleen, bone marrow and neurological cells.

-119-

34. A host cell as in claim 30 wherein said cell is an invertebrate cell.

35. A non-human animal model for Alzheimer's Disease, wherein a genome of said animal, or an ancestor thereof, has been modified by at least one recombinant
5 construct, and wherein said recombinant construct has introduced a modification selected from the group consisting of (1) insertion of nucleotide sequences encoding at least a functional domain of a heterospecific normal presenilin-interacting protein, (2) insertion of nucleotide sequences encoding at least a functional domain of a heterospecific mutant presenilin-interacting protein, (3) insertion of nucleotide
10 sequences encoding at least a functional domain of a conspecific homologue of a heterospecific mutant presenilin-interacting protein, and (4) inactivation of an endogenous presenilin-interacting protein gene.

36. An animal as in claim 35 wherein said modification is insertion of a
15 nucleotide sequence encoding at least a functional domain of a normal human presenilin-interacting protein selected from the group consisting of a mammalian S5a, GT24, p0071, Rab11, retinoid X receptor- β , cytoplasmic chaperonin, Y2H35, Y2H171, and Y2H41 protein.

20 37. An animal as in claim 35 wherein said modification is insertion of a nucleotide sequence encoding at least a functional domain of a mutant human presenilin-interacting protein selected from the group consisting of a mammalian S5a, GT24, p0071, Rab11, retinoid X receptor- β , cytoplasmic chaperonin, Y2H35, Y2H171, and Y2H41 protein.

25

-120-

38. An animal as in claim 35 wherein said animal is selected from the group consisting of rats, mice, hamsters, guinea pigs, rabbits, dogs, cats, goats, sheep, pigs, and non-human primates.

5 39. An animal as in claim 35 wherein said animal is an invertebrate.

40. A method for producing at least a functional domain of a presenilin-interacting protein comprising culturing a host cell of any of claims 30-34 under suitable conditions to produce said presenilin by expressing said nucleic acid.

10

41. A substantially pure preparation of a protein selected from the group consisting of a mammalian S5a, GT24, p0071, Rab11, retinoid X receptor- β , cytoplasmic chaperonin, Y2H35, Y2H171, and Y2H41 protein.

15 42. A substantially pure preparation of a polypeptide comprising an amino acid sequence of at least 10 consecutive amino acid residues selected from the group consisting SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, and GenBank Accession Numbers F08730, T18858, X81889, X56740, X53143, M84820, X63522, M81766, U17104, X74801, R12984, D55326, and T64843.

20

43. A substantially pure preparation of a polypeptide as in claim 42 comprising an amino acid sequence of at least 15 consecutive amino acid residues selected from said group.

-121-

44. A substantially pure preparation of a polypeptide comprising at least a presenilin-interacting domain of a presenilin-interacting protein selected from the group consisting of a mammalian S5a, GT24, p0071, Rab11, retinoid X receptor- β ,
5 cytoplasmic chaperonin, Y2H35, Y2H171, and Y2H41 protein.
45. A substantially pure preparation of a polypeptide comprising an antigenic determinant of a presenilin-interacting protein selected from the group consisting of a mammalian S5a, GT24, p0071, Rab11, retinoid X receptor- β , cytoplasmic
10 chaperonin, Y2H35, Y2H171, and Y2H41 protein.
46. A method of producing antibodies which selectively bind to a presenilin-interacting protein comprising the steps of
administering an immunogenically effective amount of a presenilin-
15 interacting protein immunogen to an animal;
allowing said animal to produce antibodies to said immunogen; and
obtaining said antibodies from said animal or from a cell culture derived therefrom.
- 20 47. A substantially pure preparation of an antibody which selectively binds to an antigenic determinant of a presenilin-interacting protein selected from the group consisting of a mammalian S5a, GT24, p0071, Rab11, retinoid X receptor- β , cytoplasmic chaperonin, Y2H35, Y2H171, and Y2H41 protein.

-122-

48. A substantially pure preparation of an antibody as in claim 47 wherein said antibody selectively binds to an antigenic determinant of a mutant presenilin-interacting protein and fails to bind to a normal presenilin-interacting protein.
- 5 49. A cell line producing an antibody of any one of claims 47-48.
50. A method for identifying compounds which can modulate the expression of a presenilin-interacting protein gene comprising
contacting a cell with a test candidate wherein said cell includes a
10 regulatory region of a presenilin-interacting protein gene operably joined to a coding region; and
detecting a change in expression of said coding region.
51. A method as in claim 50 wherein said change comprises a change in a
15 level of an mRNA transcript encoded by said coding region.
52. A method as in claim 50 wherein said change comprises a change in a level of a protein encoded by said coding region.
- 20 53. A method as in claim 50 wherein said change is a result of an activity of a protein encoded by said coding region.

-123-

54. A method as in claim 50 wherein said coding region encodes a marker protein selected from the group consisting of β -galactosidase, alkaline phosphatase, green fluorescent protein, and luciferase.

5 55. A method for identifying compounds which can selectively bind to a presenilin-interacting protein comprising the steps of
providing a preparation including at least one presenilin-interacting protein component;
contacting said preparation with a sample including at least one candidate
10 compound; and
detecting binding of said presenilin-interacting protein component to said candidate compound.

15 56. The method in 55 wherein said binding to said presenilin-interacting component is detected by an assay selected from the group consisting of: affinity chromatography, co-immunoprecipitation, a Biomolecular Interaction Assay, and a yeast two-hybrid system.

20 57. A method of identifying compounds which can modulate activity of a presenilin-interacting protein comprising the steps of
providing a cell expressing a normal or mutant presenilin-interacting protein gene;
contacting said cell with at least one candidate compound; and
detecting a change in a marker of said activity.

25

-124-

58. A method as in claim 57 wherein measurement of said marker indicates a difference between cells bearing an expressed mutant presenilin-interacting protein gene and otherwise identical cells free of an expressed mutant presenilin-interacting protein gene.

5

59. A method as in claim 57 wherein said change comprises a change in a non-specific marker of cell physiology selected from the group consisting of pH; intracellular Ca^{++} , Na^+ , or K^+ ; cyclic AMP levels; GTP/GDP ratios; phosphatidylinositol activity; and protein phosphorylation.

10

60. A method as in claim 57 wherein said change comprises a change in expression of said presenilin-interacting protein.

61. A method as in claim 57 wherein said change comprises a change in intracellular concentration or flux of an ion selected from the group consisting of Ca^{2+} , Na^+ and K^+ .

15

62. A method as in claim 57 wherein said change comprises a change in occurrence or rate of apoptosis or cell death.

20

63. A method as in claim 57 wherein said change comprises a change in production of $\text{A}\beta$ peptides.

-125-

64. A method as in claim 57 wherein said change comprises a change in phosphorylation of at least one microtubule associated protein.

65. A method as in claim 57 wherein said cell is a cell cultured in vitro.

5

66. A method as in claim 65 wherein said cell is a transformed host cell of any one of claims 30-34.

67. A method as in claim 65 wherein said cell is explanted from a host bearing
10 at least one mutant presenilin-interacting protein gene.

68. A method as in claim 65 wherein said cell is explanted from a transgenic animal of any one of claims 35-39.

15 69. A method as in claim 57 wherein said cell is a cell in a live animal.

70. A method as in claim 69 wherein said cell is a cell of a transgenic animal of any one of claims 35-39.

20 71. A method as in claim 57 wherein said cell is in a human subject in a clinical trial.

-126-

72. A diagnostic method for determining if a subject bears a mutant presenilin-interacting protein gene comprising the steps of
providing a biological sample of said subject;
- 5 detecting in said sample a mutant presenilin-interacting protein nucleic acid, a mutant presenilin-interacting protein, or a mutant presenilin-interacting protein activity.
73. A method as in claim 72, wherein a mutant presenilin-interacting protein
10 nucleic acid is detected by an assay selected from the group consisting of direct nucleotide sequencing, probe specific hybridization, restriction enzyme digest and mapping, PCR mapping, ligase-mediated PCR detection, RNase protection, electrophoretic mobility shift detection, and chemical mismatch cleavage.
- 15 74. A method as in claim 72, wherein a mutant presenilin-interacting protein is detected by an assay selected from the group consisting of an immunoassay, a protease assay, and an electrophoretic mobility assay.
- 20 75. A pharmaceutical preparation comprising a substantially pure presenilin-interacting protein and a pharmaceutically acceptable carrier.
76. A pharmaceutical preparation comprising an expression vector operably encoding a presenilin-interacting protein, wherein said expression vector may express said presenilin-interacting protein in a human subject, and a pharmaceutically
25 acceptable carrier.

-127-

77. A pharmaceutical preparation comprising an expression vector operably encoding a presenilin-interacting protein antisense sequence, wherein said expression vector may express said presenilin-interacting protein antisense sequence in a human
5 subject, and a pharmaceutically acceptable carrier.

78. A pharmaceutical preparation comprising a substantially pure antibody, wherein said antibody selectively binds to a mutant presenilin-interacting protein, and a pharmaceutically acceptable carrier.

10

79. A pharmaceutical preparation as in claim 78 wherein said preparation is essentially free of an antibody which selectively binds a normal presenilin-interacting protein.

15 80. A pharmaceutical preparation comprising a substantially pure preparation of an antigenic determinant of a mutant presenilin-interacting protein.

81. A pharmaceutical preparation as in claim 80 wherein said preparation is essentially free of an antigenic determinant of a normal presenilin-interacting protein.

20

82. A method of treatment for a patient bearing a mutant presenilin-interacting protein gene comprising the step of administering to said patient a therapeutically effective amount of the pharmaceutical preparation of any one of claims 75-81.

-128-

83. A method as in claim 82, wherein said pharmaceutical preparation is targeted to a cell type is selected from the group consisting of heart, brain, lung, liver, skeletal muscle, kidney, pancreas and neurological cells.

5

INTERNATIONAL SEARCH REPORT

Int. Patent Application No.

PC 1/CA 97/00051

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C12N15/74 C12N5/10 C07K14/47 C07K16/18
A01K67/027 C12Q1/68 G01N33/577 A61K31/70 A61K38/17
A61K39/395 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K A01K C12N G01N C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 35, 1 September 1995, pages 20615-20620, XP002029380 JOHANSSON, E., ET AL. ON: "MOLECULAR CLONING AND EXPRESSION OF A PITUITARY GLAND PROTEIN MODULATING INTESTINAL FLUID SECRETION" cited in the application see the whole document</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/--</p>	<p>1-12, 18-20, 30,31, 34, 41-47,49</p>

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

14 April 1997

Date of mailing of the international search report

25.04.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Holtorf, S

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/CA 97/00051

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>EMBL SEQUENCE DATA LIBRARY, 20 December 1994, HEIDELBERG, GERMANY, XP002029381 PAWLAK, A., ET AL. : "CHARACTERIZATION OF A LARGE POPULATION OF mRNAs FROM HUMAN TESTIS" cited in the application ACCESSION No. T18858 see the whole document ---</p>	<p>1-12, 18-20, 30,31,34</p>
X	<p>EMBL SEQUENCE DATA LIBRARY, 17 February 1995, HEIDELBERG, GERMANY, XP002029382 AUFFRAY, C., ET AL. : "IMAGE: INTEGRATED MOLECULAR ANALYSIS OF THE HUMAN GENOME AND ITS EXPRESSION" cited in the application ACCESSION No. F08730 see the whole document ---</p>	<p>1-12, 18-20, 30,31, 34, 41-47,49</p>
X	<p>EMBL SEQUENCE DATA LIBRARY, 22 July 1994, HEIDELBERG, GERMANY, XP002029383 ZAHRAOUI, A., ET AL. : "CODING SEQUENCES OF HUMAN Rab8 AND Rab11 cDNAs" cited in the application ACCESSION No. X56740 see the whole document ---</p>	<p>1-12, 18-20, 30,31, 34, 41-47,49</p>
X	<p>EMBL SEQUENCE DATA LIBRARY, 19 February 1991, HEIDELBERG, GERMANY, XP002029384 DRIVAS, G.T., ET AL.: "IDENTIFICATION AND CHARACTERIZATION OF A HUMAN HOMOLOG OF THE SCHIZOSACCHAROMYCES POMBE RAS-LIKE GENE YPT-3" cited in the application ACCESSION No. X53143 see the whole document ---</p>	<p>1-12, 18-20, 30,31, 34, 41-47,49</p>
X	<p>EMBL SEQUENCE DATA LIBRARY, 7 February 1992, HEIDELBERG, GERMANY, XP002029385 CHAMBON, P., ET AL. : "PURIFICATION, CLONING, AND RXR IDENTITY OF THE HELA CELL FACTOR WITH WHICH RAR OR TR HETERODIMERIZES TO BIND TARGET SEQUENCES EFFICIENTLY" cited in the application ACCESSION No. M84820 see the whole document ---</p>	<p>1-12, 18-20, 30,31, 34, 41-47,49</p>

-/--

INTERNATIONAL SEARCH REPORT

International Application No.

PC/CA 97/00051

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>EMBL SEQUENCE DATA LIBRARY, 31 March 1992, HEIDELBERG, GERMANY, XP002029386 FLEISCHHAUER, K., ET AL. : "ISOLATION OF A FULL-LENGTH cDNA CLONE ENCODING A N-TERMINALLY VARIANT FORM OF THE HUMAN RETINOID X RECEPTOR BETA" cited in the application ACCESSION No. X63522 see the whole document</p> <p style="text-align: center;">---</p>	<p>1-12, 18-20, 30,31, 34, 41-47,49</p>
X	<p>EMBL SEQUENCE DATA LIBRARY, 10 December 1991, HEIDELBERG, GERMANY, XP002029387 YU, V.C., ET AL. : "RXR-beta: A COREGULATOR THAT ENHANCES BINDING OF RETINOIC ACID, THYROID HORMONE, AND VITAMIN D RECEPTORS TO THEIR COGNATE RESPONSE ELEMENTS" cited in the application ACCESSION No. M81766 see the whole document</p> <p style="text-align: center;">---</p>	<p>1-12, 18-20, 30,31, 34, 41-47,49</p>
X	<p>EMBL SEQUENCE DATA LIBRARY, 7 January 1995, HEIDELBERG, GERMANY, XP002029388 SEVIGNY, G., ET AL.: "ASSIGNMENT OF THE HUMAN HOMOLOGUE OF THE mTRIC-P5 GENE (TRIC5) TO BAND 1q23 BY FLUORESCENCE IN SITU HYBRIDIZATION" cited in the application ACCESSION No. U17104 see the whole document</p> <p style="text-align: center;">---</p>	<p>1-12, 18-20, 30,31, 34, 41-47,49</p>
X	<p>EMBL SEQUENCE DATA LIBRARY, 1 January 1994, HEIDELBERG, GERMANY, XP002029389 WALKLEY, N.A., ET AL. : "CLONING , STRUCTURE AND mRNA EXPRESSION OF HUMAN Cctg, WHICH ENCODES THE CHAPERONIN SUBUNIT CCTgamma" cited in the application ACCESSION No. X74801 see the whole document</p> <p style="text-align: center;">---</p>	<p>1-12, 18-20, 30,31, 34, 41-47,49</p>
X	<p>EMBL SEQUENCE DATA LIBRARY, 22 April 1995, HEIDELBERG, GERMANY, XP002029390 HILLIER, L., ET AL. : "THE WashU-MERCK EST PROJECT" cited in the application ACCESSION No. R12984 see the whole document</p> <p style="text-align: center;">---</p>	<p>1-12, 18-20, 30,31, 34, 41-47,49</p>
	-/--	

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA 97/00051

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>EMBL SEQUENCE DATA LIBRARY, 25 August 1995, HEIDELBERG, GERMANY, XP002029391 FUJIWARA, T., ET AL .: ""UNPUBLISHED"" cited in the application ACCESSION No. D55326 see the whole document ---</p>	<p>1-12, 18-20, 30,31,34</p>
X	<p>EMBL SEQUENCE DATA LIBRARY, 6 March 1995, HEIDELBERG, GERMANY, XP002029392 HILLIER, L., ET AL .: "THE WashU-MERCK EST PROJECT" cited in the application ACCESSION No. T64843 see the whole document -----</p>	<p>1-12, 18-20, 30,31, 34, 41-47,49</p>

Title: Drafting Internet Agreements

Editors: Gregory J. Battersby and Charles W. Grimes are members of the law firm of Grimes and Battersby, LLP, with offices in Stamford, CT. The firm specializes in all areas of intellectual property practice. Widely recognized authorities in their field, Battersby and Grimes have edited or co-authored such successful publications as *The Licensing Journal*, *IP Litigator*, *Licensing Update*, *Licensing Royalty Rates*, *Licensing Desk Book*

Stock/ISBN #: 0-7355-17177

Vista #:

Price: \$165.00

Supp: \$85.00

Release Date: October

Product Type: Looseleaf binder format with form on CD-ROM

Update

Frequency:

Supplemented annually

Market Need

At any stage of doing business on the Internet -- from entering into marketing or licensing agreements with partners and arranging for the development of a web site to protecting intellectual property and delivering content online or goods in the real world -- clients need well-drafted agreements that define the rights and responsibilities of each party, provide ways to measure performance, and provide remedies in case something goes wrong.

How Title Meets Market Need

You could spend hours hunting down existing agreements that resemble your new Internet transaction, and tailor them to suit your needs, or you could get the practice-proven ready-to-use Internet forms you need in **Drafting Internet Agreements**.

Audience/Market Segments

Primary: 1. Intellectual property and commercial law attorneys both in firms and in-house, especially those specializing in information technology and computer law and licensing.

Tagline: All the tools you need to structure and negotiate winning Internet agreements.

Product Overview: This practical, timesaving resource is the first, comprehensive single volume collection of sample Internet agreements. You can use these ready-to-use forms to structure, negotiate and draft Internet-related transactions in a fraction of the time you'd ordinarily spend. Prepared by nationally known intellectual property and licensing law experts, this easy-to-use reference (and accompanying CD-ROM) offers more than 40 forms covering the full range of Internet law transactions. Each form has been developed by the co-authors or by other experienced Internet law practitioners and has been used in actual transaction during the past two years.

Organization: Each chapter includes the following:

- **A Full Agreement:** Each chapter provides a full agreement so you can see the entire transaction as a seamless whole, and a variety of agreements for closely related issues.
- **Brief Overview:** For each form, you get a brief overview, an analysis of the different kinds of forms that relate to the topic, and a description of the form's applicability and use.
- **Practice Tips:** A "Practice Tips" section before each form that identifies the "hot spots" you're likely to encounter during the transaction, and offers guidance on resolving these hotly negotiated provisions quickly.
- **Checklists:** Detailed checklists assist you in drafting the final agreement.

Types of Agreements Provided

• Internet advertising	• Internet licensing
• Internet consulting	• Technology development
• Electronic commerce	• Website agreements
• Internet joint ventures	• And many more

Features/Benefits

- **Over 40 Ready-to-Use Agreements on CD-ROM:** These forms are practice proven and will save attorneys hours of drafting time.
- **Practice Tools:** Provides practice tips, form overviews and checklists. **Benefit:** Save time and avoid overlooking crucial steps.
- **Expert Authors:** Written by leading intellectual property attorneys with extensive experience in drafting and negotiate Internet agreements.

Customer Objections

Objection: We already have our own forms in-house.

Answer: For less than one billable hour of an attorney's time you can add a storehouse of over 40 additional practice-proven forms to your practice. All of these forms have been used within the last two to three years. You can't have too many forms in your forms library.

Competition

Although there are some books in the marketplace that are specific to Internet law, there are very few which are forms books or have a large forms component to make them directly competitive.

- *E-Commerce and Internet Law*/Ian C. Ballon/Glasser LegalWorks/\$395.00/1999/2 looseleaf volumes. Practical guidance on all aspects of Internet Law. CD contains forms, contracts, checklists and sample pleadings.
- *Computer Law: Drafting and Negotiating Forms and Agreements*/Richard Raysman and Peter Brown/Law Journal Seminars-Press/\$195.00/1984/2 Looseleaf Volumes/\$147 – 1998 update price for two updates: This book focuses on computer law forms and has very few Internet related subject matter.

L&B Top 10 Cross-Sells:

• Law of the Internet	• Drafting Technology Patent License Agreements
• Law of Electronic Commerce	• Wiley Intellectual Property Law Update
• Scott on Computer & Internet Law (NE)	• Epstein on Intellectual Property
• The Licensing Journal	• Drafting License Agreements
• The Computer & Internet Lawyer	• Law of the Information Superhighway
• Internet and Tech Law Desk Reference	• Journal of Internet Law

Mrktg Mgr: David von Glahn x329 **Sr. Promo Mgr:** Maryann Young x214 **Editor:** Frank Quinn x351

From: "GEICO Auto Sales" <onlineautosales@geico.com>
To: <sdurgee@darbylaw.com>
Date: 3/14/01 12:52PM
Subject: GEICO - Let us meet your Insurance needs

You could be saving 15% or more on your car insurance --- Is there any reason not to switch to GEICO. GEICO, the 6th largest insurer of private passenger vehicles in the nation has been providing low rates to sensible drivers for nearly 65 years by working directly with our customers and cutting out the middleman.

Saving money is one good reason to insure with GEICO, but it's not the only reason. At GEICO you'll get low rates and receive 1st class service. And you can feel secure too -- GEICO offers renewal to over 98% of our policyholders each year. We'll be there for you year after year.

To continue your request for a free rate quote, just click on the link below. If you prefer, you can also receive a rate quote over the phone by calling GEICO at 1-866-688-1290 and referring to the following retention number: 010307N2710680.

https://www.geico.com/ratequote/campaign_chat.jsp?cid=RQ120012

Contact us today!

If you do not wish to receive these messages in the future, please go to this url:

<https://www.geico.com/rtqapp/control?target=campaign&email=sdurgee@darbylaw.com&deactivate=true>